2025/06/30 更新

写真a

オオツカ モトユキ
大塚 基之
Otsuka Motoyuki
所属
医歯薬学域 教授
職名
教授

学位

  • 医博 ( 東京大学 )

研究キーワード

  • ウイルス発癌

  • non-coding RNA

  • バイオマーカー

  • 消化器がん

  • 炎症性発癌

  • ゲノム医学

  • 分子生物学

  • 消化器病学

研究分野

  • ライフサイエンス / 病態医化学

  • ライフサイエンス / 免疫学

  • ライフサイエンス / 消化器内科学

  • ライフサイエンス / ウイルス学

学歴

  • 東京大学    

    1998年4月 - 2002年3月

      詳細を見る

  • 東京大学   Faculty of Medicine   School of Medicine

    1988年4月 - 1994年3月

      詳細を見る

  • 鹿児島ラ・サール高校 卒業    

    1988年3月

      詳細を見る

経歴

  • 岡山大学病院   副院長

    2025年4月 - 現在

      詳細を見る

  • 岡山大学   学術研究院医歯薬学域 消化器肝臓内科学   教授

    2023年1月 - 現在

      詳細を見る

  • 東京大学 大学院医学系研究科   器官病態内科学講座 消化器内科学   講師

    2017年4月 - 2022年12月

      詳細を見る

  • 科学技術振興機構   さきがけ研究員(兼任)

    2012年10月 - 2016年3月

      詳細を見る

  • 東京大学 医学部附属病院 消化器内科   助教

    2009年3月 - 2017年4月

      詳細を見る

  • スクリプス研究所 免疫微生物学部門   研究員

    2004年7月 - 2009年2月

      詳細を見る

  • 東京大学   医学部附属病院 消化器内科   特任講師(病院)

    2014年3月 - 2017年4月

      詳細を見る

  • ウイルス肝炎研究財団   リサーチレジデント(兼任)

    2002年12月 - 2004年7月

      詳細を見る

  • 東京大学   医学部附属病院消化器内科   研修登録医

    2002年7月 - 2004年7月

      詳細を見る

  • 東京大学   医学部附属病院消化器内科   医員

    2002年5月 - 2002年6月

      詳細を見る

  • 東京大学 医学部附属病院消化器内科   研修登録医

    2002年4月 - 2002年5月

      詳細を見る

  • ヘリックス研究所第三研究部門   研究員(兼任)

    2000年7月 - 2001年12月

      詳細を見る

  • 総合病院 国保 旭中央病院   医員

    1995年6月 - 1997年12月

      詳細を見る

  • 東京大学医学部附属病院   研修医

    1994年6月 - 1995年5月

      詳細を見る

▼全件表示

所属学協会

▼全件表示

委員歴

  • AMED課題評価委員会 委員  

    2023年7月 - 2025年3月   

      詳細を見る

  • 加藤記念バイオサイエンス振興財団 選考委員  

    2023年4月 - 2027年3月   

      詳細を見る

  • 日本消化器病学会/日本肝臓学会 NAFLD/NASHガイドライン作成委員  

      詳細を見る

 

論文

  • Acetic Acid-Indigo Carmine Chromocolonoscopy for Proximal Serrated Lesions: A Randomized, Three-Arm Colonoscopy Study. 国際誌

    Hideaki Kinugasa, Sakiko Hiraoka, Sayo Kobayashi, Minoru Matsubara, Teruya Nagahara, Reiji Higashi, Kensuke Takei, Masayasu Ohmori, Takashi Nakamura, Takao Tsuzuki, Shouichi Tanaka, Ryosuke Hirai, Junki Toyosawa, Yuki Aoyama, Yasushi Yamasaki, Toshihiro Inokuchi, Masahiro Takahara, Takehiro Tanaka, Toshiharu Mitsuhashi, Motoyuki Otsuka

    The American journal of gastroenterology   2025年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Aggressive colorectal cancer (CRC) frequently originates from serrated lesions (SLs), particularly in the proximal colon, which are challenging to detect using standard screening colonoscopy. Although duplicate examinations or chromocolonoscopies are recommended for detecting proximal SLs, evidence from randomized trials is limited. We evaluated the effectiveness of tandem colonoscopy with an acetic acid-indigo carmine mixture (AIM) for detecting SLs in the proximal colon compared to white-light imaging (WLI) and indigo carmine (IC). METHODS: This three-arm, multicenter, randomized controlled trial involving nine institutions enrolled patients undergoing colonoscopy and assigned them randomly to the WLI, IC, or AIM group. The primary outcomes were the SL-detection rate (SDR) of proximal lesions during the second examination (SDR2nd) and SL additional rate (SAR). Secondary outcomes included the detection and additional rates of other polyps, factors contributing to SAR, and complications. RESULTS: Between 2021 and 2024, 1,319 participants with 1,267 polyps were included in the analysis. With AIM, the SDR2nd and SAR were significantly higher compared to WLI or IC (WLI vs. AIM: 2.7% vs. 14.0%, p<.001; IC vs. AIM: 7.9% vs. 14.0%, p=.002, and WLI vs. AIM: 22.4% vs. 69.3%, p<.001; IC vs. AIM: 45.8% vs. 69.3%, p=.001). AIM conferred a higher adenoma-detection rate (ADR)2nd than with WLI (10.5% vs. 24.7%; p<.001) and was an independent factor for SAR (odds ratio [95% confidence interval]: 7.79 [3.76-17.08]). No major adverse events were observed. CONCLUSIONS: AIM significantly improved proximal colon SDRs and outperformed WLI and IC. The relationship between SDR and CRC incidence warrants further investigation.

    DOI: 10.14309/ajg.0000000000003411

    PubMed

    researchmap

  • Efficacy and Safety of Endoscopic Ultrasonography-Guided Ethanol Injections of Small Pancreatic Neuroendocrine Neoplasms: a prospective, multicenter study. 国際誌

    Kazuyuki Matsumoto, Hironari Kato, Takao Itoi, Masayuki Kitano, Kazuo Hara, Masaki Kuwatani, Mamoru Takenaka, Reiko Ashida, Shuntaro Mukai, Nozomi Okuno, Kazumichi Kawakubo, Tatsuhiro Yamazaki, Jun Sakurai, Yuki Nakatsuka, Michihiro Yoshida, Motoyuki Otsuka

    Endoscopy   57 ( 4 )   321 - 329   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND STUDY AIMS: Endoscopic ultrasonography (EUS)-guided ethanol injection (EI) has recently been introduced as one of the management strategies for pancreatic neuroendocrine neoplasms (PNENs). However, its role as a surgical alternative is unclear. We evaluated the efficacy and safety of EUS-EI in treating small PNENs through a prospective multicentre study. PATIENTS AND METHODS: Patients with Grade 1 tumours of ≤15 mm confirmed by pathology were included. The primary endpoint assessed efficacy and safety, measuring complete ablation using computed tomography at 1 and 6 months, prevention of adverse events (AEs) within 1 month, severe pancreatic fistula at 1 month, and diabetes mellitus (DM) incidence/worsening at 6 months. The composite endpoint of EUS-EI was compared with that of historical results of a study based on surgical treatment. RESULTS: Twenty-five patients with PNENs, with a median tumour size of 10.1 mm, were treated using EUS-EI. Seventy-six percent of the patients achieved the composite primary endpoint (19/25) (95% confidence interval [CI]=54.9%-90.6%), a proportion significantly higher than that of surgical treatment (P=0.0083). Regarding efficacy, 88% (22/25) of the patients achieved complete ablation at 1 and 6 months (95% CI=68.8%-97.5%). Regarding safety, 96% (24/25) of the patients had no severe AEs within 1 month (95% CI=79.7%-99.9%). No patients had severe pancreatic fistulas at 1 month, and 84% (21/25) of the patients had no incidence or exacerbation, or both, of DM at 6 months (95% CI=63.9%-95.5%). CONCLUSION: EUS-EI is safe and could be a potent treatment option for patients with small PNENs.

    DOI: 10.1055/a-2452-4607

    PubMed

    researchmap

  • PTBP1 protects Y RNA from cleavage leading to its apoptosis-specific degradation. 査読 国際誌

    Takeshi Kamakura, Kazuaki Kameda, Masahiko Manabe, Kan Torii, Yuki Sugiura, Seiko Ito, Shunya Nakayama, Takanobu Shimizu, Etsuko Nagashima, Kosuke Kamiya, Masahiro Oka, Masafumi Tanaka, Motoyuki Otsuka, Masato Ohtsuka, Ai Kotani

    Cell death discovery   10 ( 1 )   322 - 322   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Some RNAs such as 28S rRNA, U1 small nuclear RNA (snRNA), and Y RNAs are known to be cleaved during apoptosis. The underlying mechanism, functions, and biological significance of RNA degradation in apoptosis remain elusive. Y RNAs are non-coding RNAs widely conserved from bacteria to mammals, and are major components of Ro ribonucleoprotein (RNP) complexes which contain the 60 kDa Ro protein (SS-A) and the 50 kDa La protein (SS-B). The autoantigenic Ro and La proteins were identified by autoantibodies present in the sera from patients with Systemic lupus erythematosus (SLE) and Sjögren's syndrome (SjS). We previously identified novel, functional small RNAs named AGO-taxis small RNAs (ASRs) that are specifically bound to Argonaute protein 1 (AGO1), which are processed from Y RNAs. Cell-free analysis combined with fractionation methods revealed that the apoptosis-specific biogenesis of ASRs or cleavage of Y RNA was induced by truncation of polypyrimidine tract-binding protein 1 (PTBP1), which is an endoribonuclease inhibitor of Y RNAs by caspase 3. Caspase 3-resistant PTBP1 mutant protected cleavage of Y RNAs in apoptosis induced by staurosporine. Furthermore, caspase 3-resistant PTBP1 mutant knock-in mice showed elevated cytokines, dysregulation of the germinal center formation compared to the wild-type mice at LPS stimulation, and high positivity of antinuclear antibody. Those results suggest that cleavage of Y RNAs or biogenesis of ASR during apoptosis has critical biological functions and their deregulation result in immune dysregulation and the formation of autoantibody, possibly leading to the development of autoimmune diseases.

    DOI: 10.1038/s41420-024-02080-6

    PubMed

    researchmap

  • Virtual indigo carmine chromoendoscopy images: A novel modality for peroral cholangioscopy using artificial intelligence technology (with video). 査読 国際誌

    Ryosuke Sato, Kazuyuki Matsumoto, Hideaki Kinugasa, Masahiro Tomiya, Takayoshi Tanimoto, Akimitsu Ohto, Kei Harada, Nao Hattori, Taisuke Obata, Akihiro Matsumi, Kazuya Miyamoto, Kosaku Morimoto, Hiroyuki Terasawa, Yuki Fujii, Daisuke Uchida, Koichiro Tsutsumi, Shigeru Horiguchi, Hironari Kato, Yoshiro Kawahara, Motoyuki Otsuka

    Gastrointestinal endoscopy   100 ( 5 )   938 - 946   2024年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: Accurately diagnosing biliary strictures is crucial for surgical decisions, and although peroral cholangioscopy (POCS) aids in visual diagnosis, diagnosing malignancies or determining lesion margins via this route remains challenging. Indigo carmine is commonly used to evaluate lesions during gastrointestinal endoscopy. We aimed to establish the utility of virtual indigo carmine chromoendoscopy (VICI) converted from POCS images using artificial intelligence. METHODS: This single-center, retrospective study analyzed 40 patients with biliary strictures who underwent POCS using white light imaging (WLI) and narrow-band imaging (NBI). A "cycle-consistent adversarial network" (CycleGAN) was used to convert the WLI into VICI of POCS images. Three experienced endoscopists evaluated WLI, NBI, and VICI via POCS in all patients. The primary outcome was the visualization quality of surface structures, surface microvessels, and lesion margins. The secondary outcome was diagnostic accuracy. RESULTS: VICI showed superior visualization of the surface structures and lesion margins compared with WLI (P<0.001) and NBI (P<0.001). The diagnostic accuracies were 72.5%, 87.5%, and 90.0% in WLI alone, WLI and VICI simultaneously, and WLI and NBI simultaneously, respectively. WLI and VICI simultaneously tended to result in higher accuracy than WLI alone (P=0.083) and the results were not significantly different from WLI and NBI simultaneously (P=0.65). CONCLUSIONS: VICI in POCS proved valuable for visualizing surface structures and lesion margins and contributed to higher diagnostic accuracy comparable to NBI. In addition to NBI, VICI may be a novel supportive modality for POCS.

    DOI: 10.1016/j.gie.2024.06.013

    PubMed

    researchmap

  • Innovative submucosal injection solution for endoscopic resection with phosphorylated pullulan: a preclinical study. 査読 国際誌

    Takuya Satomi, Yukari Ochi, Takumi Okihara, Hiroki Fujii, Yasuhiro Yoshida, Katsumi Mominoki, Haruko Hirayama, Junki Toyosawa, Yasushi Yamasaki, Seiji Kawano, Yoshiro Kawahara, Hiroyuki Okada, Motoyuki Otsuka, Akihiro Matsukawa

    Gastrointestinal endoscopy   99 ( 6 )   1039 - 1047   2024年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: A submucosal injection solution is used to assist in endoscopic surgery. The high viscosity of current solutions makes them difficult to inject. In the present study, we developed an extremely low-viscosity, easy-to-use submucosal injection solution using phosphorylated pullulan (PPL). METHODS: The PPL solutions were prepared at different concentrations, and their viscosities were measured. The mucosal elevation capacity was evaluated using excised porcine stomachs. Controls included 0.4% sodium hyaluronate (SH), 0.6% sodium alginate (SA), and saline. To evaluate the practicality, the catheter injectability of 0.7% PPL was measured, and EMR and endoscopic submucosal dissection (ESD) were performed using the stomach and colorectum of live pigs. As controls, 0.4% SH and saline were used. RESULTS: The PPL solutions were of extremely low viscosity compared to the solutions of 0.4% SH and 0.6% SA. Nevertheless, the mucosal elevation capacity of PPL solutions for up to 0.7% concentration was similar to that of 0.4% SH, and 0.7% PPL was less resistant to catheter infusion than 0.4% SH and 0.6% SA. In live pig experiments with endoscopic mucosal resection and ESD, snaring after submucosal injection of 0.7% PPL was easier than with 0.4% SH, ESD with 0.7% PPL produced less bubble formation than with 0.4% SH, and the procedure time tended to be shorter with 0.7% PPL than with 0.4% SH because of the shorter injection time. CONCLUSIONS: The PPL solution is an innovative and easy-to-use submucosal injection solution.

    DOI: 10.1016/j.gie.2024.01.015

    PubMed

    researchmap

  • Methylation analysis of DCC gene in saliva samples is an efficient method for non-invasive detection of superficial hypopharyngeal cancer. 査読 国際誌

    Ryosuke Hirai, Hideaki Kinugasa, Shumpei Yamamoto, Soichiro Ako, Koichiro Tsutsumi, Makoto Abe, Koji Miyahara, Masahiro Nakagawa, Motoyuki Otsuka

    British journal of cancer   130 ( 10 )   1725 - 1731   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Advances in upper gastrointestinal endoscopic technology have enabled early detection and treatment of hypopharyngeal cancer. However, in-depth pharyngeal observations require sedation and are invasive. It is important to establish a minimally invasive and simple evaluation method to identify high-risk patients. METHODS: Eighty-seven patients with superficial hypopharyngeal cancer and 51 healthy controls were recruited. We assessed the methylation status of DCC, PTGDR1, EDNRB, and ECAD, in tissue and saliva samples and verified the diagnostic accuracy by methylation analyses of their promoter regions using quantitative methylation-specific PCR. RESULTS: Significant differences between cancer and their surrounding non-cancerous tissues were observed in the methylation values of DCC (p = 0.003), EDNRB (p = 0.001), and ECAD (p = 0.043). Using receiver operating characteristic analyses of the methylation values in saliva samples, DCC showed the highest area under the curve values for the detection of superficial hypopharyngeal cancer (0.917, 95% confidence interval = 0.864-0.970), compared with those for EDNRB (0.680) and ECAD (0.639). When the cutoff for the methylation values of DCC was set at ≥0.163, the sensitivity to detect hypopharyngeal cancer was 82.8% and the specificity was 90.2%. CONCLUSIONS: DCC methylation in saliva samples could be a non-invasive and efficient tool for early detection of hypopharyngeal cancer in high-risk patients.

    DOI: 10.1038/s41416-024-02654-2

    PubMed

    researchmap

  • MicroRNA-34a-5p: A pivotal therapeutic target in gallbladder cancer. 査読 国際誌

    Takashi Oda, Koichiro Tsutsumi, Taisuke Obata, Eijiro Ueta, Tatsuya Kikuchi, Soichiro Ako, Yuki Fujii, Tatsuhiro Yamazaki, Daisuke Uchida, Kazuyuki Matsumoto, Shigeru Horiguchi, Hironari Kato, Hiroyuki Okada, Ryota Chijimatsu, Motoyuki Otsuka

    Molecular therapy. Oncology   32 ( 1 )   200765 - 200765   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Gallbladder cancer incidence has been increasing globally, and it remains challenging to expect long prognosis with the current systemic chemotherapy. We identified a novel nucleic acid-mediated therapeutic target against gallbladder cancer by using innovative organoid-based gallbladder cancer models generated from KrasLSL-G12D/+; Trp53f/f mice. Using comprehensive microRNA expression analyses and a bioinformatics approach, we identified significant microRNA-34a-5p downregulation in both murine gallbladder cancer organoids and resected human gallbladder cancer specimens. In three different human gallbladder cancer cell lines, forced microRNA-34a-5p expression inhibited cell proliferation and induced cell-cycle arrest at the G1 phase by suppressing direct target (CDK6) expression. Furthermore, comprehensive RNA sequencing revealed the significant enrichment of gene sets related to the cell-cycle regulators after microRNA-34a-5p expression in gallbladder cancer cells. In a murine xenograft model, locally injected microRNA-34a-5p mimics significantly inhibited gallbladder cancer progression and downregulated CDK6 expression. These results provide a rationale for promising therapeutics against gallbladder cancer by microRNA-34a-5p injection, as well as a strategy to explore therapeutic targets against cancers using organoid-based models, especially for those lacking useful genetically engineered murine models, such as gallbladder cancer.

    DOI: 10.1016/j.omton.2024.200765

    PubMed

    researchmap

  • Gut Bacteria-derived Membrane Vesicles Induce Colonic Dysplasia by Inducing DNA Damage in Colon Epithelial Cells. 査読 国際誌

    Yu Miyakawa, Motoyuki Otsuka, Chikako Shibata, Takahiro Seimiya, Keisuke Yamamoto, Rei Ishibashi, Takahiro Kishikawa, Eri Tanaka, Takayuki Isagawa, Norihiko Takeda, Noriaki Kamio, Kenichi Imai, Mitsuhiro Fujishiro

    Cellular and molecular gastroenterology and hepatology   17 ( 5 )   745 - 767   2024年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND & AIMS: Colorectal cancer (CRC) is the third most common cancer in the world. Gut microbiota has recently been implicated in the development of CRC. Actinomyces odontolyticus is one of the most abundant bacteria in the gut of patients with very early stages of CRC. A odontolyticus is an anaerobic bacterium existing principally in the oral cavity, similar to Fusobacterium nucleatum, which is known as a colon carcinogenic bacterium. Here we newly determined the biological functions of A odontolyticus on colonic oncogenesis. METHODS: We examined the induction of intracellular signaling by A odontolyticus in human colonic epithelial cells (CECs). DNA damage levels in CECs were confirmed using the human induced pluripotent stem cell-derived gut organoid model and mouse colon tissues in vivo. RESULTS: A odontolyticus secretes membrane vesicles (MVs), which induce nuclear factor kappa B signaling and also produce excessive reactive oxygen species (ROS) in colon epithelial cells. We found that A odontolyticus secretes lipoteichoic acid-rich MVs, promoting inflammatory signaling via TLR2. Simultaneously, those MVs are internalized into the colon epithelial cells, co-localize with the mitochondria, and cause mitochondrial dysfunction, resulting in excessive ROS production and DNA damage. Induction of excessive DNA damage in colonic cells by A odontolyticus-derived MVs was confirmed in the gut organoid model and also in mouse colon tissues. CONCLUSIONS: A odontolyticus secretes MVs, which cause chronic inflammation and ROS production in colonic epithelial cells, leading to the initiation of CRC.

    DOI: 10.1016/j.jcmgh.2024.01.010

    PubMed

    researchmap

  • CA19-9-Positive Extracellular Vesicle Is a Risk Factor for Cancer-Associated Thrombosis in Pancreatic Cancer. 査読 国際誌

    Chikako Shibata, Motoyuki Otsuka, Kazunaga Ishigaki, Takahiro Seimiya, Takahiro Kishikawa, Mitsuhiro Fujishiro

    Gastro hep advances   3 ( 4 )   551 - 561   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: Cancer-associated venous thromboembolism (VTE) is a frequent complication associated with high mortality in patients with cancer, particularly pancreatic cancer. While biological factors such as coagulation factors released from cancer cells may underlie the mechanisms of cancer-associated VTE, the detailed mechanisms have not been determined. Here, we aimed to determine whether extracellular vesicles carrying a glycan sialyl-Lewisa, known as carbohydrate antigen 19-9 (CA19-9), which is a clinically used serum tumor marker and selectin ligand, are a significant cause of cancer-associated VTE. METHODS: Risk factors for cancer-associated VTE were determined using clinical data. EVs derived from CA19-9-deficient or overexpressing pancreatic cancer cells were characterized. The protein levels of coagulation factors on the surface of the EVs were quantified using our newly developed sensitive method. RESULTS: Higher CA19-9 levels in the sera of patients were significantly associated with the occurrence of VTE. Using CA19-9-negative or overexpressing pancreatic cancer cells, we found that EVs derived from these cells interacted with E-selectin of endothelial cells in a CA19-9-dependent manner in cell-based assays and in vitro blood vessel models. EVs derived from cancer cells have higher tissue factor levels on their surfaces, and increased tissue factor activity is induced locally, where CA19-9-positive EVs bind to activated endothelial cells. CONCLUSION: These results suggest that the binding between CA19-9-positive EVs released from cancer cells and endothelial cell E-selectin explains the increased frequency of VTE in patients with pancreatic cancer.

    DOI: 10.1016/j.gastha.2024.02.005

    PubMed

    researchmap

  • MicroRNA-451a inhibits gemcitabine-refractory biliary tract cancer progression by suppressing the MIF-mediated PI3K/AKT pathway. 査読 国際誌

    Taisuke Obata, Koichiro Tsutsumi, Eijiro Ueta, Takashi Oda, Tatsuya Kikuchi, Soichiro Ako, Yuki Fujii, Tatsuhiro Yamazaki, Daisuke Uchida, Kazuyuki Matsumoto, Shigeru Horiguchi, Hironari Kato, Hiroyuki Okada, Motoyuki Otsuka

    Molecular therapy. Nucleic acids   34   102054 - 102054   2023年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Gemcitabine is an effective chemotherapeutic agent for biliary tract cancers (BTCs), including gallbladder cancer (GBC) and cholangiocarcinoma (CCA). However, few other effective agents are currently available, particularly for GEM-refractory BTCs. We previously identified microRNA-451a (miR-451a) as a potential therapeutic target in GBC. To elucidate the antineoplastic effects of miR-451a and its underlying mechanisms, we transfected miR-451a into GBC, gemcitabine-resistant GBC (GR-GBC), and gemcitabine-resistant CCA (GR-CCA) cell lines. Furthermore, mimicking in vivo conditions, tumorigenic GBC organoids and three-dimensional (3D) cell culture systems were employed to investigate the anti-proliferative effects of miR-451a on BTCs, and its effect on stem cell properties. We found that miR-451a significantly inhibited cell proliferation, induced apoptosis, and reduced chemoresistant phenotypes, such as epithelial-mesenchymal transition, in both GBC and GR-GBC. The principal mechanism is probably the negative regulation of the phosphatidylinositol 3-kinase/AKT pathway, partially accomplished by directly downregulating macrophage migration inhibitory factor. The Gene Expression Omnibus database revealed that miR-451a was the most significantly downregulated microRNA in CCA tissues. The introduction of miR-451a resulted in similar antineoplastic effects in GR-CCA. Furthermore, miR-451a reduced cell viability in 3D spheroid models and tumorigenic GBC organoids. These findings suggest that the supplementation of miR-451a is a potential treatment strategy for GEM-refractory BTCs.

    DOI: 10.1016/j.omtn.2023.102054

    PubMed

    researchmap

  • Cabozantinib inhibits HBV-RNA transcription by decreasing STAT3 binding to the enhancer region of cccDNA. 査読 国際誌

    Kazuyoshi Funato, Nozomi Miyake, Kazuma Sekiba, Yu Miyakawa, Takahiro Seimiya, Chikako Shibata, Takahiro Kishikawa, Motoyuki Otsuka

    Hepatology communications   7 ( 11 )   2023年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Precision medicine and customized therapeutics based on the features of each patient are important for maximizing therapeutic effects. Because most cases of HCC occur in the damaged liver through various etiologies, such as hepatitis virus infection, steatohepatitis, and autoimmune hepatitis, there should be a rationale for the choice of therapeutic options based on these etiologies. Although cabozantinib, an oral multikinase inhibitor, has demonstrated clinical effectiveness in advanced HCC, subgroup analyses showed a lower HR for death in HBV-related HCC. This study aimed to determine the therapeutic effects of cabozantinib in HBV-related HCC. METHODS: Using HBV infection models and gene knockout cells, we determined the crucial signaling axis responsible for the effects of cabozantinib on HBV. A chromatin immunoprecipitation assay was performed to determine the interaction between the signaling molecules and HBV DNA. Agonists and inhibitors were used for confirmation. RESULTS: Cabozantinib inhibited HBV replication through the HGF-mesenchymal-epithelial transition factor-signal transducer and activator of transcription 3 (MET-STAT3) signaling axis. The importance of STAT3 in viral replication has been confirmed using gene-edited STAT3 knockout cells. The chromatin immunoprecipitation assay revealed that the binding levels of phosphorylated STAT3 to enhancer region 1 of HBV covalently closed circular DNA were significantly increased by HGF stimulation. CONCLUSIONS: Cabozantinib has favorable therapeutic effects on HBV-related HCC because it inhibits HCC not only directly but also indirectly by means of inhibitory effects on HBV.

    DOI: 10.1097/HC9.0000000000000313

    PubMed

    researchmap

  • Extracellular vesicle‑mediated RNA editing may underlie the heterogeneity and spread of hepatocellular carcinoma in human tissue and in vitro. 査読 国際誌

    Chikako Shibata, Motoyuki Otsuka, Takayuki Shimizu, Takahiro Seimiya, Takahiro Kishikawa, Taku Aoki, Mitsuhiro Fujishiro

    Oncology reports   50 ( 5 )   2023年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Extracellular vesicles (EVs) produced by various cells, including tumor cells, carry biomolecules to neighboring cells. In hepatocellular carcinoma (HCC), adenosine to inosine RNA editing of antizyme inhibitor 1 (AZIN1), specifically regulated by adenosine deaminase acting on RNA‑1 (ADAR1), promotes carcinogenesis. The present study examined if EVs and ADAR1 in the EVs released from HCC cells are transferred to neighboring cells in co‑culture systems and reporter assay. Distribution of the ADAR1 expression in human tissues were examined by immunohistochemistry. EVs released from HCC cells containing ADAR1 were delivered to neighboring HCC cells and non‑cancerous hepatocytes. The increased ADAR1 protein levels resulted in serine to glycine substitution at residue 367 of AZIN1, which augmented transformation potential and increased aggressive behavior of cancer cells. In clinically resected samples, ADAR1 distribution was highly heterogeneous within the tumor specimen and denser in non‑cancerous tissue surrounding the HCC tissue. These observations suggested that ADAR1 protein may be delivered from HCC cells to neighboring cells via EVs and that EV‑mediated RNA editing may serve a pivotal role in determining HCC heterogeneity and spread.

    DOI: 10.3892/or.2023.8631

    PubMed

    researchmap

  • An unusual case of gastric polyposis. 査読 国際誌

    Masaya Iwamuro, Seiji Kawano, Motoyuki Otsuka

    Gastroenterology   165 ( 5 )   1110 - 1113   2023年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2023.07.027

    PubMed

    researchmap

  • A rare case of severe colitis associated with a pancreatic neuroendocrine tumor. 査読 国際誌

    Ryosuke Sato, Shigeru Horiguchi, Motoyuki Otsuka

    Gastroenterology   166 ( 1 )   e13-e16   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2023.07.012

    PubMed

    researchmap

  • Machine learning for individualized prediction of hepatocellular carcinoma development after the eradication of hepatitis C virus with antivirals. 査読 国際誌

    Tatsuya Minami, Masaya Sato, Hidenori Toyoda, Satoshi Yasuda, Tomoharu Yamada, Takuma Nakatsuka, Kenichiro Enooku, Hayato Nakagawa, Hidetaka Fujinaga, Masashi Izumiya, Yasuo Tanaka, Motoyuki Otsuka, Takamasa Ohki, Masahiro Arai, Yoshinari Asaoka, Atsushi Tanaka, Kiyomi Yasuda, Hideaki Miura, Itsuro Ogata, Toshiro Kamoshida, Kazuaki Inoue, Ryo Nakagomi, Masatoshi Akamatsu, Hiroshi Mitsui, Hajime Fujie, Keiji Ogura, Koji Uchino, Hideo Yoshida, Kazuyuki Hanajiri, Tomonori Wada, Kiyohiko Kurai, Hisato Maekawa, Yuji Kondo, Shuntaro Obi, Takuma Teratani, Naohiko Masaki, Kayo Nagashima, Takashi Ishikawa, Naoya Kato, Hiroshi Yotsuyanagi, Kyoji Moriya, Takashi Kumada, Mitsuhiro Fujishiro, Kazuhiko Koike, Ryosuke Tateishi

    Journal of hepatology   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: Accurate risk stratification for hepatocellular carcinoma (HCC) after achieving a sustained viral response (SVR) is necessary for optimal surveillance. We aimed to develop and validate a machine learning (ML) model to predict the risk of HCC after achieving an SVR in individual patients. METHODS: In this multicenter cohort study, 1742 patients with chronic hepatitis C who achieved an SVR were enrolled. Five ML models were developed including DeepSurv, gradient boosting survival analysis, random survival forest (RSF), survival support vector machine, and a conventional Cox proportional hazard model. Model performance was evaluated using Harrel' c-index and was externally validated in an independent cohort (977 patients). RESULTS: During the mean observation period of 5.4 years, 122 patients developed HCC (83 in the derivation cohort and 39 in the external validation cohort). The RSF model showed the best discrimination ability using seven parameters at the achievement of an SVR with a c-index of 0.839 in the external validation cohort and a high discriminative ability when the patients were categorized into three risk groups (P <0.001). Furthermore, this RSF model enabled the generation of an individualized predictive curve for HCC occurrence for each patient with an app available online. CONCLUSIONS: We developed and externally validated an RSF model with good predictive performance for the risk of HCC after an SVR. The application of this novel model is available on the website. This model could provide the data to consider an effective surveillance method. Further studies are needed to make recommendations for surveillance policies tailored to the medical situation in each country. IMPACT AND IMPLICATIONS: A novel prediction model for HCC occurrence in patients after hepatitis C virus eradication was developed using machine learning algorithms. This model, using seven commonly measured parameters, has been shown to have a good predictive ability for HCC development and could provide a personalized surveillance system.

    DOI: 10.1016/j.jhep.2023.05.042

    PubMed

    researchmap

  • Recent advances in extracellular vesicles in gastrointestinal cancer and lymphoma. 査読 国際誌

    Motoyuki Otsuka, Ai Kotani

    Cancer science   114 ( 6 )   2230 - 2237   2023年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Extracellular vesicles (EVs) are intercellular communication agents that transfer microRNAs (miRNAs), other non-coding RNAs (ncRNAs), messenger RNAs (mRNAs), proteins, lipids, metabolites, and other molecules from donor cells (e.g., cancer cells) to recipient cells (e.g., stromal cells). In 2007, miRNAs were reported to be abundant among the ncRNAs present in EVs. Since then, many studies have investigated the functions of miRNAs and have attempted to apply these molecules to aid in the diagnosis and treatment of cancer. Research on EVs has expanded, particularly in the field of cancer, because cancer cells heavily secrete EVs. The cargo of these EVs, especially those in small EVs such as exosomes, is assumed to work cooperatively and significantly in the tumor microenvironment and to promote metastasis. In this review, we first summarize recent studies on EVs in gastrointestinal cancer and highlight studies on human satellite II RNAs, which are a type of ncRNA found in EVs and possessing repetitive sequences. Second, since several recent studies have revealed that phospholipids, which are components of EV membranes, play important roles in intercellular communication and in the generation of lipid mediators in the tumor microenvironment, we review the reported roles of these molecules and discuss their potential use in the design of new cancer treatments.

    DOI: 10.1111/cas.15771

    PubMed

    researchmap

  • Combination of serum human satellite RNA and miR-21-5p levels as a biomarker for pancreatic cancer. 査読 国際誌

    Takahiro Seimiya, Tatsunori Suzuki, Takuma Iwata, Takahiro Kishikawa, Kazuma Sekiba, Chikako Shibata, Kazunaga Ishigaki, Hiroaki Fujiwara, Hiroki Oyama, Sachiko Kanai, Tatsuya Sato, Yousuke Nakai, Rei Ishibashi, Masaru Moriyama, Ryo Nakagawa, Hideaki Ijichi, Motoyuki Otsuka, Kazuhiko Koike

    iScience   26 ( 2 )   106021 - 106021   2023年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis due to the difficulty of its diagnosis. Because human satellite II (HSATII) RNA, a satellite repeat RNA, is highly and specifically expressed in human PDAC, the serum HSATII RNA level may be a biomarker of PDAC. To measure the serum HSATII RNA level with high sensitivity and reproducibility, we previously developed a convenient method, tandem repeat amplification by nuclease protection (TRAP) combined with droplet digital PCR (ddPCR). Here, we refined the original method by simultaneously measuring the serum miR-21-5p level to enhance the detection of PDAC. The resulting PDAC-Index, constructed using serum HSATII RNA and miR-21-5p levels, discriminated patients with PDAC with high accuracy. We verified the clinical usefulness of the PDAC-Index as a supportive test in difficult-to-diagnose cases. The PDAC-Index has satisfactory diagnostic performance and may routinely be applied for detecting PDAC.

    DOI: 10.1016/j.isci.2023.106021

    PubMed

    researchmap

  • Overcoming T-cell exhaustion: new therapeutic targets in HCC immunotherapy. 招待 査読 国際誌

    Takahiro Seimiya, Motoyuki Otsuka, Mitsuhiro Fujishiro

    Hepatology (Baltimore, Md.)   78 ( 4 )   1009 - 1011   2023年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1097/HEP.0000000000000039

    PubMed

    researchmap

  • Lipolysis by pancreatic cancer-derived extracellular vesicles in cancer-associated cachexia via specific integrins. 査読 国際誌

    Chikako Shibata, Motoyuki Otsuka, Takahiro Seimiya, Takahiro Kishikawa, Kazunaga Ishigaki, Mitsuhiro Fujishiro

    Clinical and translational medicine   12 ( 11 )   e1089   2022年11月

     詳細を見る

    記述言語:英語  

    DOI: 10.1002/ctm2.1089

    PubMed

    researchmap

  • Circulating Tumor DNA Guiding Adjuvant Therapy in Colon Cancer. 査読 国際誌

    Motoyuki Otsuka

    The New England Journal of Medicine   387 ( 8 )   759 - 760   2022年8月

     詳細を見る

    記述言語:英語  

    DOI: 10.1056/NEJMc2209374

    PubMed

    researchmap

  • MNX1-HNF1B Axis Is Indispensable for Intraductal Papillary Mucinous Neoplasm Lineages. 査読 国際誌

    Hiroyuki Kato, Keisuke Tateishi, Hiroaki Fujiwara, Takuma Nakatsuka, Keisuke Yamamoto, Yotaro Kudo, Yoku Hayakawa, Hayato Nakagawa, Yasuo Tanaka, Hideaki Ijichi, Motoyuki Otsuka, Dosuke Iwadate, Hiroki Oyama, Sachiko Kanai, Kensaku Noguchi, Tatsunori Suzuki, Tatsuya Sato, Ryunosuke Hakuta, Kazunaga Ishigaki, Kei Saito, Tomotaka Saito, Naminatsu Takahara, Takahiro Kishikawa, Tsuyoshi Hamada, Ryota Takahashi, Koji Miyabayashi, Suguru Mizuno, Hirofumi Kogure, Yousuke Nakai, Yoshihiro Hirata, Atsushi Toyoda, Kazuki Ichikawa, Wei Qu, Shinichi Morishita, Junichi Arita, Mariko Tanaka, Tetsuo Ushiku, Kiyoshi Hasegawa, Mitsuhiro Fujishiro, Kazuhiko Koike

    Gastroenterology   162 ( 4 )   1272 - 1287   2022年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND & AIMS: Chromatin architecture governs cell lineages by regulating the specific gene expression; however, its role in the diversity of cancer development remains unknown. Among pancreatic cancers, pancreatic ductal adenocarcinoma (PDAC) and intraductal papillary mucinous neoplasms (IPMN) with an associated invasive carcinoma (IPMNinv) arise from 2 distinct precursors, and their fundamental differences remain obscure. Here, we aimed to assess the difference of chromatin architecture regulating the transcriptional signatures or biological features in pancreatic cancers. METHODS: We established 28 human organoids from distinct subtypes of pancreatic tumors, including IPMN, IPMNinv, and PDAC. We performed exome sequencing (seq), RNA-seq, assay for transposase-accessible chromatin-seq, chromatin immunoprecipitation-seq, high-throughput chromosome conformation capture, and phenotypic analyses with short hairpin RNA or clustered regularly interspaced short palindromic repeats interference. RESULTS: Established organoids successfully reproduced the histology of primary tumors. IPMN and IPMNinv organoids harbored GNAS, RNF43, or KLF4 mutations and showed the distinct expression profiles compared with PDAC. Chromatin accessibility profiles revealed the gain of stomach-specific open regions in IPMN and the pattern of diverse gastrointestinal tissues in IPMNinv. In contrast, PDAC presented an impressive loss of accessible regions compared with normal pancreatic ducts. Transcription factor footprint analysis and functional assays identified that MNX1 and HNF1B were biologically indispensable for IPMN lineages. The upregulation of MNX1 was specifically marked in the human IPMN lineage tissues. The MNX1-HNF1B axis governed a set of genes, including MYC, SOX9, and OLFM4, which are known to be essential for gastrointestinal stem cells. High-throughput chromosome conformation capture analysis suggested the HNF1B target genes to be 3-dimensionally connected in the genome of IPMNinv. CONCLUSIONS: Our organoid analyses identified the MNX1-HNF1B axis to be biologically significant in IPMN lineages.

    DOI: 10.1053/j.gastro.2021.12.254

    PubMed

    researchmap

  • WWP1 inactivation enhances efficacy of PI3K inhibitors while suppressing their toxicities in breast cancer models. 査読 国際誌

    Takahiro Kishikawa, Hiroshi Higuchi, Limei Wang, Nivedita Panch, Valerie Maymi, Sachem Best, Samuel Lee, Genso Notoya, Alex Toker, Lydia E Matesic, Gerburg M Wulf, Wenyi Wei, Motoyuki Otsuka, Kazuhiko Koike, John G Clohessy, Yu-Ru Lee, Pier Paolo Pandolfi

    The Journal of clinical investigation   131 ( 24 )   2021年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway is a pervasive event in tumorigenesis due to PI3K mutation and dysfunction of phosphatase and tensin homolog deleted on chromosome 10 (PTEN). Pharmacological inhibition of PI3K has resulted in variable clinical outcomes, however, raising questions regarding the possible mechanisms of unresponsiveness and resistance to treatment. WWP1 is an oncogenic HECT-type ubiquitin E3 ligase frequently amplified and mutated in multiple cancers, as well as in the germ lines of patients predisposed to cancer, and was recently found to activate PI3K signaling through PTEN inactivation. Here, we demonstrate that PTEN dissociated from the plasma membrane upon treatment with PI3K inhibitors through WWP1 activation, whereas WWP1 genetic or pharmacological inhibition restored PTEN membrane localization, synergizing with PI3K inhibitors to suppress tumor growth both in vitro and in vivo. Furthermore, we demonstrate that WWP1 inhibition attenuated hyperglycemia and the consequent insulin feedback, which is a major tumor-promoting side effect of PI3K inhibitors. Mechanistically, we found that AMPKα2 was ubiquitinated and, in turn, inhibited in its activatory phosphorylation by WWP1, whereas WWP1 inhibition facilitated AMPKα2 activity in the muscle to compensate for the reduction in glucose uptake observed upon PI3K inhibition. Thus, our identification of the cell-autonomous and systemic roles of WWP1 inhibition expands the therapeutic potential of PI3K inhibitors and reveals new avenues of combination cancer therapy.

    DOI: 10.1172/JCI140436

    PubMed

    researchmap

  • HBx-induced degradation of Smc5/6 complex impairs homologous recombination-mediated repair of damaged DNA. 査読 国際誌

    Kazuma Sekiba, Motoyuki Otsuka, Kazuyoshi Funato, Yu Miyakawa, Eri Tanaka, Takahiro Seimiya, Mari Yamagami, Takeya Tsutsumi, Kazuya Okushin, Kei Miyakawa, Akihide Ryo, Kazuhiko Koike

    Journal of hepatology   76 ( 1 )   53 - 62   2021年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND & AIMS: Hepatitis B virus (HBV) causes hepatocellular carcinoma (HCC). While the need for HBV regulatory protein X (HBx) for viral transcription via impairment of the structural maintenance of chromosome 5/6 (Smc5/6) complex was recently demonstrated, HBx is also a potent driver of HCC. However, the mechanism by which HBx expression induces hepatocarcinogenesis is unclear. METHODS: Degradation of Smc5/6 complex and accumulation of DNA damage were observed in both in vivo and in vitro HBV infection models. Rescue experiments were performed using nitazoxanide (NTZ), which inhibits degradation of the Smc5/6 complex by HBx. RESULTS: Degradation of the Smc5/6 complex triggered by HBx impaired homologous recombination (HR) repair of DNA double-strand breaks (DSBs), leading to cellular transformation. We found that DNA damage accumulated in the liver tissue of HBV-infected humanized chimeric mice, HBx-transgenic mice, and human tissues. HBx suppressed the HR repair of DSBs, including that induced by the clustered regularly interspaced short palindromic repeats-Cas9 system, in an Smc5/6-dependent manner, which was rescued by restoring the Smc5/6 complex. NTZ restored HR repair in, and colony formation by, HBx-expressing cells. CONCLUSIONS: Degradation of the Smc5/6 complex by HBx increases viral transcription and promotes cellular transformation by impairing HR repair of DSBs. LAY SUMMARY: HBV regulatory protein X (HBx) degrades the structural maintenance of chromosome 5/6 (Smc5/6) complex, which is required for viral replication. We found that degradation of the Smc5/6 complex also plays a key role in the accumulation of DNA damage, as well as in HBx-mediated tumorigenesis.

    DOI: 10.1016/j.jhep.2021.08.010

    PubMed

    researchmap

  • Impact of Obesity and Heavy Alcohol Consumption on Hepatocellular Carcinoma Development after HCV Eradication with Antivirals. 査読 国際誌

    Tatsuya Minami, Ryosuke Tateishi, Naoto Fujiwara, Ryo Nakagomi, Takuma Nakatsuka, Masaya Sato, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Hidetaka Fujinaga, Masashi Izumiya, Kazuyuki Hanajiri, Yoshinari Asaoka, Yuji Kondo, Yasuo Tanaka, Motoyuki Otsuka, Takamasa Ohki, Masahiro Arai, Atsushi Tanaka, Kiyomi Yasuda, Hideaki Miura, Itsuro Ogata, Toshiro Kamoshida, Kazuaki Inoue, Yukihiro Koike, Masatoshi Akamatsu, Hiroshi Mitsui, Hajime Fujie, Keiji Ogura, Hideo Yoshida, Tomonori Wada, Kiyohiko Kurai, Hisato Maekawa, Shuntaro Obi, Takuma Teratani, Naohiko Masaki, Kayo Nagashima, Takashi Ishikawa, Naoya Kato, Kyoji Moriya, Hiroshi Yotsuyanagi, Kazuhiko Koike

    Liver cancer   10 ( 4 )   309 - 319   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background and Aims: It remains unclear whether obesity increases the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C who achieved a sustained virological response (SVR) with antiviral therapy. Methods: In this multicenter cohort study, we enrolled patients with chronic hepatitis C who achieved SVR with interferon (IFN)-based therapy (IFN group) or direct-acting antiviral (DAA) therapy (DAA group) between January 1, 1990, and December 31, 2018. The patients underwent regular surveillance for HCC. Cumulative incidence of and the risk factors for HCC development after SVR were assessed using the Kaplan-Meier method and Cox proportional hazard regression analysis, respectively. Results: Among 2,055 patients (840 in the IFN group and 1,215 in the DAA group), 75 developed HCC (41 in the IFN group and 34 in the DAA group) during the mean observation period of 4.1 years. The incidence rates of HCC at 1, 2, and 3 years were 1.2, 1.9, and 3.0%, respectively. Multivariate analysis revealed that in addition to older age, lower albumin level, lower platelet count, higher alpha-fetoprotein level, and absence of dyslipidemia, obesity (body mass index ≥25 kg/m2) and heavy alcohol consumption (≥60 g/day) were independent risk factors for HCC development, with adjusted hazard ratio (HR) of 2.53 (95% confidence interval [CI]: 1.51-4.25) and 2.56 (95% CI: 1.14-5.75), respectively. The adjusted HR was not significant between the 2 groups (DAA vs. IFN; HR 1.19, 95% CI: 0.61-2.33). Conclusions: Obesity and heavy alcohol consumption increased the risk of HCC development after SVR.

    DOI: 10.1159/000513705

    PubMed

    researchmap

  • Aberrant expression of a novel circular RNA in pancreatic cancer. 査読 国際誌

    Takahiro Seimiya, Motoyuki Otsuka, Takuma Iwata, Eri Tanaka, Kazuma Sekiba, Chikako Shibata, Masaru Moriyama, Ryo Nakagawa, Reo Maruyama, Kazuhiko Koike

    Journal of human genetics   66 ( 2 )   181 - 191   2021年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Circular RNAs (circRNAs) are single-stranded, covalently closed RNA molecules that are produced from pre-mRNAs through a process known as back-splicing. Although circRNAs are expressed under specific conditions, current understanding of their comprehensive expression status is still limited. Here, we performed a large-scale circRNA profiling analysis in human pancreatic ductal adenocarcinoma (PDAC) tissues, using circular RNA-specific RNA sequencing. We identified more than 40,000 previously unknown circRNAs, some of which were upregulated in PDAC tissues, compared with normal pancreatic tissues. We determined the full-length sequence of a circRNA upregulated in PDAC, which was derived from two noncoding RNA loci on chromosome 12. The novel circRNA, named circPDAC RNA, was not expressed in normal human cells, but was expressed in PDAC and other carcinoma cells. While postulated biological functions, such as peptide production from the circPDAC RNA, were not detected, its aberrant expression was confirmed in other PDAC tissues and in serum from a PDAC patient. These results demonstrate that comprehensive studies are necessary to reveal the expression status of circRNAs and that the circPDAC RNA identified here might serve as a novel biomarker for cancers, including PDAC.

    DOI: 10.1038/s10038-020-00826-5

    PubMed

    researchmap

  • Should Level of HBV RNA be Used to Determine When Patients Should Stop Treatment With Nucleos(t)ide Analogues. 査読 国際誌

    Motoyuki Otsuka, Kazuhiko Koike

    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association   18 ( 3 )   551 - 552   2020年3月

     詳細を見る

  • Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus. 査読 国際誌

    Kazuma Sekiba, Motoyuki Otsuka, Motoko Ohno, Mari Yamagami, Takahiro Kishikawa, Takahiro Seimiya, Tatsunori Suzuki, Eri Tanaka, Rei Ishibashi, Kazuyoshi Funato, Kazuhiko Koike

    Hepatology (Baltimore, Md.)   69 ( 5 )   1903 - 1915   2019年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatitis B virus (HBV) infection is a major health concern worldwide. To prevent HBV-related mortality, elimination of viral proteins is considered the ultimate goal of HBV treatment; however, currently available nucleos(t)ide analogs rarely achieve this goal, as viral transcription from episomal viral covalently closed circular DNA (cccDNA) is not prevented. HBV regulatory protein X was recently found to target the protein structural maintenance of chromosomes 5/6 (Smc5/6) for ubiquitination and degradation by DDB1-CUL4-ROC1 E3 ligase, resulting in enhanced viral transcription from cccDNA. This ubiquitin-dependent proteasomal pathway requires an additional ubiquitin-like protein for activation, neuronal precursor cell-expressed developmentally down-regulated protein 8 (NEDD8). Here, we show that pevonedistat, a NEDD8-activating enzyme inhibitor, works efficiently as an antiviral agent. Pevonedistat significantly restored Smc5/6 protein levels and suppressed viral transcription and protein production in the HBV minicircle system in in vitro HBV replication models and in human primary hepatocytes infected naturally with HBV. Conclusion: These results indicate that pevonedistat is a promising compound to treat chronic HBV infection.

    DOI: 10.1002/hep.30491

    PubMed

    researchmap

  • Repression of MicroRNA Function Mediates Inflammation-associated Colon Tumorigenesis 査読

    Takeshi Yoshikawa, Jianfeng Wu, Motoyuki Otsuka, Takahiro Kishikawa, Nobumi Suzuki, Akemi Takata, Motoko Ohno, Rei Ishibashi, Mari Yamagami, Ryo Nakagawa, Naoya Kato, Masaaki Miyazawa, Jiahuai Han, Kazuhiko Koike

    Gastroenterology   152 ( 3 )   631 - 643   2017年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2016.10.043

    Web of Science

    PubMed

    researchmap

  • Satellite RNAs promote pancreatic oncogenic processes via the dysfunction of YBX1 査読

    Takahiro Kishikawa, Motoyuki Otsuka, Takeshi Yoshikawa, Motoko Ohno, Hideaki Ijichi, Kazuhiko Koike

    Nature Communications   7 ( 1 )   13006   2016年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/ncomms13006

    Web of Science

    PubMed

    researchmap

  • Quantitation of circulating satellite RNAs in pancreatic cancer patients. 査読 国際誌

    Takahiro Kishikawa, Motoyuki Otsuka, Takeshi Yoshikawa, Motoko Ohno, Keisuke Yamamoto, Natsuyo Yamamoto, Ai Kotani, Kazuhiko Koike

    JCI insight   1 ( 8 )   e86646   2016年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pancreatic ductal adenocarcinoma (Pdac) is a malignancy with a poor prognosis due to difficulties in early detection. Although promising biomarkers are increasingly reported, such methods are not yet easy to apply clinically, mainly due to their low reproducibility or technical difficulties. In this study, we developed a convenient and sensitive method for quantifying aberrantly expressed satellite repeat RNAs in sera, which can be used to efficiently detect patients with Pdac. Here, we introduce a Tandem Repeat Amplification by nuclease Protection (TRAP) method combined with droplet digital PCR (ddPCR) to detect human satellite II (HSATII) RNAs, which are specifically expressed in human Pdacs at greater levels than normal tissues but are difficult to measure due to their repetitive sequences and irregularities. HSATII RNA core sequence levels in sera were significantly higher in Pdac patients compared with noncancer patients (median copy number: 14.75 and 3.17 per μl in the training set and 17.35 and 2.9 in the validation set, respectively). In addition, patients with intraductal papillary mucinous neoplasm (IPMN), a precancerous lesion of Pdac, could also be efficiently detected. This method can be routinely applied to screen patients with Pdac and high-risk patients, facilitating the development of preventive medicine for this disease.

    DOI: 10.1172/jci.insight.86646

    PubMed

    researchmap

  • Regulation of NKT cell-mediated immune responses to tumours and liver inflammation by mitochondrial PGAM5-Drp1 signalling 査読

    Young Jun Kang, Bo-Ram Bang, Kyung Ho Han, Lixin Hong, Eun-Jin Shim, Jianhui Ma, Richard A. Lerner, Motoyuki Otsuka

    Nature Communications   6 ( 1 )   8371   2015年12月

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Springer Science and Business Media {LLC}  

    DOI: 10.1038/ncomms9371

    PubMed

    researchmap

  • The TNF Family Member 4-1BBL Sustains Inflammation by Interacting with TLR Signaling Components During Late-Phase Activation 査読

    Jianhui Ma, Bo-Ram Bang, Jiawei Lu, So-Young Eun, Motoyuki Otsuka, Michael Croft, Peter Tobias, Jiahuai Han, Osamu Takeuchi, Shizuo Akira, Michael Karin, Hideo Yagita, Young Jun Kang

    Science Signaling   6 ( 295 )   ra87   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1126/scisignal.2004431

    Web of Science

    PubMed

    researchmap

  • Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. 査読

    Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K, Ikeda S, Hirayama A, Yamamoto T, Yoshida H, Otsuka M, Tsuji S, Yatomi Y, Sakuragawa T, Watanabe H, Nihei K, Saito T, Kawata S, Suzuki H, Tomita M, Suematsu M

    Journal of Hepatology   55 ( 4 )   896 - 905   2011年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.jhep.2011.01.031

    Web of Science

    PubMed

    researchmap

  • MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. 査読

    Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, Kondo Y, Kang YJ, Kishikawa T, Kato N, Xie Z, Zhang WJ, Yoshida H, Omata M, Nepveu A, Koike K

    Nature Communications   2   338   2011年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/ncomms1345

    Web of Science

    PubMed

    researchmap

  • Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma 査読

    Nature Genetics   43 ( 5 )   455 - +   2011年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/ng.809

    Web of Science

    PubMed

    researchmap

  • Distinct Effects of p38 alpha Deletion in Myeloid Lineage and Gut Epithelia in Mouse Models of Inflammatory Bowel Disease 査読

    Gastroenterology   138 ( 4 )   1255 - U83   2010年4月

     詳細を見る

  • Impaired microRNA processing causes corpus luteum insufficiency and infertility in mice 査読

    Journal of Clinical Investigation   118 ( 5 )   1944 - 1954   2008年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1172/JCI33680

    Web of Science

    PubMed

    researchmap

  • Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression 査読

    Immunity   27 ( 1 )   123 - 134   2007年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.immuni.2007.05.014

    Web of Science

    PubMed

    CiNii Article

    researchmap

  • Cell surface 4-1BBL mediates sequential signaling pathways 'downstream' of TLR and is required for sustained TNF production in macrophages 査読

    Nature Immunology   8 ( 6 )   601 - 609   2007年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/ni1471

    Web of Science

    PubMed

    CiNii Article

    researchmap

  • Endoscopic ultrasound-guided ethanol injection with prophylactic pancreatic stenting for a pancreatic neuroendocrine neoplasm. 国際誌

    Kazuyuki Matsumoto, Yuki Fujii, Daisuke Uchida, Akihiro Matsumi, Kazuya Miyamoto, Ryosuke Sato, Motoyuki Otsuka

    Endoscopy   57 ( S 01 )   E537-E538   2025年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1055/a-2603-5560

    PubMed

    researchmap

  • Underwater endoscopic papillectomy of a duodenal adenoma extending to the papilla using a forward-viewing endoscope. 国際誌

    Takashi Yamamoto, Yasushi Yamasaki, Yuki Fujii, Kazuyuki Matsumoto, Motoyuki Otsuka

    Endoscopy   57 ( S 01 )   E667-E668   2025年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1055/a-2616-8142

    PubMed

    researchmap

  • Temporal changes in computed tomography findings of a persimmon bezoar: A case report. 国際誌

    Masaya Iwamuro, Tomoki Yoshikawa, Tomohiro Kamio, Shoichiro Hirata, Katsunori Matsueda, Daisuke Kametaka, Motoyuki Otsuka

    World journal of clinical cases   13 ( 18 )   103426 - 103426   2025年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Gastric bezoars are masses of indigestible material that accumulate in the stomach, causing nausea, abdominal pain, and vomiting. Persimmon bezoars (diospyrobezoars), which comprise tannins and fibers from persimmons, are relatively rare but may cause significant gastric complications, including gastric outlet obstruction or ileus. Although computed tomography (CT) is a useful imaging tool, diagnosing bezoars can be challenging because their density is similar to that of food debris and gastric content. CASE SUMMARY: Here, we report the case of a 72-year-old woman with a persimmon bezoar that was diagnosed using serial CT imaging and confirmed by endoscopy. CT performed over several months revealed changes in the internal structure and density of the bezoar, suggesting progressive hardening. The patient had a history of a partial gastrectomy and excessive persimmon consumption, both of which are risk factors for bezoar formation. Endoscopic fragmentation of the bezoar successfully resolved symptoms. CONCLUSION: Gastric bezoars, particularly persimmon bezoars, present diagnostic challenges because of their variable imaging characteristics. Serial CT can document temporal changes in bezoar density, potentially reflecting changes in hardness. Early diagnosis and endoscopic treatment are essential for effective management, particularly in patients with predisposing factors. This case underscores the importance of considering bezoars in the differential diagnosis of gastric masses, and highlights the value of CT for monitoring changes in bezoar characteristics over time.

    DOI: 10.12998/wjcc.v13.i18.103426

    PubMed

    researchmap

  • Distinct age-related effects of homologous recombination deficiency on genomic profiling and treatment efficacy in gastric cancer.

    Yoshie Maki, Yoshiyasu Kono, Toshiki Ozato, Hideki Yamamoto, Akira Hirasawa, Daisuke Ennishi, Shuta Tomida, Shinichi Toyooka, Kenta Hamada, Masaya Iwamuro, Seiji Kawano, Motoyuki Otsuka

    Journal of gastroenterology   2025年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The incidence of gastric cancer among younger patients is increasing globally, with growing attention being paid to the role of homologous recombination deficiency (HRD). However, the effect of HRD on treatment outcomes and prognosis in this population remains unclear. METHODS: We analyzed clinical and genomic data from the Center for Cancer Genomics and Advanced Therapeutics database. Younger patients (≤ 39 years, n = 140) were compared with older patients (≥ 65 years, n = 1118) diagnosed with gastric cancer. This study focused on mutations in homologous recombination repair (HRR) genes and their association with tumor mutation burden (TMB), microsatellite instability (MSI), and treatment outcomes. RESULTS: In older patients, HRD was associated with higher TMB and microsatellite instability-high (MSI-H) status, whereas no such correlations were observed in younger patients. Notably, MSI-H status was not observed in the younger group. Younger patients with HRD had a significantly shorter time to treatment failure (TTF) and overall survival (OS) than those without HRD. Conversely, in older patients, there was no significant difference in TTF or OS based on HRD status. CONCLUSION: HRR gene mutations influence genomic profiling, TMB, and MSI differently depending on the age of gastric cancer onset, suggesting potential effects on treatment efficacy and prognosis.

    DOI: 10.1007/s00535-025-02267-3

    PubMed

    researchmap

  • The new assay type IV collagen 7S (CLEIA) is a useful test to identify progressive fibrosis in chronic liver disease: A study based on magnetic resonance elastography. 国際誌

    Miwa Kawanaka, Takashi Fushimi, Tomohiro Tanikawa, Noriiyo Urata, Ken Haruma, Hirofumi Kawamoto, Motoyuki Otsuka

    Hepatology research : the official journal of the Japan Society of Hepatology   2025年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Liver fibrosis is a critical prognostic factor for chronic liver disease that influences morbidity and mortality. Type IV collagen 7S, measured using a chemiluminescent enzyme immunoassay, was evaluated as a novel noninvasive biomarker with its cutoff value determined via magnetic resonance elastography (MRE) to eliminate sampling bias. A two-step approach combining the fibrosis-4 (FIB-4) index and type IV collagen 7S demonstrated potential in enhancing risk stratification and clinical utility. METHODS: This study included 307 patients with chronic liver disease and 235 with metabolic dysfunction-associated steatotic liver disease. Type IV collagen 7S was compared with biomarkers such as FIB-4 index, M2BPGi, and hyaluronic acid. Diagnostic accuracy was assessed using AUROC, sensitivity, specificity, positive predictive value (PPV), and negative predictive value, with cutoffs determined via the Youden Index. Subgroup analyses evaluated performance based on ALT levels (≤30 and >30 U/L) and age (≤60 and >60 years). A two-step risk stratification model incorporating type IV collagen 7S was developed for intermediate FIB-4 index groups (1.3-2.66) to assess its utility. RESULTS: For liver stiffness assessed using MRE, type IV collagen 7S showed the highest correlation (ρ = 0.591, p < 0.001) and outperformed other biomarkers, particularly for F ≥ 2. Its performance was notable in patients with low ALT levels (≤30 U/L) and in elderly patients (>60 years). In the intermediate FIB-4 index group, the two-stage model reduced over triage by 20%, increased specificity from 55% to 78% and enhanced PPV by 13%. CONCLUSIONS: The novel assay, type IV collagen 7S, is a highly effective and noninvasive biomarker for liver fibrosis. The performance of type IV collagen 7S tends to have robustness under the difference of ALT. Its combination with the FIB-4 index enhances diagnostic precision, particularly in intermediate-risk patients, reinforcing its role in refining fibrosis staging and optimizing patient management.

    DOI: 10.1111/hepr.14202

    PubMed

    researchmap

  • A study on the timing of small-bowel capsule endoscopy and its impact on the detection rate of bleeding sources. 国際誌

    Daisuke Kametaka, Masaya Iwamuro, Toshihiro Inokuchi, Seiji Kawano, Sakiko Hiraoka, Motoyuki Otsuka

    BMC gastroenterology   25 ( 1 )   434 - 434   2025年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Small-bowel capsule endoscopy (SBCE) is an essential diagnostic tool for obscure gastrointestinal bleeding, particularly for identifying bleeding sources in the small intestine. The timing of SBCE is thought to affect its diagnostic yield; however, the optimal timing remains unknown. METHODS: This retrospective study analyzed 131 patients with overt gastrointestinal bleeding managed with SBCE at our institution between May 2015 and December 2022. Patients were categorized into four groups based on the interval between their last bleeding episode and SBCE: 1–7, 8–14, 15–28, and ≥ 29 days. RESULTS: Positive findings were observed in approximately 50% of the cases across all intervals, with no statistically significant differences in the detection rates. Vascular lesions were detected primarily within 1–14 days, whereas inflammatory lesions, tumors, and diverticula were identified across all intervals. Notably, 25% of the patients with negative SBCE findings were later diagnosed with sources of non-small bowel bleeding, highlighting the value of follow-up endoscopic evaluations. CONCLUSIONS: Our findings suggest that SBCE can be effective regardless of the time after a bleeding event, contrary to previous recommendations emphasizing its early use. Clinicians should consider performing SBCE whenever feasible to improve the diagnostic outcomes for gastrointestinal bleeding, irrespective of the elapsed time since the last episode.

    DOI: 10.1186/s12876-025-04044-1

    PubMed

    researchmap

  • Corrigendum to Risk factors and treatment strategies for cholecystitis after metallic stent placement for malignant biliary obstruction: a multicenter retrospective study. Gastrointestinal Endoscopy. Volume 100, Issue 1, July 2024, Pages 76-84. 国際誌

    Akihiro Matsumi, Hironari Kato, Taiji Ogawa, Toru Ueki, Masaki Wato, Masakuni Fujii, Tatsuya Toyokawa, Ryo Harada, Yuki Ishihara, Masahiro Takatani, Hirofumi Tsugeno, Naoko Yunoki, Takeshi Tomoda, Toshiharu Mitsuhashi, Motoyuki Otsuka

    Gastrointestinal endoscopy   2025年6月

     詳細を見る

  • Correction: Clinical Significance of Prior Ramucirumab Use on the Effectiveness of Nivolumab as the Third-Line Regimen in Gastric Cancer: A Multicenter Retrospective Study. 国際誌

    Yuka Obayashi, Shoichiro Hirata, Yoshiyasu Kono, Makoto Abe, Koji Miyahara, Masahiro Nakagawa, Michihiro Ishida, Yasuhiro Choda, Kenta Hamada, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Motoyuki Otsuka

    Drugs - real world outcomes   12 ( 2 )   335 - 336   2025年6月

     詳細を見る

  • A novel approach to evaluate the therapeutic efficacy of durvalumab and tremelimumab combination therapy in hepatocellular carcinoma. 国際誌

    Tetsu Tomonari, Shigeo Shimose, Issei Saeki, Joji Tani, Yuichi Honma, Takanori Ito, Mamiko Takeuchi, Takehito Naito, Yasuto Takeuchi, Ryu Sasaki, Kyo Sasaki, Takeshi Hatanaka, Satoru Kakizaki, Yuki Kanayama, Atsushi Naganuma, Norikazu Tanabe, Hironori Tanaka, Yutaka Kawano, Yasushi Sato, Sohji Nishina, Hisamitsu Miyaaki, Motoyuki Otsuka, Hiroki Kawashima, Masaru Harada, Hideki Kobara, Taro Takami, Takumi Kawaguchi, Tetsuji Takayama

    Hepatology research : the official journal of the Japan Society of Hepatology   2025年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: This study aimed to evaluate the efficacy of durvalumab + tremelimumab (Dur + Tre) in real-world clinical practice, characterize "stable disease (SD)," and identify SD responders (SD-R) who benefit from Dur + Tre treatment. METHODS: This multicenter observational study included 212 patients with unresectable hepatocellular carcinoma (u-HCC) treated with Dur + Tre between March 2023 and November 2024. The patients were categorized into 95 first-line and 117 later-line cases, respectively. Sequential cutoff points for depth of response (DOR) and progression-free survival (PFS) were tested to identify subgroups with survival outcomes comparable to those of responders. RESULTS: Disease control rate (DCR) and PFS were significantly better in the first-line setting for both response evaluation criteria in solid tumors (RECIST) and modified RECIST (mRECIST) criteria. Patients who achieved PFS of ≥84 days or RECIST DOR of ≤-10% were classified as SD-R, as they had long-term survival outcomes similar to those with PR or CR. Furthermore, the CR + PR + SD-R group had significantly better survival outcomes than the other groups (p < 0.01), and multivariate analysis confirmed that SD-R was an independent prognostic factor with the strongest impact on survival outcomes (hazard ratio = 0.11). CONCLUSIONS: In real-world clinical practice, Dur + Tre is highly effective as a first-line treatment for u-HCC. Additionally, patients with SD who met the SD-R criteria (PFS ≥84 days or RECIST DOR ≤-10%) showed survival outcomes comparable to those of patients with PR or CR. These findings may help identify patients who are most likely to benefit from treatment and improve their prognoses.

    DOI: 10.1111/hepr.14212

    PubMed

    researchmap

  • Endoscopic Bridging Stent Placement Improves Bile Leaks After Hepatic Surgery. 国際誌

    Taisuke Obata, Kazuyuki Matsumoto, Kei Harada, Nao Hattori, Ryosuke Sato, Akihiro Matsumi, Kazuya Miyamoto, Hiroyuki Terasawa, Yuki Fujii, Daisuke Uchida, Shigeru Horiguchi, Koichiro Tsutsumi, Motoyuki Otsuka

    Journal of clinical medicine   14 ( 10 )   2025年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background: Endoscopic treatment is one of the first-line treatments for bile leaks after hepatic surgery. However, detailed reports of endoscopic treatment for bile leaks after hepatic resection (HR) or liver transplantation (LT) are scarce. The outcomes of endoscopic treatment for bile leaks after hepatic surgery were examined, and factors related to successful treatment were identified. Methods: A total of 122 patients underwent endoscopic treatment for bile leaks after hepatic surgery. The diagnosis of a bile leak is based on the ISGLS criteria. The decision to perform endoscopic retrograde cholangiography (ERC) is made based on the amount of drainage output, laboratory data, clinical symptoms, and CT scan findings. In our study, the site of the bile leak was assessed using ERC. Endoscopic stents were placed to bridge across the bile leak site as much as possible. Otherwise, stents were placed near the leak site. Endoscopic stents were replaced every 2-3 months until an improvement in the bile leak was observed with or without biliary strictures. The outcomes of endoscopic treatment and the factors related to clinical success were evaluated. Results: Seventy-four patients with HR and forty-eight patients with LT were treated endoscopically. Technical and clinical success was achieved in 89% (109/122) and 82% (100/122) of patients, respectively. Three (2%) patients died from uncontrollable bile leaks. Bridging stent placement (p < 0.001), coexistent percutaneous drainage (p = 0.0025), and leak severity (p = 0.015) were identified as independent factors related to the clinical success of endoscopic treatment. During a median observation period of 1162 days after the achievement of clinical success, bile leak recurrence was observed in only three cases (3%). Conclusions: Endoscopic treatment is safe and effective for bile leaks after hepatic surgery. Bridging stent placement across the leak site is the most crucial factor for clinical success.

    DOI: 10.3390/jcm14103381

    PubMed

    researchmap

  • Efficient diagnosis for endoscopic remission in Crohn's diseases by the combination of three non-invasive markers. 国際誌

    Kensuke Takei, Toshihiro Inokuchi, Sakiko Hiraoka, Mikako Ishiguro, Junki Toyosawa, Yuki Aoyama, Shoko Igawa, Keiko Takeuchi, Yasushi Yamasaki, Hideaki Kinugasa, Masahiro Takahara, Seiji Kawano, Toshiharu Mitsuhashi, Motoyuki Otsuka

    BMC gastroenterology   25 ( 1 )   364 - 364   2025年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Serum C-reactive protein (CRP), leucine-rich alpha-2 glycoprotein (LRG), and fecal calprotectin (Fcal) are non-invasive markers used to assess Crohn's disease (CD) severity. However, the accuracy of these markers alone is often limited, and most previous reports have evaluated the efficacy of each marker individually. We aimed to improve the diagnostic performance of endoscopic remission (ER) of CD by combining these 3 markers. METHODS: We tested the diagnostic ability of various combinations of these 3 markers for endoscopic severity in 230 consecutive patients with CD from September 2014 to July 2023. The modified Simple Endoscopic Score for Crohn's disease (mSES-CD) was used to determine endoscopic severity. RESULTS: Each of the 3 markers was correlated with mSED-CD (LRG: r = 0.69, CRP: r = 0.60, and Fcal: r = 0.67). A combination of 2 of the 3 markers did not increase the diagnostic accuracy of ER. However, by combining all 3 markers, the diagnostic ability for ER was improved in comparison to the diagnostic ability of the 3 individual markers, assuming that ER was obtained if 2 or 3 markers were negative. The sensitivity, specificity, and accuracy were 89%, 83%, and 86%, respectively. Additionally, we established a 2-step method using Fcal values after evaluating the 2 serum markers. This method was most useful for reducing both the patient burden and costs. CONCLUSIONS: The newly established 2-step method allowed for a higher accuracy in the non-invasive diagnosis of ER when the 3 markers were combined.

    DOI: 10.1186/s12876-025-03880-5

    PubMed

    researchmap

  • Genomic landscape and clinical impact of homologous recombination repair gene mutation in small bowel adenocarcinoma. 国際誌

    Toshiki Ozato, Yoshiyasu Kono, Shigeru Horiguchi, Koichiro Tsutsumi, Hideki Yamamoto, Akira Hirasawa, Daisuke Ennishi, Shuta Tomida, Shinichi Toyooka, Motoyuki Otsuka

    European journal of cancer (Oxford, England : 1990)   220   115401 - 115401   2025年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare malignancy with a poor prognosis and limited treatment options. Although homologous recombination deficiency has been studied as a biomarker for other cancer types, the clinical and genomic implications of homologous recombination repair (HRR) gene mutations in SBA remain unclear. METHODS: We retrospectively analyzed the data of 628 patients with advanced or recurrent SBA from a nationwide genomic database. Patients were categorized into HRR mutation and non-HRR mutation groups and compared for their clinical and genomic characteristics including tumor mutational burden (TMB) and microsatellite instability-high (MSI-H) were compared. Treatment efficacy and overall survival (OS) were assessed based on HRR gene mutation status and primary tumor site (duodenal adenocarcinoma [DA] vs. small intestinal carcinoma [SIC]). RESULTS: Patients with the HRR mutations had higher frequencies of TMB and MSI-H than those without the mutation (P < 0.0001). In DA, HRR gene mutation positivity was associated with improved OS and higher overall response rates (ORR) to platinum-based chemotherapy (OS: not reached vs. 23.5 months, P = 0.040; ORR: 33 % vs. 19 %, P = 0.046), whereas no significant associations were observed with SIC. CONCLUSION: HRR gene mutation may be a potential biomarker for platinum-based chemotherapy efficacy in SBA, especially in DA, highlighting the need for site-specific therapies.

    DOI: 10.1016/j.ejca.2025.115401

    PubMed

    researchmap

  • Successful removal of a buried lumen-apposing metal stent without complications using pancreatic drainage and a hemostatic agent. 国際誌

    Yuki Fujii, Kazuyuki Matsumoto, Motoyuki Otsuka

    Clinical endoscopy   58 ( 3 )   476 - 477   2025年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.5946/ce.2024.233

    PubMed

    researchmap

  • Pseudoachalasia Due to Malignant Pleural Mesothelioma Involving the Esophagus. 国際誌

    Manami Honda, Masaya Iwamuro, Kazuya Miyamoto, Takehiro Tanaka, Motoyuki Otsuka

    Cureus   17 ( 5 )   e84161   2025年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We report a rare case of pseudoachalasia secondary to malignant pleural mesothelioma involving the esophagus. A 66-year-old man presented with progressive dysphagia, weight loss, and postprandial hiccups. Endoscopic examination showed esophageal dilation with luminal narrowing at the esophagogastric junction, but no mucosal abnormalities. Computed tomography revealed an irregular-shaped mass extending from the peri-esophagogastric junction to the retroperitoneum, accompanied by pleural effusion, right-sided hydronephrosis, and multiple hepatic lesions. Endoscopic ultrasound-guided fine-needle aspiration from the mass lesion through the esophageal lumen revealed epithelioid malignant mesothelioma. This case highlights the importance of considering malignant mesothelioma in the differential diagnosis of pseudoachalasia, particularly when imaging reveals extrinsic esophageal compression without mucosal lesions.

    DOI: 10.7759/cureus.84161

    PubMed

    researchmap

  • High complete resection rates of underwater endoscopic mucosal resection for intermediate-sized sessile serrated lesions. 国際誌

    Junki Toyosawa, Masayasu Ohmori, Yasushi Yamasaki, Yuki Aoyama, Shoko Igawa, Keiko Takeuchi, Toshihiro Inokuchi, Hideaki Kinugasa, Masahiro Takahara, Sakiko Hiraoka, Takehiro Tanaka, Motoyuki Otsuka

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Sessile serrated lesions (SSLs) pose a risk of carcinoma, necessitating endoscopic resection. Conventional endoscopic mucosal resection (EMR) often fails to achieve complete resection for intermediate-sized SSLs. Although underwater EMR (UEMR) is being increasingly used for colon polyps, its efficacy for SSLs remains unclear. This study evaluated the complete resection rate of UEMR for intermediate-sized SSLs. METHODS: This prospective, single-arm, observational study was conducted at two institutions. Patients with endoscopically diagnosed intermediate-sized SSLs (10-20 mm) were enrolled. UEMR was performed, and specimens were histologically assessed. Post-UEMR lesions were closely examined, and biopsies were taken to check for residuals. Follow-up colonoscopy was performed 1 year later to evaluate recurrence. The primary end-point was the complete resection rate, defined as no residual in biopsy specimens. The secondary end-points were the rates of R0 resection, en bloc resection, recurrence, adverse events, and factors regarding procedural difficulty. RESULTS: In total, 103 patients with 133 lesions were consecutively identified. Twenty-seven cases with 30 lesions were excluded by criteria; 103 endoscopically diagnosed SSLs were enrolled. The median postresection lesion size was 12 mm (range 8-23). The R0 and en bloc resection rates were 61% and 91%, respectively. The overall complete resection rate was 97% (95% confidence interval 91.8-99.0%). Follow-up colonoscopy in 87 lesions showed no recurrence. Only one patient (1%) experienced delayed bleeding. Snaring difficulty was significantly associated with piecemeal resection. CONCLUSION: The complete resection rate of UEMR for intermediate-sized SSLs was acceptable. UEMR may become a standard treatment for intermediate-sized SSLs.

    DOI: 10.1111/den.15035

    PubMed

    researchmap

  • Two Cases of Esophageal Mucosal Damage Observed after Peroral Endoscopic Myotomy for Esophageal Motility Disorders.

    Shoichiro Hirata, Tomohiro Kamio, Takuya Satomi, Kenta Hamada, Hiroyuki Sakae, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Noriaki Manabe, Motoyuki Otsuka

    Internal medicine (Tokyo, Japan)   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    This report presents two cases of esophageal mucosal damage following peroral endoscopic myotomy (POEM) for esophageal motility disorders. In the first case, delayed perforation and mediastinitis occurred on postoperative day 15 and the patient was treated with endoscopic clipping and antibiotics. In the second case, although no perforation was observed, extensive mucosal injury developed the day after POEM which was successfully managed by fasting and antibiotic therapy. These findings highlight the need for careful patient management to minimize the risks associated with POEM, while maximizing its therapeutic benefits.

    DOI: 10.2169/internalmedicine.4943-24

    PubMed

    researchmap

  • Gastrointestinal Stromal Tumors in the Stomach With Tumor Growth and Hemorrhage During Conservative Management: A Report of Two Cases. 国際誌

    Masaya Iwamuro, Satoru Kikuchi, Shinji Kuroda, Takehiro Tanaka, Motoyuki Otsuka

    Cureus   17 ( 4 )   e82046   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Gastrointestinal stromal tumors (GISTs) are often detected incidentally during esophagogastroduodenoscopy. Although surgical resection is the standard treatment for GISTs, patients with significant comorbidities may not be eligible for surgery and are managed conservatively. Herein, we report two cases of gastric GISTs that were initially observed during the management of other comorbidities but subsequently became enlarged, resulting in gastrointestinal bleeding. These cases highlight the potential risks of tumor progression and bleeding in patients undergoing conservative management.

    DOI: 10.7759/cureus.82046

    PubMed

    researchmap

  • Antitumor effects and immune-mediated adverse events of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma. 国際誌

    Takanori Ito, Shigeo Shimose, Joji Tani, Tetsu Tomonari, Issei Saeki, Yasuto Takeuchi, Takeshi Hatanaka, Kyo Sasaki, Satoru Kakizaki, Yuki Kanayama, Naoki Yoshioka, Takehito Naito, Mamiko Takeuchi, Tetsuya Yasunaka, Masahiro Sakata, Hideki Iwamoto, Satoshi Itano, Tomotake Shirono, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Sohji Nishina, Motoyuki Otsuka, Taro Takami, Tetsuji Takayama, Takumi Kawaguchi, Hiroki Kawashima

    Hepatology research : the official journal of the Japan Society of Hepatology   55 ( 4 )   577 - 587   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Durvalumab plus tremelimumab (Dur/Tre) is a first-line systemic treatment option for unresectable hepatocellular carcinoma (uHCC). However, the management of severe immune-mediated adverse events (imAEs) is challenging. Therefore, we investigated the relationship between severe imAEs and antitumor responses in patients with uHCC treated with Dur/Tre. METHODS: We included 157 patients with uHCC treated with Dur/Tre in this multicenter, retrospective study and analyzed the relationship between progression-free survival (PFS)/antitumor response and severe imAEs requiring high-dose corticosteroid treatment. RESULTS: Thirty-two patients (20.4%) developed severe imAEs, including enterocolitis/diarrhea (n = 10), liver injury (n = 9), interstitial lung disease (n = 5), rashes (n = 4), cytokine-release syndrome/fever (n = 2), pancreatitis (n = 2), and others (n = 4) (median follow-up period, 6.8 months). Infliximab was administered in six patients with steroid-refractory enterocolitis. Although the objective response rate (ORR) and disease control rate (DCR) were significantly higher with first-line therapy than with later-line therapy (p = 0.026), the frequency of severe imAEs was not significantly different (p = 0.221). The ORR and DCR in patients with and without severe imAEs were 15.6% and 17.6% and 65.6% and 47.2%, respectively, with no significant differences. Five patients with severe imAEs, including rashes and liver injury, showed objective responses (partial response + complete response). Among patients who achieved an objective response, the PFS at 10 months was good (100% and 70.3% with and without high-dose corticosteroids, respectively). CONCLUSIONS: Severe imAEs of Dur/Tre treatment requiring high-dose corticosteroid treatment did not affect antitumor efficacy, which differed depending on the type of imAEs. Therefore, appropriately managing imAEs is essential to guide sequential treatment.

    DOI: 10.1111/hepr.14151

    PubMed

    researchmap

  • Frequency and Characteristics of Gastrointestinal Diseases in Patients With Neurofibromatosis. 国際誌

    Manami Honda, Masaya Iwamuro, Takehiro Tanaka, Yasushi Yamasaki, Seiji Kawano, Sakiko Hiraoka, Yoshiro Kawahara, Motoyuki Otsuka

    JGH open : an open access journal of gastroenterology and hepatology   9 ( 4 )   e70151   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Patients with neurofibromatosis (NF) frequently experience gastrointestinal symptoms, but the specific characteristics of these lesions are not well understood. METHODS: To investigate the prevalence and nature of gastrointestinal diseases in this population, we analyzed the gastrointestinal lesions identified through endoscopic examinations in patients with NF. RESULTS: We included 225 patients with NF type 1 (NF1) and 15 with NF type 2 (NF2). None of the NF2 patients underwent endoscopy. Among the NF1 patients, 27 received endoscopies, and 13 (59%) had gastrointestinal lesions. These 13 patients were predominantly male (10 males and three females), with a median age of 53 years (range: 19-76 years). The identified lesions included colorectal polyps (n = 6), gastrointestinal stromal tumors ([GIST], n = 4), subepithelial lesions (n = 3), gastric fundic gland polyps (n = 3), diffuse intestinal ganglioneuromatosis (n = 2), esophageal polyps (n = 2), a Schwann cell hamartoma (n = 1), esophageal cancer (n = 1), and a gastric hyperplastic polyp (n = 1). All GISTs and one case of diffuse intestinal ganglioneuromatosis were surgically resected. Interestingly, six out of 13 patients were asymptomatic. Additionally, all patients who required surgery were 40 years of age or older. CONCLUSIONS: These findings suggest that routine endoscopic examinations, along with imaging techniques like computed tomography and magnetic resonance imaging, could be beneficial for the early detection of gastrointestinal lesions in NF1 patients aged 40 and above.

    DOI: 10.1002/jgh3.70151

    PubMed

    researchmap

  • Genomic Differences and Distinct TP53 Mutation Site-Linked Chemosensitivity in Early- and Late-Onset Gastric Cancer. 国際誌

    Tomohiro Kamio, Yoshiyasu Kono, Kensuke Hirosuna, Toshiki Ozato, Hideki Yamamoto, Akira Hirasawa, Daisuke Ennishi, Shuta Tomida, Shinichi Toyooka, Motoyuki Otsuka

    Cancer medicine   14 ( 8 )   e70793   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Gastric cancer (GC) in younger patients often exhibits aggressive behavior and a poorer prognosis than that in older patients. Although the clinical differences may stem from oncogenic gene variations, it is unclear whether genetic differences exist between these groups. This study compared the genetic profiles of early- and late-onset GC and evaluated their impact on treatment outcomes. METHODS: We analyzed genetic data from 1284 patients with GC in the Japanese nationwide Center for Cancer Genomics and Advanced Therapeutics (C-CAT) database, comparing early-onset (≤ 39 years; n = 143) and late-onset (≥ 65 years; n = 1141) groups. The influence of TP53 mutations on the time to treatment failure (TTF) with platinum-based chemotherapy and the sensitivity of cancer cells with different TP53 mutation sites to oxaliplatin were assessed in vitro. RESULTS: Early- and late-onset GC showed distinct genetic profiles, with fewer neoantigen-associated genetic changes observed in early-onset cases. In particular, TP53 has distinct mutation sites; R175H and R273 mutations are more frequent in early- and late-onset GC, respectively. The R175H mutation showed higher sensitivity to oxaliplatin in vitro, consistent with the longer TTF in early-onset patients (17.3 vs. 7.0 months, p = 0.013) when focusing on the patients with TP53 mutations. CONCLUSION: Genomic differences, particularly in TP53 mutation sites, between early- and late-onset GC support the need for age-specific treatment strategies.

    DOI: 10.1002/cam4.70793

    PubMed

    researchmap

  • Microsatellite-high intrahepatic cholangiocarcinoma with favorable treatment outcome using pembrolizumab.

    Shigeru Horiguchi, Hironari Kato, Kazuya Miyamoto, Kosaku Morimoto, Akihiro Matsumi, Hiroyuki Terasawa, Yuki Fujii, Kazuyuki Matsumoto, Takehiro Tanaka, Motoyuki Otsuka

    Clinical journal of gastroenterology   18 ( 2 )   363 - 368   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Intrahepatic cholangiocarcinoma has a poor prognosis. In unresectable cases, the survival period is short despite combination therapy with cytotoxic anticancer agents and immune checkpoint inhibitors. The usefulness of immune checkpoint inhibitors against malignant tumors with microsatellite instability-high (MSI-H) mutations was shown in the KEYNOTE158 study; however, data for intrahepatic cholangiocarcinoma are insufficient. In the present case, a 65-year-old man with intrahepatic cholangiocarcinoma and lymph node metastasis could not be treated with a combination of gemcitabine, CDDP, and S-1. A comprehensive cancer genomic profiling (CGP) test showed MLH1 pathogenic mutation and MSI-H. When pembrolizumab was administered, the tumor shrinkage effect was rapidly observed, which was sustained even after 30 months. No pathogenic mutations were observed in the germline test, and MSI-high was considered to be due to the MLH1 pathogenic mutation occurring sporadically in somatic cells. MSI-H intrahepatic cholangiocarcinoma is extremely rare. However, because pembrolizumab is expected to be effective, CGP testing should be actively performed.

    DOI: 10.1007/s12328-025-02103-4

    PubMed

    researchmap

  • Endoscopic ultrasonography-guided removal of a stent that had migrated into the pancreas post-pancreaticojejunostomy: A case report. 国際誌

    Satoshi Kajitani, Kazuyuki Matsumoto, Kentaro Oki, Akihiro Matsumi, Kazuya Miyamoto, Yuki Fujii, Daisuke Uchida, Koichiro Tsutsumi, Shigeru Horiguchi, Motoyuki Otsuka

    DEN open   5 ( 1 )   e70096   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A 64-year-old woman had undergone subtotal stomach-preserving pancreaticoduodenectomy for locally advanced pancreatic head cancer. She had an uneventful postoperative course with no recurrence. However, approximately 18 months after surgery, she presented with recurrent abdominal pain. Although contrast-enhanced computed tomography abdominal radiographs showed internal stent migration to the residual pancreas, dilatation of the tail side of the pancreatic duct was observed. The impaired internal stent was considered to be the cause of the abdominal pain. An attempt to remove the stent via balloon-assisted endoscopy was unsuccessful as the pancreaticojejunostomy site could not be reached. Consequently, endoscopic ultrasonography-guided pancreatic duct drainage was performed, and a plastic stent was placed through the jejunal site to the stomach. Two months later, the endosonographically/endoscopic ultrasonography-guided created route was dilated, and an endoscopic introducer was inserted into the pancreatic duct. Biopsy forceps were advanced through the sheath, allowing the successful removal of the stent by direct grasping. The symptoms of the patient improved, and she was discharged without complications.

    DOI: 10.1002/deo2.70096

    PubMed

    researchmap

  • Endoscopic features of gastric neuroendocrine tumors. 国際誌

    Katsunori Matsueda, Noriya Uedo, Masanori Kitamura, Takashi Kanesaka, Muneshin Morita, Satoki Shichijo, Akira Maekawa, Yoji Takeuchi, Koji Higashino, Tomoki Michida, Ryu Ishihara, Seiji Kawano, Motoyuki Otsuka

    DEN open   5 ( 1 )   e70088   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: The endoscopic features of gastric neuroendocrine tumors (G-NETs) remain unclarified. The present study investigated the endoscopic features of G-NETs in relation to the clinicopathological findings. METHODS: This retrospective study analyzed consecutive patients with G-NETs who received endoscopic or surgical treatment between January 2005 and December 2023. The endoscopic and clinicopathological findings of the lesions were analyzed to provide diagnostic information. RESULTS: Among 29 patients, the characteristic endoscopic findings of G-NETs on white-light images were reddish color (66%), dilated vessels (83%), submucosal tumor-like marginal elevation (59%), and central depression (48%). The gross appearance of G-NETs was classified into two macroscopic subtypes: reddish polypoid lesions (n = 17) and submucosal tumor-like lesions (n = 9). Magnifying narrow-band imaging endoscopy revealed an absent microsurface pattern plus an irregular microvascular pattern in all cases of reddish polypoid lesions with central depressions (100%, 9/9). The findings of a reddish polypoid lesion and an absent microsurface pattern plus an irregular microvascular pattern corresponded to the subepithelial NET component close to the non-neoplastic surface epithelium. Additionally, reddish polypoid lesions were significantly more frequent in type 1 G-NETs than in type 3 G-NETs (80% vs. 11%, p < 0.001), while submucosal tumor-like lesions were significantly more frequent in type 3 G-NETs than in type 1 G-NETs (78% vs. 10%, p < 0.001). CONCLUSIONS: These endoscopic features should increase the index of suspicion and help clinicians to correctly diagnose G-NETs through the pathological examination of biopsy specimens.

    DOI: 10.1002/deo2.70088

    PubMed

    researchmap

  • Efficacy and safety of endoscopic ultrasonography-guided radiofrequency ablation of small pancreatic neuroendocrine neoplasms: A prospective, pilot study. 国際誌

    Kazuyuki Matsumoto, Daisuke Uchida, Yasuto Takeuchi, Hironari Kato, Yuki Fujii, Kei Harada, Nao Hattori, Ryosuke Sato, Taisuke Obata, Akihiro Matsumi, Kazuya Miyamoto, Shigeru Horiguchi, Koichiro Tsutsumi, Kazuya Yasui, Ryo Harada, Masakuni Fujii, Motoyuki Otsuka

    DEN open   5 ( 1 )   e70073   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVES: Endoscopic ultrasonography (EUS)-guided radiofrequency ablation has recently been introduced as one of the management strategies for small pancreatic neuroendocrine neoplasms (PNENs). However, prospective data on its safety and efficacy remain limited. METHODS: This prospective pilot study was conducted at Okayama University Hospital from May 2023 to December 2024. Patients with grade 1 PNENs ≤15 mm, confirmed by EUS-guided fine-needle aspiration, were included. The primary endpoint was safety (adverse events [AEs] evaluated according to the 2010 guidelines of the American Society for Gastrointestinal Endoscopy. Severe AEs were defined as moderate or higher in American Society for Gastrointestinal Endoscopy grading and grade ≥3. Secondary endpoints included efficacy (complete response on contrast-enhanced computed tomography at 1 and 6 months), treatment details, device failure, diabetes mellitus exacerbation, and overall survival at 6 months. RESULTS: Five patients with non-functional PNENs (median age: 64 years; median tumor size: 10 mm) were treated. AEs occurred in two patients (40%, 2/5), although none was severe. Both patients developed asymptomatic pseudocysts, one experienced mild pancreatitis, and both resolved with conservative treatment. The complete response rates on contrast-enhanced computed tomography at one and 6 months were 100%. The median procedure time was 16 min without any device failure, and the median hospitalization was 5 days. None of the patients developed new-onset or worsening diabetes mellitus. The 6-month overall survival rate was 100%. CONCLUSION: EUS-guided radiofrequency ablation demonstrated a high complete response rate with no severe AEs in this pilot study, suggesting a minimally invasive option for small, low-grade PNENs (jRCTs062230014).

    DOI: 10.1002/deo2.70073

    PubMed

    researchmap

  • A case of pancreatic ductal adenocarcinoma growing within the pancreatic duct mimicking an intraductal tubulopapillary neoplasm.

    Ryosuke Sato, Kazuyuki Matsumoto, Mayu Uka, Kosei Takagi, Kenji Nishida, Takehiro Tanaka, Yuki Fujii, Koichiro Tsutsumi, Shigeru Horiguchi, Motoyuki Otsuka

    Clinical journal of gastroenterology   18 ( 2 )   376 - 382   2025年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We herein report a case of pancreatic ductal adenocarcinoma (PDAC) that developed within the pancreatic duct and was initially diagnosed as an intraductal tubulopapillary neoplasm (ITPN). A 76-year-old man presented with weight loss and main pancreatic duct dilation. The imaging studies revealed a 30-mm hypovascular tumor within the main duct of the pancreatic head. An endoscopic examination with a biopsy revealed high-grade atypical epithelial cells with immunostaining patterns suggestive of ITPN. Following robot-assisted pancreaticoduodenectomy, postoperative pathology revealed conflicting features: nodular/cribriform infiltrations typical of ITPN and non-lobular replacement with scattered infiltrations characteristic of PDAC. A comprehensive genomic profiling test detected KRAS and TP53 mutations, leading to the final diagnosis of PDAC (fT3N1aM0, stage IIB). The patient received adjuvant S-1 chemotherapy and remained recurrence-free for 15 months post-surgery. This case highlights the diagnostic challenges of differentiating intraductal pancreatic tumors and demonstrates the utility of integrating genetic testing with conventional diagnostic modalities for an accurate diagnosis and appropriate treatment selection.

    DOI: 10.1007/s12328-025-02098-y

    PubMed

    researchmap

  • Comparison of Midazolam and Diazepam for Sedation in Patients Undergoing Double-Balloon Endoscopic Retrograde Cholangiopancreatography: A Propensity Score-Matched Analysis. 国際誌

    Yuki Fujii, Kazuyuki Matsumoto, Akihiro Matsumi, Kazuya Miyamoto, Daisuke Uchida, Shigeru Horiguchi, Koichiro Tsutsumi, Toshiharu Mitsuhashi, Motoyuki Otsuka

    Journal of clinical medicine   14 ( 7 )   2025年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Objective: The sedation method used in double-balloon endoscopic retrograde cholangiopancreatography (DB-ERCP) varies across countries and between healthcare facilities. No previous studies have compared the effects of different benzodiazepines on sedation during endoscopic procedures. This study aimed to compare the effects of midazolam and diazepam sedation on DB-ERCP outcomes. Methods: This retrospective cohort study analyzed consecutive patients who underwent DB-ERCP between January 2017 and February 2024. A total of 203 patients who were sedated with diazepam (n = 94) or midazolam (n = 109) were analyzed. Propensity score matching was applied to adjust for baseline group differences. The primary outcome was the incidence of sedation-related adverse events (AEs). Secondary outcomes included inadequate sedation requiring additional sedatives and risk factors for sedation-related AEs. Results: Sedation-related AEs were more frequent with diazepam (28% [21/75]) than with midazolam (14% [11/75]; p = 0.046). Hypoxia occurred more frequently with diazepam (19% [14/75]) than with midazolam (5% [4/75]; p = 0.012). However, no significant differences were observed between the two groups for hypotension (p = 0.41) and bradycardia (p = 1.0). Poor sedation requiring other sedatives occurred significantly more often with diazepam (8% [6/75]) compared with midazolam sedation (0% [0/75], p = 0.012). Multivariate analysis identified diazepam sedation (odds ratio, 2.3; 95% confidence interval, 1.0-5.3; p = 0.048) as the sole risk factor for sedation-related AEs. Conclusions: Midazolam is safer and more effective than diazepam sedation in patients undergoing DB-ERCP.

    DOI: 10.3390/jcm14072287

    PubMed

    researchmap

  • Clinical Significance of Lymphatic Involvement in Intramucosal (pT1a) Gastric Cancer Resected by Endoscopic Submucosal Dissection. 国際誌

    Katsunori Matsueda, Yoshiyasu Kono, Koji Miyahara, Masahiro Nakagawa, Hirokazu Mouri, Kazuhiro Matsueda, Kenta Hamada, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Takehiro Tanaka, Motoyuki Otsuka

    Journal of gastroenterology and hepatology   40 ( 3 )   712 - 719   2025年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: Lymphatic involvement is sometimes detected during routine examination of intramucosal (pT1a) gastric cancer resected endoscopically. However, its clinical significance and association with the risk of metastasis remain unknown. METHODS: This was a retrospective cohort study of 6797 consecutive patients with pT1a gastric cancers treated by endoscopic submucosal dissection (ESD) at three institutions in Japan from January 2005 to August 2023. Patients with 49 uncommon-type gastric cancer types were excluded. The risk of metastasis for pT1a cancers with lymphatic involvement was quantified by comparing lymph node metastasis and/or metastatic recurrence in patient groups who underwent additional surgery post-ESD or did not undergo surgery but were followed up for > 3 years. RESULTS: Among the 6748 pT1a cancers treated by ESD, 41 lesions (0.6%) had histologically confirmed lymphatic involvement. Among the 41 patients, 1 was excluded from the analysis of metastasis risk because the follow-up period after ESD without additional surgery was ≤ 3 years. Metastasis was identified in 1 of 40 patients analyzed (2.5%; 95% confidence interval [CI] 0.4%-12.9%), and was not detected in any of the 25 patients with pure differentiated-type lesions (0.0%; 95% CI 0.0%-13.7%). CONCLUSIONS: The low prevalence of metastasis after ESD for pT1a gastric cancer with lymphatic involvement, particularly in patients with pure differentiated-type lesions, suggests a low risk of metastatic recurrence.

    DOI: 10.1111/jgh.16854

    PubMed

    researchmap

  • Cholecystectomy Is Linked to Worse Clinical Outcomes in Primary Sclerosing Cholangitis. 国際誌

    Nozomi Miyake, Kengo Yasugi, Akinobu Takaki, Kazuyuki Matsumoto, Motoyuki Otsuka

    Cureus   17 ( 3 )   e80184   2025年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Recent findings have suggested that gallbladder-derived retinoic acid signaling plays a crucial role in the regeneration of damaged intrahepatic biliary ducts. This retrospective cohort study analyzed the clinical records of 20 patients with primary sclerosing cholangitis (PSC) treated at our hospital between 2013 and 2024. We investigated the clinical implications of gallbladder removal in patients with PSC, a progressive cholangiopathy with limited therapeutic options. We retrospectively analyzed the data of patients with PSC and compared patients with and without prior cholecystectomy to assess the impact on disease progression using the Mayo risk score, Fibrosis-4 (FIB4) index, and other clinical parameters. Our findings indicated that cholecystectomy was associated with worse Mayo risk scores (p = 0.0004) and an elevated FIB4 index (p = 0.021), suggesting a potential link between gallbladder removal and accelerated disease progression. Furthermore, mortality and transplant-free survival analysis revealed significantly worse outcomes in the cholecystectomy group (odds ratio = 21.0, p = 0.032). However, given the retrospective nature and small sample size of this study, selection bias cannot be excluded, and further research is needed to confirm these findings. These findings support the hypothesis that gallbladder-derived factors, such as retinoic acid, may influence PSC progression and highlight the need for further research into therapeutic interventions targeting this pathway.

    DOI: 10.7759/cureus.80184

    PubMed

    researchmap

  • Advanced prostate cancer diagnosed through colonoscopy. 国際誌

    Masaya Iwamuro, Takehiro Tanaka, Seiji Kawano, Nobumasa Ikeda, Motoyuki Otsuka

    Gastrointestinal endoscopy   2025年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.gie.2025.02.032

    PubMed

    researchmap

  • Unraveling a Rare Case: Diarrhea, Alopecia, and Polyposis. 国際誌

    Hidetaka Mizushima, Hideaki Kinugasa, Motoyuki Otsuka

    Gastroenterology   2025年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2025.02.005

    PubMed

    researchmap

  • Changes of leucine-rich alpha 2 glycoprotein could be a marker of changes of endoscopic and histologic activity of ulcerative colitis. 国際誌

    Yuki Aoyama, Sakiko Hiraoka, Eriko Yasutomi, Toshihiro Inokuchi, Takehiro Tanaka, Kensuke Takei, Shoko Igawa, Keiko Takeuchi, Masahiro Takahara, Junki Toyosawa, Yasushi Yamasaki, Hideaki Kinugasa, Jun Kato, Hiroyuki Okada, Motoyuki Otsuka

    Scientific reports   15 ( 1 )   5248 - 5248   2025年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Leucine-rich alpha 2 glycoprotein (LRG) is one of the serum biomarkers for disease activity of ulcerative colitis (UC). We focused on the correlation between the changes of LRG and the changes of endoscopic and histologic activity of UC, in comparison to the changes of fecal calprotectin (Fcal), fecal immunochemical test (FIT), and C-reactive protein (CRP). Seventy-nine patients with two or more colonoscopies were enrolled, and 123 paired colonoscopies and 121 paired biopsies were examined. With regard to the change of endoscopic/histologic activity between the preceding and subsequent colonoscopy, there was improvement (n = 29/45), unchanging (n = 63/36), and worsening (n = 31/40). The correlations between the changes of marker levels and endoscopic/histologic activity were Fcal; r = 0.50/0.39 and FIT; r = 0.41/0.40, LRG; r = 0.42/0.40 and CRP; r = 0.22/0.17. Furthermore, when the correlation between the changes of LRG levels and the changes of endoscopic/histological activity was compared with those of other markers, the correlation of LRG tended to be superior to those of CRP (CRP vs. LRG; p = 0.08/0.01). LRG is equivalent to fecal markers and superior to CRP, when inferring changes in disease activity of UC based on changes in its level.

    DOI: 10.1038/s41598-025-89615-8

    PubMed

    researchmap

  • Clinical Variables that Predict Liver-related Events in Steatotic Liver Disease Diagnosed by a Liver Biopsy.

    Shinnosuke Okubo, Akinobu Takaki, Ikumi Sato, Takuya Adachi, Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Hideki Onishi, Satoshi Hirohata, Motoyuki Otsuka

    Internal medicine (Tokyo, Japan)   2025年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Objective Identifying patients at high risk of steatotic liver disease (SLD) is crucial. The liver fibrosis stage is the most reliable marker of liver-related mortality. However, noninvasive risk stratification methods remain controversial. Therefore, we analyzed the risk of liver-related events in patients who underwent a liver biopsy for metabolic dysfunction-associated steatotic liver disease (MASLD) or cryptogenic SLD at our hospital. Methods We retrospectively reviewed the clinical course of the patients to identify the occurrence of liver-related events. Patients This study included 146 patients diagnosed with SLD through a liver biopsy. Results Liver-related events occurred in 20 patients and were more frequent in those with advanced fibrosis than in those without advanced fibrosis. However, patients with advanced steatosis exhibit reduced disease progression. Patients with obesity and/or diabetes complications had a lower stage of fibrosis and better prognosis than the others. The non-invasive fibrosis-4 (FIB-4) index and non-alcoholic fatty liver disease (NAFLD) prognosis-related "NAFLD outcomes score (NOS)" effectively differentiated patients with disease progression. Standard laboratory data analyses revealed that high total bilirubin and low albumin levels were risk factors. A multivariate analysis with significant factors other than NOS score revealed that the absence of obesity and/or diabetes complications, a high FIB-4 index, and a high total bilirubin level were independent factors for liver-related events. Conclusion A high NOS score, absence of obesity and/or diabetes complications, a high FIB-4 index, and high total bilirubin levels are risk factors for disease progression. Patients with lean phenotypes or non-diabetic SLD should also be assessed using noninvasive markers to determine their risks and potential outcomes.

    DOI: 10.2169/internalmedicine.4770-24

    PubMed

    researchmap

  • Natural Course and Long-Term Outcomes of Gastric Subepithelial Lesions: A Systematic Review. 国際誌

    Masaya Iwamuro, Hiroyuki Okada, Motoyuki Otsuka

    Journal of clinical medicine   14 ( 4 )   2025年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background/Objectives: Gastric subepithelial lesions (SELs) are often incidentally detected during endoscopic examinations, with most patients being asymptomatic and lesions measuring <20 mm. Despite their generally indolent nature, certain SELs, such as gastrointestinal stromal tumors, require resection. Current guidelines recommend periodic surveillance; however, the natural course and long-term outcomes of gastric SELs have not been sufficiently investigated. This systematic review aimed to synthesize evidence on the progression, growth rate, and risk factors associated with gastric SELs to inform clinical management strategies. Methods: A comprehensive search of PubMed was conducted for peer-reviewed studies published between January 2000 and November 2024. Eligible studies included original studies on the follow-up and progression of gastric SELs. Non-English articles, reviews, case reports, and unrelated topics were excluded. In total, 277 articles were screened, with 15 additional articles identified through manual screening. Ultimately, 41 articles were included in the analysis. The study protocol is registered in PROSPERO (CRD42024614865). Results: Large-scale studies reported low growth rates of 2.0-8.5% over 2.0-5.0 years, while smaller studies reported a broader range of growth rates of 5.4-28.4%. The factors contributing to these discrepancies include patient selection, follow-up duration, and growth criteria. Risk factors for lesion size increase include larger initial lesion size, irregular margins, heterogeneous echo patterns, and certain tumor locations. Conclusions: These findings underscore the need for individualized management strategies based on lesion size, imaging characteristics, and risk factors. The close monitoring of high-risk lesions is crucial for timely intervention. Standardized growth criteria and optimized follow-up protocols are essential for improving clinical decision making and patient outcomes.

    DOI: 10.3390/jcm14041055

    PubMed

    researchmap

  • Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up. 国際誌

    Ryosuke Sato, Katsuyuki Hotta, Toshio Kubo, Shigeru Horiguchi, Hironari Kato, Kazuyuki Matsumoto, Toshiyuki Kozuki, Heiichiro Udono, Katsuyuki Kiura, Motoyuki Otsuka

    Cureus   17 ( 2 )   e79001   2025年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We report a case of poorly differentiated pancreatic cancer that showed an exceptional response to combination therapy with nivolumab and metformin. A 58-year-old man presented with epigastric pain and was diagnosed with locally advanced pancreatic cancer with para-aortic lymph node metastasis. After disease progression following modified FOLFIRINOX therapy (a combination of fluorouracil, leucovorin, irinotecan, and oxaliplatin), the patient was enrolled in a phase Ib clinical trial of nivolumab (3 mg/kg biweekly) combined with metformin (750 mg/day). Post-treatment imaging showed marked tumor shrinkage with normalization of the tumor markers. During treatment, the patient was diagnosed with early-stage lung cancer and underwent successful left S1+S2 segmentectomy with temporary suspension of immunotherapy. The therapeutic response of pancreatic cancer has been sustained for seven years, with minimal residual disease. This unprecedented response duration is particularly noteworthy considering his microsatellite stability, which typically predicts a limited response to immune checkpoint inhibition. This case demonstrates an exceptional response to nivolumab and metformin combination therapy in poorly differentiated pancreatic cancer. The remarkable durability of the response suggests the need for further investigation to identify patients most likely to benefit from this therapeutic approach.

    DOI: 10.7759/cureus.79001

    PubMed

    researchmap

  • Gastric Metastasis of Renal Cell Carcinoma Initially Diagnosed by Esophagogastroduodenoscopy. 国際誌

    Masaya Iwamuro, Tomohiro Kamio, Shoichiro Hirata, Takehiro Tanaka, Motoyuki Otsuka

    Cureus   17 ( 2 )   e79651   2025年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Here, we report a rare case of renal cell carcinoma (RCC) initially detected as a gastric metastasis. A 58-year-old man with epigastric discomfort underwent esophagogastroduodenoscopy, which revealed a reddish semi-pedunculated lesion with a whitish coating. Biopsy and imaging confirmed clear cell RCC metastasis. Contrast-enhanced computed tomography (CT) revealed a primary renal tumor with pancreatic and lymph node metastases. Despite chemotherapy treatment, the patient died after 10 months. Gastric metastases from RCC, although rare, should be considered in highly vascular gastric lesions with white coatings. Clinicians must be vigilant for metastatic diseases with atypical gastric findings.

    DOI: 10.7759/cureus.79651

    PubMed

    researchmap

  • Update on the treatment navigation for functional cure of chronic hepatitis B: Expert consensus 2.0. 国際誌

    Di Wu, Jia-Horng Kao, Teerha Piratvisuth, Xiaojing Wang, Patrick T F Kennedy, Motoyuki Otsuka, Sang Hoon Ahn, Yasuhito Tanaka, Guiqiang Wang, Zhenghong Yuan, Wenhui Li, Young-Suk Lim, Junqi Niu, Fengmin Lu, Wenhong Zhang, Zhiliang Gao, Apichat Kaewdech, Meifang Han, Weiming Yan, Hong Ren, Peng Hu, Sainan Shu, Paul Yien Kwo, Fu-Sheng Wang, Man-Fung Yuen, Qin Ning

    Clinical and molecular hepatology   31 ( Suppl )   S134-S164   2025年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    As new evidence emerges, treatment strategies toward the functional cure of chronic hepatitis B are evolving. In 2019, a panel of national hepatologists published a Consensus Statement on the functional cure of chronic hepatitis B. Currently, an international group of hepatologists has been assembled to evaluate research since the publication of the original consensus, and to collaboratively develop the updated statements. The 2.0 Consensus was aimed to update the original consensus with the latest available studies, and provide a comprehensive overview of the current relevant scientific literatures regarding functional cure of hepatitis B, with a particular focus on issues that are not yet fully clarified. These cover the definition of functional cure of hepatitis B, its mechanisms and barriers, the effective strategies and treatment roadmap to achieve this endpoint, in particular new surrogate biomarkers used to measure efficacy or to predict response, and the appropriate approach to pursuing a functional cure in special populations, the development of emerging antivirals and immunomodulators with potential for curing hepatitis B. The statements are primarily intended to offer international guidance for clinicians in their practice to enhance the functional cure rate of chronic hepatitis B.

    DOI: 10.3350/cmh.2024.0780

    PubMed

    researchmap

  • Bleeding Risk During Colorectal Endoscopic Mucosal Resection With Continued Anticoagulant Therapy: A Multicenter Study. 国際誌

    Sayo Kobayashi, Keita Harada, Toru Nawa, Tomoo Fujisawa, Toru Ueki, Junichiro Nasu, Yuki Morito, Tatsuya Toyokawa, Tomoki Inaba, Masahide Kita, Ryuta Takenaka, Masafumi Inoue, Reiji Higashi, Takao Tsuduki, Minoru Matsubara, Yasushi Yamasaki, Hiroyuki Okada, Motoyuki Otsuka

    Cureus   17 ( 1 )   e76753   2025年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background and aims Endoscopic mucosal resection (EMR) is a standard preventive method for colorectal cancer. Managing patients on anticoagulants during EMR is challenging because of balancing bleeding and thrombotic risks. Updated guidelines recommend continuing anticoagulants over heparin bridging; however, data on bleeding risks with continuing anticoagulants remain limited. This multicenter prospective study evaluated bleeding rates in patients who continued oral anticoagulants during EMR. Methods Patients on warfarin or direct oral anticoagulants (DOACs) undergoing EMR were enrolled from 12 tertiary hospitals. Warfarin was maintained on the day of EMR, while DOACs were paused on the day of EMR and resumed afterward. Post-EMR mucosal defects were closed with clips per protocol. Adverse events were monitored for 30 days. The primary endpoint was the major bleeding rate, defined as immediate bleeding requiring difficult hemostasis or delayed bleeding necessitating endoscopic intervention. The secondary endpoints were minor bleeding, other adverse events, and differences in bleeding rates between warfarin and DOACs. Results Among 107 patients (341 polyps; mean size = 6.7 mm), major bleeding occurred in five (4.7%) patients (95% confidence interval: 2.0%-10.5%), and all cases were managed endoscopically. Minor bleeding and thromboembolism events occurred in eight (7.5%) patients and one (0.9%) patient, respectively. No significant differences in bleeding rates were observed between warfarin and DOACs. Major bleeding rates were lower than those reported for heparin bridging. Conclusions Continuing anticoagulant therapy during EMR was associated with a low major bleeding rate (4.7%) and minimal thrombotic events, supporting its safety as an alternative to heparin bridging.

    DOI: 10.7759/cureus.76753

    PubMed

    researchmap

  • Clipping closure length is a crucial factor for delayed bleeding after endoscopic papillectomy: a retrospective multicenter cohort study. 国際誌

    Yuki Fujii, Kazuyuki Matsumoto, Kiyoaki Ochi, Hitomi Himei, Ichiro Sakakihara, Eijiro Ueta, Tatsuya Toyokawa, Ryo Harada, Taiji Ogawa, Takeshi Tomoda, Hironari Kato, Ryosuke Sato, Taisuke Obata, Akihiro Matsumi, Kazuya Miyamoto, Daisuke Uchida, Shigeru Horiguchi, Koichiro Tsutsumi, Motoyuki Otsuka

    Therapeutic advances in gastroenterology   18   17562848251326450 - 17562848251326450   2025年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Bleeding is a serious and frequent adverse event that occurs during and after endoscopic papillectomy (EP). Previous studies have highlighted the effectiveness of preventive clipping closure of the resection site in preventing post-EP bleeding. However, the optimal length of closure remained unclear. OBJECTIVES: We aimed to clarify the optimal clipping length at the post-EP resection site to prevent delayed bleeding. DESIGN: This study was a multicenter retrospective cohort study. METHODS: We retrospectively analyzed patients who were consecutively admitted to nine high-volume centers for EP between November 2003 and October 2023. The primary outcome was the frequency of delayed bleeding based on the closure length. The optimal closure length rate of the resected site to prevent delayed bleeding was determined using a receiver operating characteristic curve. Secondary outcomes were the incidence, treatment outcomes, and risk factors for post-EP delayed bleeding. RESULTS: A total of 130 patients who underwent EP were analyzed. Delayed bleeding was observed in 22 (17%) patients, occurring more frequently in cases without clipping closure than in those with clipping closure (28% (13/47) vs 11% (9/83); p = 0.014). Among 83 patients who underwent clipping closure, delayed bleeding occurred more frequently with a closure length rate <65% than in those with a closure rate ⩾65% (25% (5/20) vs 6% (4/63); p = 0.019). Multivariate analysis showed that a closure rate <65% was the risk factor for delayed bleeding (odds ratio, 6.3; 95% confidence interval, 1.2-33; p = 0.030) in cases with clipping. CONCLUSION: Clipping closure was effective in preventing delayed bleeding, and closure length rate ⩾65% of the resected site significantly reduced post-EP delayed bleeding.

    DOI: 10.1177/17562848251326450

    PubMed

    researchmap

  • Myeloid Sarcoma in the Small Intestine.

    Masaya Iwamuro, Tomohiro Kamio, Shoichiro Hirata, Katsunori Matsueda, Daisuke Kametaka, Takehiro Tanaka, Seiji Kawano, Motoyuki Otsuka

    Internal medicine (Tokyo, Japan)   2024年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Myeloid sarcoma is a rare extramedullary tumor of immature myeloid cells that is often associated with acute myeloid leukemia (AML). We herein report an 81-year-old man who presented with intestinal obstruction due to myeloid sarcoma of the small intestine. Diagnostic challenges were overcome using double-balloon enteroscopy and a biopsy, which confirmed the diagnosis of myeloid sarcoma. The patient subsequently developed AML but responded well to chemotherapy. This case underscores the importance of considering myeloid sarcoma in the differential diagnosis of small-bowel tumors. Highlighting the significance of a histological analysis, even in patients presenting with small bowel obstruction, the early diagnosis and treatment are crucial for improving outcomes, particularly in patients without a history of hematologic malignancies.

    DOI: 10.2169/internalmedicine.4664-24

    PubMed

    researchmap

  • WWP1 inhibition suppresses the proliferation of pancreatic cancer cells by regulating the PI3K-AKT pathway.

    Genso Notoya, Takahiro Kishikawa, Kengo Yasugi, Takuma Iwata, Takahiro Seimiya, Koji Miyabayashi, Ryota Takahashi, Keisuke Yamamoto, Hideaki Ijichi, Motoyuki Otsuka, Mitsuhiro Fujishiro

    Journal of gastroenterology   60 ( 3 )   370 - 384   2024年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The proto-oncogene WWP1 is overexpressed in various cancers and contributes to tumor growth and poor prognosis. Recently, WWP1 inhibition was reported to suppress tumor development and cell proliferation by activating the PTEN function. However, the expression profiles and clinical significance of WWP1 in pancreatic ductal adenocarcinoma (PDAC) tissues remain undetermined. Therefore, this study aimed to evaluate the WWP1 expression in PDAC and investigate the therapeutic potential of WWP1 inhibition. METHODS: Cellular proliferation assays were performed using a doxycycline-inducible shWWP1 expression system. Transcriptome analyses were conducted to identify the altered pathways in WWP1-depleted cells. PTEN ubiquitination by WWP1 was confirmed using immunoprecipitation assays. In vivo xenograft and drug screening assays were performed to evaluate the clinical significance of WWP1 inhibition. RESULTS: WWP1 was significantly upregulated in PDAC tissues and associated with poor prognosis. WWP1 depletion significantly reduced the proliferation of PDAC cell lines, correlating with the suppression of the PI3K-AKT pathway. Mechanistically, as reported in other cancer types, PTEN is a target of WWP1 in PDAC cells. PTEN silencing abrogated the growth-inhibitory effects in WWP1-depleted cells, suggesting that the anti-tumor effects of WWP1 inhibition are mediated through PTEN activation. In vivo xenograft studies confirmed that WWP1 depletion substantially inhibited tumor growth. Moreover, drug screening assays revealed that WWP1 depletion had an additive effect with the PI3K-AKT pathway inhibitors on hindering tumor growth. CONCLUSION: WWP1 inhibition enhances the anti-tumor effects of PI3K-AKT pathway inhibitors through PTEN activation. Thus, WWP1 could be a potential therapeutic target in PDAC.

    DOI: 10.1007/s00535-024-02192-x

    PubMed

    researchmap

  • APASL clinical practice guidelines on systemic therapy for hepatocellular carcinoma-2024. 国際誌

    George Lau, Shuntaro Obi, Jian Zhou, Ryosuke Tateishi, Shukui Qin, Haitao Zhao, Motoyuki Otsuka, Sadahisa Ogasawara, Jacob George, Pierce K H Chow, Jianqiang Cai, Shuichiro Shiina, Naoya Kato, Osamu Yokosuka, Kyoko Oura, Thomas Yau, Stephen L Chan, Ming Kuang, Yoshiyuki Ueno, Minshan Chen, Ann-Lii Cheng, Gregory Cheng, Wan-Long Chuang, Oidov Baatarkhuu, Feng Bi, Yock Young Dan, Rino A Gani, Atsushi Tanaka, Wasim Jafri, Ji-Dong Jia, Jia-Horng Kao, Kiyoshi Hasegawa, Patrick Lau, Jeong Min Lee, Jun Liang, Zhenwen Liu, Yinying Lu, Hongming Pan, Diana A Payawal, Salimur Rahman, Jinsil Seong, Feng Shen, Gamal Shiha, Tianqiang Song, Hui-Chuan Sun, Tsutomu Masaki, Ekaphop Sirachainan, Lai Wei, Jin Mo Yang, Jose D Sallano, Yanqiao Zhang, Tawesak Tanwandee, AKadir Dokmeci, Shu-Sen Zheng, Jia Fan, Sheung-Tat Fan, Shiv Kumar Sarin, Masao Omata

    Hepatology international   18 ( 6 )   1661 - 1683   2024年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In Asia-Pacific region, hepatocellular carcinoma is a serious health threat attributing to over 600,000 deaths each year and account for over 70% of global cases. Clinically, the major unmet needs are recurrence after curative-intent surgery, liver transplantation or local ablation and disease progression in those with hepatocellular carcinoma not eligible for resection or failed locoregional therapy. In the recent few years, new targeted therapy and immune-checkpoint inhibitors have been registered as systemic therapy to address these issues. Notably, new forms of systemic therapy, either as first-line or second-line therapy for unresectable hepatocellular or those not eligible for locoregional therapy, are now available. New data is also emerging with the use of systemic therapy to prevent hepatocellular carcinoma recurrence after curative-intent resection or local ablation therapy and to retard disease progression after locoregional therapy. In the future, further implementation of immune-checkpoint inhibitors and other forms of immunotherapy are expected to bring a new paradigm to the management of hepatocellular carcinoma. New insight related to immune-related adverse events with the use of immunotherapy has allso enabled optimization of the therapeutic approach to patients with hepatocellular carcinoma. The purpose of this clinical practice guideline is to provide an up-to-date recommendation based on clinical evidence and experience from expert Asia-Pacific key opinion leaders in the field of hepatocellular carcinoma. Three key questions will be addressed, namely: (1) Which patients with hepatocellular carcinoma should be considered for systemic therapy? (2) Which systemic therapy should be used? (3) How should a patient planned for immune checkpoint-based systemic therapy be managed and monitored?

    DOI: 10.1007/s12072-024-10732-z

    PubMed

    researchmap

  • Analysis of painful situations during unsedated esophagogastroduodenoscopy. 国際誌

    Hiromitsu Kanzaki, Sakiko Kuraoka, Takuya Satomi, Shotaro Okanoue, Kenta Hamada, Yoshiyasu Kono, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Hiroyuki Okada, Motoyuki Otsuka

    Endoscopy international open   12 ( 11 )   E1267-E1276   2024年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Background and study aims Although esophagogastroduodenoscopy (EGD) is a widely used technique, the procedure is often associated with discomfort. This study aimed to analyze painful situations, their frequency, and factors associated with patient discomfort during EGD. Patients and methods This prospective observational study included patients scheduled to undergo EGD. Seven endoscopists recruited patients scheduled for EGD screening or surveillance. Each endoscopist enrolled 20 patients, performing 10 EGD procedures using ultraslim endoscopes and 10 with standard-sized endoscopes. Data regarding painful situations and frequency were collected using specialized buttons pressed by the patients during EGD. A survey about overall discomfort was conducted after the procedure. Results We analyzed data from 140 patients. Esophageal insertion and duodenal observation were associated with the highest incidence of pressing the pain button, accounting for 59.3% and 40.7% of the cases, respectively. The factor associated with pressing the pain button during esophageal insertion was endoscopist experience (< 10 years). In contrast, younger age and female sex were the factors associated with pressing the pain button during duodenal observation. In the post-procedure survey, 63.6% of patients reported discomfort. Factors associated with patient discomfort included pressing the pain button during esophageal insertion (odds ratio [OR]: 2.84, P = 0.01) and previous painful EGD experience (OR: 2.41, P = 0.03). Concusions This study provides objective data on painful situations, their frequency, and related factors during EGD. Further research and interventions focusing on pain reduction during endoscopic procedures are warranted. The results of this study will help endoscopists manage painful situations and potentially improve skills.

    DOI: 10.1055/a-2401-6804

    PubMed

    researchmap

  • Black Hairy Tongue Observed During Esophagogastroduodenoscopy. 国際誌

    Masaya Iwamuro, Takehiro Tanaka, Motoyuki Otsuka

    Cureus   16 ( 11 )   e74331   2024年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Black hairy tongue, also known as lingua villosa nigra, is a benign oral condition characterized by a dark discoloration and "hairy" appearance on the tongue's dorsal surface, resulting from elongated filiform papillae. This condition is associated with risk factors such as smoking, poor oral hygiene, and diabetes, which increase susceptibility to microbial colonization, particularly by Candida species. Although commonly diagnosed by visual inspection, black hairy tongue is infrequently observed during endoscopic procedures. We report a case of a 69-year-old Japanese man with poorly controlled type 2 diabetes (hemoglobin A1c of 9.7%) and a significant smoking history of 49 pack-years. During a routine esophagogastroduodenoscopy, a dark lesion was detected on the dorsal surface of the tongue. Detailed imaging and biopsy revealed elongated papillae with fungal hyphae, confirming a diagnosis of candidiasis. This case underscores the value of esophagogastroduodenoscopy and histopathological examination in diagnosing black hairy tongue and distinguishing it from other pigmented lesions. Recognizing black hairy tongue as a potential finding during endoscopy may aid in prompt diagnosis, especially in patients with predisposing factors like smoking and diabetes.

    DOI: 10.7759/cureus.74331

    PubMed

    researchmap

  • 増大号 炎症性腸疾患2024 主題 炎症性腸疾患の内科治療 基本治療薬(5-ASA製剤,副腎皮質ステロイド,チオプリン製剤)

    平岡 佐規子, 石黒 美佳子, 豊澤 惇希, 青山 祐樹, 井川 翔子, 竹内 桂子, 山崎 泰史, 井口 俊博, 衣笠 秀明, 髙原 政宏, 大塚 基之, 金谷 信彦, 近藤 喜太, 田中 健大

    胃と腸   59 ( 10 )   1453 - 1461   2024年10月

     詳細を見る

    出版者・発行元:株式会社医学書院  

    DOI: 10.11477/mf.1403203745

    researchmap

  • Short- and longer-term learning effects from virtual scale endoscopy videos: a useful tool for colorectal lesion size estimation (with video). 国際誌

    Ryosuke Hirai, Hideaki Kinugasa, Mikako Ishiguro, Junki Toyosawa, Yuki Aoyama, Shoko Igawa, Yasushi Yamasaki, Toshihiro Inokuchi, Masahiro Takahara, Seiji Kawano, Sakiko Hiraoka, Motoyuki Otsuka

    Gastrointestinal endoscopy   101 ( 5 )   1030 - 1037   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: Accurate assessment of colorectal polyp size is crucial for determining treatment and surveillance policies. However, visual estimation of lesion diameter is often inaccurate, making simple and effective educational tools essential. We aimed to evaluate the learning effects of virtual scale endoscopy (VSE). METHODS: Thirty-three endoscopists first watched pre-learning videos for SET1. They then estimated the diameters of 20 lesions and referred to instructional videos with VSE for self-study. Subsequently, they watched the post-learning videos for SET2 and estimated the lesion diameters. The error between the estimated and correct lesion sizes of both sets was compared. To evaluate longer-term learning effects, participants answered SET3 and SET4, which consisted of the same questions as SET2 and SET1, respectively, 2-3 months later without watching the instructional video for SET2. RESULTS: The error in the participants' estimation of the correct lesion diameter improved from SET1 to SET2 (34.7 mm ± 6.6 vs. 30.7 mm ± 7.7; p = 0.048), with a significant learning effect and error improvement specifically among non-experts (35.2 mm ± 5.3 vs. 30 mm ± 6.8; p = 0.028). In the SET3 and SET4, participants' errors indicated that the learning effect was well maintained (SET2 vs. SET3; 30.7 mm ± 7.7 vs. 28.6 mm ± 7.2; p = 0.1, and SET1 and SET4: 34.7 mm ± 6.6 vs. 31.7 mm ± 7.1; p = 0.025). CONCLUSIONS: VSE videos are a valuable learning tool for estimating lesion diameter, particularly for novice endoscopists, both in the short- and longer-term.

    DOI: 10.1016/j.gie.2024.10.038

    PubMed

    researchmap

  • Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma. 国際誌

    Kyo Sasaki, Miwa Kawanaka, Yasuyuki Tomiyama, Akinobu Takaki, Motoyuki Otsuka, Fusao Ikeda, Naoko Yoshioka, Hideaki Kaneto, Jun Wada, Tetsuya Fukuda, Keisuke Hino, Sohji Nishina

    Hepatology research : the official journal of the Japan Society of Hepatology   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    AIM: Type 2 diabetes mellitus (T2DM) is a well-known risk factor for hepatocellular carcinoma (HCC). However, HCC is often diagnosed at an advanced stage in patients with diabetes because of the lack of the best criteria for surveillance candidates. The aim of this study was to identify risk factors for HCC development in patients with diabetes with nonviral chronic liver disease. METHOD: Three hundred thirty T2DM patients with nonviral chronic liver disease who underwent surveillance for HCC by imaging techniques between 2009 and 2020 were enrolled in this multicenter cross-sectional retrospective study. The clinical and laboratory parameters of patients with and without HCC were compared. RESULTS: Age ≥65 years, alcohol intake, lack of hepatic steatosis, triglyceride level <111 mg/dL, Mac2 binding protein glycosylation isomer (M2BPGi) ≥0.9 cut-off index (COI), α-fetoprotein concentration ≥5 ng/mL, and des-γ-carboxy prothrombin concentration ≥26 mAU/mL were independently associated with HCC development. When stratified by age, only alcohol intake (odds ratio [OR] 114.19, p < 0.001) was associated with HCC development in patients aged <65 years, and medication for diabetes mellitus (OR 5.72, p = 0.001), lack of hepatic steatosis (OR 4.47, p = 0.002), lactate dehydrogenase ≥198 IU/L (OR 2.751, p = 0.031), M2BPGi ≥1.18 COI (OR 9.05, p < 0.001), and FIB-4 index ≥2.59 (OR 3.22, p = 0.017) were associated with HCC development in patients aged ≥65 years. CONCLUSIONS: In addition to age and advanced liver fibrosis, alcohol intake in younger T2DM patients and medication for DM and lack of hepatic steatosis in older T2DM patients should be considered for HCC surveillance by imaging.

    DOI: 10.1111/hepr.14124

    PubMed

    researchmap

  • Clinical Significance of Prior Ramucirumab Use on the Effectiveness of Nivolumab as the Third-Line Regimen in Gastric Cancer: A Multicenter Retrospective Study. 国際誌

    Yuka Obayashi, Shoichiro Hirata, Yoshiyasu Kono, Makoto Abe, Koji Miyahara, Masahiro Nakagawa, Michihiro Ishida, Yasuhiro Choda, Kenta Hamada, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Motoyuki Otsuka

    Drugs - real world outcomes   11 ( 4 )   557 - 564   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND OBJECTIVE: Because vascular endothelial growth factor inhibition has been suggested to improve immune cell function in the cancer microenvironment, we examined whether using ramucirumab (RAM) before nivolumab usage is more effective in advanced gastric cancer. METHODS: This was a multicenter retrospective observational study. We analyzed patients who received nivolumab monotherapy as the third-line regimen for unresectable advanced or recurrent gastric cancer between October 2017 and December 2022. They were divided into the RAM (RAM-treated) group and the non-RAM (non-treated) group according to the RAM usage in the second-line regimen. The primary outcome was to compare the overall survival after nivolumab administration in the third-line regimen between the RAM and non-RAM groups. RESULTS: Fifty-two patients were included in the present study: 42 patients in the RAM group and ten patients in the non-RAM group. The median overall survival was significantly longer in the RAM group than in the non-RAM group (8.5 months vs 6.9 months, p < 0.05). In the RAM group, patients without peritoneal metastasis had significantly better median overall survival than those with peritoneal metastasis (23.8 months vs 7.7 months, p = 0.0033). Multivariate Cox-proportional hazards analyses showed that the presence of peritoneal metastasis (hazard ratio, 2.4; 95% confidence interval 1.0-5.7) alone was significantly associated with overall survival in the RAM group. CONCLUSIONS: The use of RAM prior to nivolumab monotherapy may contribute to prolonged survival in patients with gastric cancer, especially those without peritoneal metastasis.

    DOI: 10.1007/s40801-024-00460-z

    PubMed

    researchmap

  • Long-term outcomes of endoscopic resection of superficial esophageal squamous cell carcinoma in late-elderly patients. 国際誌

    Katsunori Matsueda, Seiji Kawano, Keisuke Fukui, Shoichiro Hirata, Takuya Satomi, Shoko Inoo, Kenta Hamada, Yoshiyasu Kono, Masaya Iwamuro, Yoshiro Kawahara, Motoyuki Otsuka

    Journal of gastroenterology and hepatology   39 ( 12 )   2664 - 2671   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: As the population ages, the number of elderly patients with superficial esophageal squamous cell carcinoma (ESCC) is increasing. We aimed to clarify the indications for endoscopic resection (ER) in late-elderly patients with ESCC in terms of life expectancy. METHODS: Patients aged ≥75 years who underwent ER for ESCC at our institution from January 2005 to December 2018 were enrolled. Clinical data, including the Eastern Cooperative Oncology Group performance status, American Society of Anesthesiologists physical status (ASA-PS), Charlson comorbidity index, and prognostic nutritional index (PNI), were collected at the time of ER. The main outcome measure was overall survival (OS). RESULTS: Two hundred eight consecutive patients were enrolled. The patients' median age was 78 years (range, 75-89 years). The 5-year follow-up rate was 88.5% (median follow-up period, 6.6 years). The 5-year OS rate was 79.2% (95% confidence interval [CI], 72.2-84.8), and 5-year net survival standardized for age, sex, and calendar year was 1.04 (95% CI, 0.98-1.09). In the multivariate analysis, an ASA-PS of 3 (hazard ratio, 2.45; 95% CI, 1.16-5.17) and PNI of <44.0 (hazard ratio, 2.73; 95% CI, 1.38-5.40) were independent prognostic factors. When neither of these factors was met, the 5-year OS rate was 87.8% (95% CI, 80.0-92.9), and 5-year net survival was 1.08 (95% CI, 1.02-1.14). CONCLUSIONS: ER for ESCC in late-elderly patients may improve life expectancy. ER is recommended in patients with a good ASA-PS and PNI.

    DOI: 10.1111/jgh.16764

    PubMed

    researchmap

  • Rates and risk factors of bleeding after gastric endoscopic submucosal dissection with continuous warfarin or 1-day withdrawal of direct oral anticoagulants. 国際誌

    Shoichiro Hirata, Kenta Hamada, Masaya Iwamuro, Hirokazu Mouri, Koji Miyahara, Takao Tsuzuki, Kenji Yamauchi, Sayo Kobayashi, Sakuma Takahashi, Ryuta Takenaka, Shinichiro Hori, Masafumi Inoue, Tatsuya Toyokawa, Mamoru Nishimura, Shuhei Ishiyama, Jiro Miyaike, Ryo Kato, Minoru Matsubara, Naoko Yunoki, Hiromitsu Kanzaki, Yoshiro Kawahara, Hiroyuki Okada, Hideki Ishikawa, Motoyuki Otsuka

    Journal of gastroenterology and hepatology   39 ( 12 )   2760 - 2766   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIM: The 2017 Japanese guidelines recommend continuing warfarin therapy during the perioperative period or discontinuing direct oral anticoagulants (DOACs) only on the day of endoscopic submucosal dissection for early gastric cancer. However, their safety has not been sufficiently explored. This study aimed to validate this management method. METHODS: This retrospective, multicenter study analyzed the characteristics and outcomes of patients who underwent gastric endoscopic submucosal dissection between July 2017 and June 2019. The patients were categorized according to the use of warfarin or DOACs. RESULTS: Among the 62 eligible patients, 53 (85%) were male (median age, 76 years). Warfarin was used in 10 patients (16%) and DOACs in 52 patients (84%). Fourteen patients taking DOACs (27%) used concomitant antiplatelet agents, with seven patients (13%) continuing treatment at the time of the endoscopic procedure. No postprocedural bleeding occurred in patients receiving warfarin (0%), whereas 10 cases (19%) of bleeding occurred in patients receiving DOACs: rivaroxaban, 0% (0/22); dabigatran, 0% (0/2); edoxaban, 43% (6/14); and apixaban, 29% (4/14). The type of anticoagulant (P < 0.01) and continuation of antiplatelet therapy (P = 0.02) were risk factors for postprocedural bleeding in patients receiving DOACs. Intraprocedural bleeding requiring transfusion or symptomatic thromboembolic events were not reported. CONCLUSIONS: Continuous warfarin therapy is preferred. DOAC withdrawal 1 day before a procedure is associated with a high bleeding rate, which may differ for different types of anticoagulants. The continuation of antiplatelet medications in patients receiving DOACs carries a high risk of bleeding and is a future challenge.

    DOI: 10.1111/jgh.16757

    PubMed

    researchmap

  • A Case of Esophageal Squamous Cell Carcinoma Detected After Peroral Endoscopic Myotomy in a Patient With Achalasia. 国際誌

    Tomohiro Kamio, Shoichiro Hirata, Kenta Hamada, Masaya Iwamuro, Motoyuki Otsuka

    Cureus   16 ( 10 )   e71604   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Achalasia, a chronic esophageal motility disorder, increases the risk of esophageal squamous cell carcinoma. Despite effective treatment with peroral endoscopic myotomy (POEM), patients remain at risk of malignancy. We present the case of a 75-year-old Japanese woman diagnosed with achalasia who was found to have esophageal squamous cell carcinoma three months after POEM. Early detection through endoscopic surveillance and biopsy led to successful endoscopic submucosal dissection. This case underscores the need for ongoing surveillance of patients with achalasia post-POEM to ensure early identification and treatment of potential malignancies.

    DOI: 10.7759/cureus.71604

    PubMed

    researchmap

  • Gingival Bleeding in a Heavy Drinker. 国際誌

    Masaya Iwamuro, Tomohiro Kamio, Motoyuki Otsuka

    Cureus   16 ( 10 )   e71133   2024年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    This case report presents a 34-year-old Japanese man with hematemesis who was ultimately diagnosed with gingival bleeding due to periodontitis via esophagogastroduodenoscopy. Although endoscopic examination revealed no gastrointestinal lesions, persistent bleeding from the gums was observed, highlighting the need to consider non-gastrointestinal sources of bleeding in such scenarios. Heavy alcohol consumption likely contributed to poor oral health and increased the risk of oral bleeding. This case emphasizes the importance of thorough endoscopic evaluation of the oral and pharyngolaryngeal regions, particularly when common gastrointestinal sources of bleeding are excluded. A comprehensive diagnostic approach is essential to avoid overlooking less common causes of bleeding.

    DOI: 10.7759/cureus.71133

    PubMed

    researchmap

  • Effectiveness of data-augmentation on deep learning in evaluating rapid on-site cytopathology at endoscopic ultrasound-guided fine needle aspiration. 国際誌

    Yuki Fujii, Daisuke Uchida, Ryosuke Sato, Taisuke Obata, Matsumi Akihiro, Kazuya Miyamoto, Kosaku Morimoto, Hiroyuki Terasawa, Tatsuhiro Yamazaki, Kazuyuki Matsumoto, Shigeru Horiguchi, Koichiro Tsutsumi, Hironari Kato, Hirofumi Inoue, Ten Cho, Takayoshi Tanimoto, Akimitsu Ohto, Yoshiro Kawahara, Motoyuki Otsuka

    Scientific reports   14 ( 1 )   22441 - 22441   2024年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Rapid on-site cytopathology evaluation (ROSE) has been considered an effective method to increase the diagnostic ability of endoscopic ultrasound-guided fine needle aspiration (EUS-FNA); however, ROSE is unavailable in most institutes worldwide due to the shortage of cytopathologists. To overcome this situation, we created an artificial intelligence (AI)-based system (the ROSE-AI system), which was trained with the augmented data to evaluate the slide images acquired by EUS-FNA. This study aimed to clarify the effects of such data-augmentation on establishing an effective ROSE-AI system by comparing the efficacy of various data-augmentation techniques. The ROSE-AI system was trained with increased data obtained by the various data-augmentation techniques, including geometric transformation, color space transformation, and kernel filtering. By performing five-fold cross-validation, we compared the efficacy of each data-augmentation technique on the increasing diagnostic abilities of the ROSE-AI system. We collected 4059 divided EUS-FNA slide images from 36 patients with pancreatic cancer and nine patients with non-pancreatic cancer. The diagnostic ability of the ROSE-AI system without data augmentation had a sensitivity, specificity, and accuracy of 87.5%, 79.7%, and 83.7%, respectively. While, some data-augmentation techniques decreased diagnostic ability, the ROSE-AI system trained only with the augmented data using the geometric transformation technique had the highest diagnostic accuracy (88.2%). We successfully developed a prototype ROSE-AI system with high diagnostic ability. Each data-augmentation technique may have various compatibilities with AI-mediated diagnostics, and the geometric transformation was the most effective for the ROSE-AI system.

    DOI: 10.1038/s41598-024-72312-3

    PubMed

    researchmap

  • Gastric adenocarcinoma and proximal polyposis of the stomachに対する内視鏡診療の現状と今後の課題

    川野 誠司, 田中 健大, 大塚 基之

    Gastroenterological Endoscopy   66 ( 9 )   1663 - 1671   2024年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • Adverse events after different endoscopic resection procedures for small and intermediate-sized colorectal polyps. 査読 国際誌

    Junki Toyosawa, Yasushi Yamasaki, Yuki Aoyama, Kensuke Takei, Shoko Igawa, Toshihiro Inokuchi, Hideaki Kinugasa, Masahiro Takahara, Sakiko Hiraoka, Hiroyuki Okada, Motoyuki Otsuka

    Digestive diseases (Basel, Switzerland)   42 ( 6 )   1 - 9   2024年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND STUDY AIMS: Cold snare polypectomy (CSP) and underwater endoscopic mucosal resection (UEMR) have been developed recently, in addition to conventional methods, but adverse events of each method have not been fully clarified. We compared outcomes of each method for the appropriate choice. PATIENTS AND METHODS: Patients who underwent CSP, endoscopic mucosal resection (EMR)/hot snare polypectomy (HSP) or UEMR for small and intermediate-sized colorectal polyps between April 2017 and June 2020 were retrospectively examined. The rate of adverse events and recurrences due to each method were determined as main outcomes. Clinical factors related with adverse events were examined. RESULTS: A total of 1,025 patients with 3,163 polyps underwent polypectomy using any of the methods. CSP, EMR/HSP and UEMR were performed for 704 (22.2%), 2,145 (67.8%) and 314 polyps (9.9%), and median size for each method was 4, 6 and 7 mm, respectively. Delayed bleeding for CSP, EMR/HSP and UEMR was 0%, 0.2% and 0.6% (P = 0.15), and perforation was 0%, 0.1% and 0%, respectively (P = 0.62). Recurrence after CSP, EMR/HSP and UEMR was 0.1%, 0.04% and 1.0%, respectively (P &lt; 0.01). Recurrence for UEMR was significantly higher in the early stage of procedure introduction (P = 0.001). Oral anticoagulants were the risk factor for delayed bleeding (P &lt; 0.01, respectively). CONCLUSIONS: There was no significant difference regarding adverse events among each method for small and intermediate-sized polyps, although recurrence rate after UEMR was higher than other methods.

    DOI: 10.1159/000540365

    PubMed

    researchmap

  • Initial clinical experience with durvalumab plus tremelimumab in patients with unresectable hepatocellular carcinoma in real‑world practice. 査読 国際誌

    Shigeo Shimose, Issei Saeki, Tetsu Tomonari, Takanori Ito, Joji Tani, Yasuto Takeuchi, Naoki Yoshioka, Takehito Naito, Mamiko Takeuchi, Satoru Kakizaki, Takeshi Hatanaka, Kyo Sasaki, Tetsuya Yasunaka, Masahiro Sakata, Hideki Iwamoto, Satoshi Itano, Tomotake Shirono, Norikazu Tanabe, Takafumi Yamamoto, Atsushi Naganuma, Soji Nishina, Motoyuki Otsuka, Hiroki Kawashima, Tetsuji Takayama, Taro Takami, Takumi Kawaguchi

    Oncology letters   28 ( 2 )   397 - 397   2024年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Although durvalumab plus tremelimumab (Dur/Tre) has been approved as first-line therapy for patients with unresectable hepatocellular carcinoma (u-HCC), its outcomes in real-world clinical practice are unclear. The present study aimed to evaluate the efficacy and safety of Dur/Tre treatment. This multicenter study was conducted between March 2023 and January 2024, and included 120 patients with u-HCC treated with Dur/Tre. Among the patients, 44 had no history of systemic treatment. Progression-free survival (PFS), therapeutic response and adverse events (AEs) were assessed. The objective response rate (ORR) and disease control rates (DCR) were 15.8 and 53.3%, respectively. The median PFS was 3.9 months. The incidence rates of AEs of any grade and those grade 3 or higher were 83.3 and 36.7%, respectively. Liver injury was the most frequent AE of any grade and grade 3 or higher. Although there was no significant difference in ORR and PFS between the first and later line groups (ORR 15.8 vs. 15.7%, P=0.986; PFS 4.5 vs. 3.6 months, P=0.213), there was a significant difference in DCR between the two groups (65.8 vs. 45.9%, P=0.034). No significant differences were noted between the first- and later-line treatment groups regarding the incidence rate of AEs. Decision tree analysis revealed that poor liver function and advanced age were significant variables for discontinuation owing to AEs. In conclusion, Dur/Tre as first-line therapy had better disease control responses compared with later-line therapy; however, this regimen should be carefully administered to patients with deteriorating hepatic function or advanced age.

    DOI: 10.3892/ol.2024.14530

    PubMed

    researchmap

  • Gastric syphilis displaying multiple annular lesions. 査読 国際誌

    Masaya Iwamuro, Takehiro Tanaka, Motoyuki Otsuka

    Gastrointestinal endoscopy   100 ( 2 )   332 - 333   2024年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.gie.2024.03.001

    PubMed

    researchmap

  • 【膵・胆道癌の発生・進展メカニズムを探る】胆道癌の薬剤耐性メカニズム

    堤 康一郎, 小幡 泰介, 織田 崇志, 松三 明宏, 宮本 和也, 寺澤 裕之, 藤井 佑樹, 内田 大輔, 松本 和幸, 堀口 繁, 大塚 基之

    胆と膵   45 ( 8 )   857 - 862   2024年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    researchmap

  • 【今推しの肝胆膵研究手法と疾患モデル】新規モデルによる肝胆膵研究 胆嚢オルガノイドを用いた新規治療の開発

    織田 崇志, 堤 康一郎, 大塚 基之

    肝胆膵   89 ( 2 )   249 - 254   2024年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • 【膵・胆道癌の発生・進展メカニズムを探る】膵癌の薬剤耐性メカニズム

    寺澤 裕之, 堤 康一郎, 原田 圭, 服部 直, 菊池 達也, 小幡 泰介, 佐藤 亮介, 織田 崇志, 松三 明宏, 宮本 和也, 藤井 佑樹, 赤穂 宗一郎, 内田 大輔, 松本 和幸, 堀口 繁, 大塚 基之

    胆と膵   45 ( 8 )   801 - 806   2024年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    researchmap

  • 【膵・胆道癌の発生・進展メカニズムを探る】胆道癌の薬剤耐性メカニズム

    堤 康一郎, 小幡 泰介, 織田 崇志, 松三 明宏, 宮本 和也, 寺澤 裕之, 藤井 佑樹, 内田 大輔, 松本 和幸, 堀口 繁, 大塚 基之

    胆と膵   45 ( 8 )   857 - 862   2024年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    researchmap

  • 【膵・胆道癌の発生・進展メカニズムを探る】膵癌の薬剤耐性メカニズム

    寺澤 裕之, 堤 康一郎, 原田 圭, 服部 直, 菊池 達也, 小幡 泰介, 佐藤 亮介, 織田 崇志, 松三 明宏, 宮本 和也, 藤井 佑樹, 赤穂 宗一郎, 内田 大輔, 松本 和幸, 堀口 繁, 大塚 基之

    胆と膵   45 ( 8 )   801 - 806   2024年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    researchmap

  • 【今推しの肝胆膵研究手法と疾患モデル】新規モデルによる肝胆膵研究 胆嚢オルガノイドを用いた新規治療の開発

    織田 崇志, 堤 康一郎, 大塚 基之

    肝胆膵   89 ( 2 )   249 - 254   2024年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • Recent updates on treatment options for primary follicular lymphoma of the gastrointestinal tract. 査読 国際誌

    Masaya Iwamuro, Takehiro Tanaka, Daisuke Ennishi, Motoyuki Otsuka

    Expert review of gastroenterology & hepatology   18 ( 7 )   1 - 9   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Primary gastrointestinal follicular lymphoma is a subtype of follicular lymphoma that originates directly from the gastrointestinal tract. Pathologically, it exhibits substantial similarities with the secondary gastrointestinal involvement observed in nodal follicular lymphoma. However, primary gastrointestinal follicular lymphoma presents clinically distinct features, necessitating divergent considerations in treatment selection compared with nodal follicular lymphoma. AREAS COVERED: This narrative review focused on recent articles (2018-2023) regarding the long-term prognosis and treatment options for gastrointestinal follicular lymphoma. In addition, a brief overview of gastrointestinal follicular lymphomas is provided. EXPERT OPINION: Patients with primary gastrointestinal follicular lymphoma often present with a low tumor burden. Lymphoma lesions typically remain asymptomatic for several years or may undergo spontaneous regression without immediate treatment. Therefore, a 'watch and wait' approach is justified. Conversely, when large tumor masses are identified in the gastrointestinal tract, the potential for tumor bleeding or intestinal obstruction requires timely therapeutic interventions.

    DOI: 10.1080/17474124.2024.2380337

    PubMed

    researchmap

  • Characteristics of Early Gastric Cancer in a Patient with a History of Helicobacter pylori Infection and No History of Eradication Therapy. 査読

    Sakiko Kuraoka, Seiji Kawano, Shoko Ino, Takuya Satomi, Kenta Hamada, Yoshiyasu Kono, Masaya Iwamuro, Yoshiro Kawahara, Takehiro Tanaka, Hiroyuki Okada, Motoyuki Otsuka

    Internal medicine (Tokyo, Japan)   64 ( 3 )   343 - 350   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Objective The characteristics of gastric cancer in patients with atrophic mucosa and no apparent history of Helicobacter pylori eradication have not been thoroughly investigated. Therefore, this study examined the clinicopathological characteristics of gastric cancer in these patients. Methods We retrospectively examined the endoscopic and pathological characteristics of gastric cancer in patients who underwent endoscopic submucosal dissection. Patients or Materials We divided the patients into 2 groups: those with gastric atrophy and no history of eradication (group A; n =102) and those with a history of eradication (group B; n =161). In group A, patients were further divided into mild atrophy (group C) and severe atrophy (group D) groups, while group B was further divided into those who underwent eradication treatment >5 years ago (group E) and those who underwent eradication 1-5 years ago (group F). Results Group A comprised significantly older individuals (75±8.0 vs. 71±7.5 years old, p <0.001) with a higher frequency of elevated gastric cancer than group B (32.4% vs. 17.4%, p =0.006). Compared with group E, group A was older and had a greater incidence of elevated gastric cancer. The incidence of gastric cancer in the U or M region was lower in group C than in group D. Conclusion Gastric cancer in patients with gastric atrophy and no history of eradication was associated with an older age and higher frequency of elevated-type morphology than in those with a history of eradication.

    DOI: 10.2169/internalmedicine.3617-24

    PubMed

    researchmap

  • Colorectal Ganglioneuromas Associated with Cowden Syndrome.

    Toshiki Ozato, Yasushi Yamasaki, Toshihiro Inokuchi, Motoyuki Otsuka

    Internal medicine (Tokyo, Japan)   63 ( 13 )   1959 - 1960   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.2169/internalmedicine.2496-23

    PubMed

    researchmap

  • Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab". 国際誌

    Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso, Kazuya Kariyama, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Toshifumi Tada, Tetsuya Yasunaka, Masahiro Sakata, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Akinobu Takaki, Motoyuki Otsuka

    Liver international : official journal of the International Association for the Study of the Liver   44 ( 7 )   1736 - 1737   2024年7月

     詳細を見る

    記述言語:英語  

    DOI: 10.1111/liv.15964

    PubMed

    researchmap

  • Small Intestinal Complications of Intestinal Transplant-Associated Microangiopathy Post-stem Cell Transplantation. 国際誌

    Daisuke Kametaka, Masaya Iwamuro, Takehiro Tanaka, Ken-Ichi Matsuoka, Motoyuki Otsuka

    Cureus   16 ( 7 )   e64111   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    We present the case of a patient who underwent human leukocyte antigen-haploidentical transplantation for T-cell acute lymphoblastic leukemia. Seven weeks after transplantation, the patient developed intestinal transplant-associated microangiopathy (iTAM). Although the iTAM was resolved temporarily, it recurred. Video capsule enteroscopy revealed multiple erosions and shallow ulcers in the jejunum and ileum. To the best of our knowledge, this is the first report to present images of possible small intestinal lesions in iTAM. The small intestinal mucosal images presented herein may potentially aid in the management of similar patients.

    DOI: 10.7759/cureus.64111

    PubMed

    researchmap

  • Risk factors and treatment strategies for cholecystitis after metallic stent placement for malignant biliary obstruction: a multicenter retrospective study. 査読 国際誌

    Akihiro Matsumi, Hironari Kato, Taiji Ogawa, Toru Ueki, Masaki Wato, Masakuni Fujii, Tatsuya Toyokawa, Ryo Harada, Yuki Ishihara, Masahiro Takatani, Hirofumi Tsugeno, Naoko Yunoki, Takeshi Tomoda, Toshiharu Mitsuhashi, Motoyuki Otsuka

    Gastrointestinal endoscopy   100 ( 1 )   76 - 84   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: Cholecystitis can occur after self-expandable metallic stent (SEMS) placement for malignant biliary obstruction (MBO), but the best treatment option for cholecystitis has not been determined. Here, we aimed to identify the risk factors of cholecystitis after SEMS placement and determine the best treatment option. METHODS: Incidence, treatments, and predictive factors of cholecystitis were retrospectively evaluated in 1084 patients with distal MBO (DMBO) and 353 patients with hilar MBO (HMBO) who underwent SEMS placement at 12 institutions from January 2012 to March 2021. RESULTS: Cholecystitis occurred in 7.5% of patients with DMBO and 5.9% of patients with HMBO. The recurrence rate was significantly lower (P = .043) and the recurrence-free period significantly longer (P = .039) in endoscopic procedures than in percutaneous procedures for cholecystitis treatment. EUS-guided gallbladder drainage (EUS-GBD) was better in terms of technical success, procedure time, and recurrence-free period than endoscopic transpapillary gallbladder drainage. Obstruction across the cystic duct orifice by tumor (P = .015) and by stent (P = .037) were independent risk factors for cholecystitis in DMBO. Cases with multiple SEMS placements (odds ratio [OR], 11; 95% confidence interval [CI], 0.68-190; P = .091) and with gallbladder stones (OR, 2.3; 95% CI ,0.92-5.6; P = .075) had a higher risk for cholecystitis in HMBO. CONCLUSIONS: The incidences of cholecystitis after SEMS placement for DMBO and HMBO were similar. EUS-GBD is the optimal treatment option for patients with cholecystitis after SEMS placement for MBO.

    DOI: 10.1016/j.gie.2024.02.019

    PubMed

    researchmap

  • 後期高齢者におけるIPMNの治療移行割合及び長期経過についての検討

    宮本 和也, 松本 和幸, 服部 直, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 森本 光作, 寺澤 裕之, 藤井 佑樹, 内田 大輔, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    膵臓   39 ( 3 )   A425 - A425   2024年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本膵臓学会  

    researchmap

  • 膵EUS-FNA診断の功罪 嚢胞・壊死を伴う膵管癌に対するFNA/B合併症リスクの検討

    寺澤 裕之, 松本 和幸, 田中 健大, 友田 健, 小川 泰司, 石原 裕基, 菊池 達也, 小幡 泰介, 織田 崇志, 松三 明宏, 宮本 和也, 森本 光作, 藤井 佑樹, 山崎 辰洋, 内田 大輔, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    膵臓   39 ( 3 )   A234 - A234   2024年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本膵臓学会  

    researchmap

  • Predictive factors for transition to conversion therapy in hepatocellular carcinoma using atezolizumab plus bevacizumab. 国際誌

    Tatsuya Kikuchi, Yasuto Takeuchi, Kazuhiro Nouso, Kazuya Kariyama, Kenji Kuwaki, Junichi Toshimori, Shota Iwado, Akio Moriya, Hiroaki Hagihara, Hiroyuki Takabatake, Toshifumi Tada, Tetsuya Yasunaka, Masahiro Sakata, Masahiko Sue, Nozomi Miyake, Takuya Adachi, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Akinobu Takaki, Motoyuki Otsuka

    Liver international : official journal of the International Association for the Study of the Liver   44 ( 6 )   1456 - 1463   2024年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: To identify predictive factors associated with successful transition to conversion therapy following combination therapy with atezolizumab and bevacizumab in the treatment of unresectable hepatocellular carcinoma (HCC). METHODS: In total, 188 patients with HCC, who received atezolizumab plus bevacizumab combination therapy as the first-line chemotherapy, were studied. Patients who achieved complete response (CR) with systemic chemotherapy alone were excluded. Clinical factors possibly linked to successful transition to conversion therapy and the achievement of cancer-free status were identified. RESULTS: Fifteen (8.0%) patients underwent conversion therapy. In the conversion group, there was a significantly higher proportion of patients with Barcelona Clinic Liver Cancer (BCLC) stage A or B (73.3% versus [vs.] 45.1%; p = .03) and tended to have lower Child-Pugh scores and alpha-fetoprotein levels. Multivariate analysis revealed that BCLC stage was a predictive factor for the implementation of conversion therapy (A or B; odds ratio 3.7 [95% CI: 1.1-13]; p = .04). Furthermore, 10 (66.7%) patients achieved cancer-free status and exhibited a smaller number of intrahepatic lesions at the start of treatment (3.5 vs. 7; p < .01), and a shorter interval between systemic chemotherapy induction and conversion therapy (131 vs. 404 days; p < .01). In addition, the rate of achieving cancer-free status by undergoing surgical resection or ablation therapy was significantly higher (p = .03). CONCLUSION: BCLC stage was the sole predictive factor for successful transition to conversion therapy when using combination therapy with atezolizumab and bevacizumab to treat HCC. Furthermore, a small number of intrahepatic lesions and early transition to conversion therapy were associated with the achievement of cancer-free status.

    DOI: 10.1111/liv.15907

    PubMed

    researchmap

  • A Duodenal Ulcer and Biliopancreatic Lesions: What is the Culprit? 査読 国際誌

    Ryosuke Sato, Kazuyuki Matsumoto, Motoyuki Otsuka

    Gastroenterology   167 ( 7 )   1266 - 1269   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2024.05.027

    PubMed

    researchmap

  • Current status of endoscopic ultrasound-guided antitumor treatment for pancreatic cancer. 査読 国際誌

    Kazuyuki Matsumoto, Hironari Kato, Koichiro Tsutsumi, Motoyuki Otsuka

    Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society   37 ( 1 )   18 - 28   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Endoscopic ultrasound (EUS) was developed in the 1990s and has significantly transformed pancreatic tumor diagnosis. Subsequently, EUS has rapidly shifted from being a purely diagnostic procedure to being used in a wide range of interventional procedures. Recently, new therapeutic techniques, such as EUS-guided fine needle injection (EUS-FNI) or radiofrequency ablation (RFA), have been developed to deliver various antitumor agents. Despite technological advancements, pancreatic cancer (PC) has a poor prognosis and improvements in treatment outcomes are urgently required. One of the reasons for the limited response to antitumor agents in PC is the abundant desmoplasia and hypovascular nature of the tumor, complicating drug delivery into the tumor. Thus, changing the tumor microenvironment may be important to enhance the effectiveness of chemotherapy, and direct injection of antitumor agents into the tumor under EUS guidance can help overcome treatment challenges in PC. Treatment approaches using the EUS-FNI or RFA technique are expected to further improve the prognosis of PC. Therefore, this study reviewed the existing literature on EUS-guided antitumor therapy, specifically highlighting its application in PC to address the current challenges and to identify potential advancements in the field.

    DOI: 10.1111/den.14815

    PubMed

    researchmap

  • Impact of Nutritional Status on Neutrophil-to-Lymphocyte Ratio as a Predictor of Efficacy and Adverse Events of Immune Check-Point Inhibitors. 査読 国際誌

    Masahiko Sue, Yasuto Takeuchi, Shoichiro Hirata, Akinobu Takaki, Motoyuki Otsuka

    Cancers   16 ( 10 )   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The neutrophil -to-lymphocyte ratio (NLR) is useful for predicting the effectiveness of treatment with immune checkpoint inhibitors (ICIs) and immune-related adverse events (irAEs). Because a growing body of evidence has recently shown that the number of lymphocytes that comprise NLR fluctuates according to nutritional status, this study examined whether the usefulness of NLR varies in ICI treatment due to changes in nutritional status. A retrospective analysis was performed on 1234 patients who received ICI treatment for malignant tumors at our hospital. Progression-free survival (PFS) was significantly prolonged in patients with NLR < 4. Multivariate analysis revealed that the factors associated with the occurrence of irAE were NLR < 4 and the use of ipilimumab. However, when limited to cases with serum albumin levels <3.8 g/dL, lymphocyte counts significantly decreased, and the associations between NLR and PFS and between NLR and irAE occurrence disappeared. In contrast, when limited to the cases with serum albumin levels ≥3.8 g/dL, the associations remained, with significantly prolonged PFS and significantly increased irAE occurrence at NLR < 4. NLR may be a good predictive tool for PFS and irAE occurrence during ICI treatment when a good nutritional status is maintained.

    DOI: 10.3390/cancers16101811

    PubMed

    researchmap

  • Association of screening tool scores with overall survival in older patients with unresectable gastrointestinal or biliary pancreatic cancer: A retrospective study. 国際誌

    Shoko Inoo, Yoshiyasu Kono, Hiromitsu Kanzaki, Shigeru Horiguchi, Hironari Kato, Yasushi Yamasaki, Shoichiro Hirata, Sakiko Kuraoka, Katsunori Matsueda, Shotaro Okanoue, Takuya Satomi, Kenta Hamada, Masaya Iwamuro, Seiji Kawano, Yoshiro Kawahara, Hiroyuki Okada, Motoyuki Otsuka

    Journal of geriatric oncology   15 ( 4 )   101714 - 101714   2024年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.jgo.2024.101714

    PubMed

    researchmap

  • Drug-induced mucosal alterations observed during esophagogastroduodenoscopy. 国際誌

    Masaya Iwamuro, Seiji Kawano, Motoyuki Otsuka

    World journal of gastroenterology   30 ( 16 )   2220 - 2232   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Several features of drug-induced mucosal alterations have been observed in the upper gastrointestinal tract, i.e., the esophagus, stomach, and duodenum. These include pill-induced esophagitis, desquamative esophagitis, worsening of gastroesophageal reflux, chemotherapy-induced esophagitis, proton pump inhibitor-induced gastric mucosal changes, medication-induced gastric erosions and ulcers, pseudomelanosis of the stomach, olmesartan-related gastric mucosal inflammation, lanthanum deposition in the stomach, zinc acetate hydrate tablet-induced gastric ulcer, immune-related adverse event gastritis, olmesartan-asso-ciated sprue-like enteropathy, pseudomelanosis of the duodenum, and lanthanum deposition in the duodenum. For endoscopists, acquiring accurate knowledge regarding these diverse drug-induced mucosal alterations is crucial not only for the correct diagnosis of these lesions but also for differential diag-nosis of other conditions. This minireview aims to provide essential information on drug-induced mucosal alterations observed on esophagogastroduodenoscopy, along with representative endoscopic images.

    DOI: 10.3748/wjg.v30.i16.2220

    PubMed

    researchmap

  • Endoscopic manifestation of intestinal transplant-associated microangiopathy after stem cell transplantation. 国際誌

    Masaya Iwamuro, Daisuke Ennishi, Nobuharu Fujii, Ken-Ichi Matsuoka, Takehiro Tanaka, Toshihiro Inokuchi, Sakiko Hiraoka, Motoyuki Otsuka

    BMC gastroenterology   24 ( 1 )   140 - 140   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Endoscopic features of intestinal transplant-associated microangiopathy (iTAM) have not been comprehensively investigated. This study aimed to examine the endoscopic characteristics of patients diagnosed with iTAM. METHODS: This retrospective analysis included 14 patients pathologically diagnosed with iTAM after stem cell transplantation for hematolymphoid neoplasms (n = 13) or thalassemia (n = 1). The sex, age at diagnosis, endoscopic features, and prognosis of each patient were assessed. Serological markers for diagnosing transplant-associated thrombotic microangiopathy were also evaluated. RESULTS: The mean age at the time of iTAM diagnosis was 40.2 years. Patients diagnosed based on the pathognomonic pathological changes of iTAM presented with diverse symptoms at the times of endoscopic examinations, including diarrhea (n = 10), abdominal pain (n = 5), nausea (n = 4), appetite loss (n = 2), bloody stools (n = 2), abdominal discomfort (n = 1), and vomiting (n = 1). At the final follow-up, six patients survived, while eight patients succumbed, with a median time of 100.5 days (range: 52-247) post-diagnosis. Endoscopic manifestations included erythematous mucosa (n = 14), erosions (n = 13), ulcers (n = 9), mucosal edema (n = 9), granular mucosa (n = 9), and villous atrophy (n = 4). Erosions and/or ulcers were primarily observed in the colon (10/14, 71%), followed by the ileum (9/13, 69%), stomach (4/10, 40%), cecum (5/14, 36%), duodenum (3/10, 30%), rectum (4/14, 29%), and esophagus (1/10, 10%). Cytomegalovirus infection (n = 4) and graft-versus-host disease (n = 2) coexisted within the gastrointestinal tract. Patients had de novo prolonged or progressive thrombocytopenia (6/14, 43%), decreased hemoglobin concentration (4/14, 29%), reduced serum haptoglobin level (3/14, 21%), and a sudden and persistent increase in lactate dehydrogenase level (2/14, 14%). Peripheral blood samples from 12 patients were evaluated for schistocytes, with none exceeding 4%. CONCLUSIONS: This study provides a comprehensive exploration of the endoscopic characteristics of iTAM. Notably, all patients exhibited erythematous mucosa throughout the gastrointestinal tract, accompanied by prevalent manifestations, such as erosions (93%), ulcers (64%), mucosal edema (64%), granular mucosa (64%), and villous atrophy (29%). Because of the low positivity for serological markers of transplant-associated thrombotic microangiopathy in patients with iTAM, endoscopic evaluation and biopsy of these lesions are crucial, even in the absence of these serological features.

    DOI: 10.1186/s12876-024-03221-y

    PubMed

    researchmap

  • Detection of residual stones by peroral direct cholangioscopy in patients with intrahepatic stones after hepaticojejunostomy: A prospective study (with video). 国際誌

    Kazuyuki Matsumoto, Hironari Kato, Akihiro Matsumi, Kazuya Miyamoto, Kosaku Morimoto, Yuki Fujii, Ryosuke Sato, Nao Hattori, Taisuke Obata, Hiroyuki Terasawa, Daisuke Uchida, Shigeru Horiguchi, Koichiro Tsutsumi, Motoyuki Otsuka

    Gastrointestinal endoscopy   100 ( 3 )   457 - 463   2024年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND AND AIMS: The difficulty of radiographic confirmation of the presence of stones remains a challenge in the treatment of intrahepatic bile duct (IHBD) stones in patients after hepaticojejunostomy (HJ). Peroral direct cholangioscopy (PDCS) enables direct observation of the bile duct and is useful for detecting and removing residual stones; however, its effectiveness is not clearly established in this clinical context. METHODS: This single-center, single-arm, prospective study included 44 patients with IHBD who underwent bowel reconstruction with HJ during the study period. Stone removal was performed by short-type double-balloon enteroscopy (DBE). Following balloon-occluded cholangiography, the DBE was exchanged for an ultraslim endoscope through the balloon overtube for PDCS. The primary endpoint was the rate of residual stones detected by PDCS. Secondary endpoints were success rate of PDCS, residual stone removal with PDCS, procedure time for PDCS, procedure-related adverse events, and stone recurrence rate. RESULTS: PDCS was successful in 39/44 patients (89%), among whom residual stones were detected in 16 (41%) (95% CI: 28%-54%). Twelve patients (75%) had residual stones <5 mm. Stone removal was successful in 15 (94%) patients and median procedure time for PDCS was 16 (IQR: 10-26) min. The rate of procedure-related adverse events was 7% (3/44), all of which improved with conservative treatment. During median follow-up of 2.1 years (IQR: 1.4-3.3), the overall probability of recurrence-free status at 1, 2, and 3 years was 100%, 92%, and 86%, respectively. CONCLUSIONS: PDCS is a safe and effective procedure for complete stone removal in patients with IHBD stones after HJ.

    DOI: 10.1016/j.gie.2024.04.014

    PubMed

    researchmap

  • UnderwaterとUnder-gelでの大腸腫瘍性病変に対する境界診断能の検討

    豊澤 惇希, 山崎 泰史, 青山 祐樹, 井川 翔子, 井口 俊博, 衣笠 秀明, 高原 政宏, 平岡 佐規子, 大塚 基之

    Gastroenterological Endoscopy   66 ( Suppl.1 )   969 - 969   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 結節を有するIPMNの良悪性診断における新規TIC解析プログラムを用いた造影EUSの有用性

    宮本 和也, 内田 大輔, 服部 直, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 森本 光作, 寺澤 裕之, 藤井 佑樹, 松本 和幸, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    Gastroenterological Endoscopy   66 ( Suppl.1 )   977 - 977   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 肝細胞癌の病態解明のためのトランスレーショナルリサーチ 血清抗PD1自己抗体高値はアテゾリズマブ/ベバシズマブ治療予後不良の予測因子となる

    高木 章乃夫, 松本 和幸, 佐々木 裕貴, 須江 真彦, 足立 卓哉, 和田 望, 竹内 康人, 大西 秀樹, 白羽 英則, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A236 - A236   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 経口胆道鏡検査におけるAIを用いた色素内視鏡画像への疑似変換

    佐藤 亮介, 松本 和幸, 冨谷 昌弘, 谷本 太郁由, 大戸 彰三, 原田 圭, 服部 直, 小幡 泰介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 藤井 佑樹, 内田 大輔, 衣笠 秀明, 堤 康一郎, 堀口 繁, 加藤 博也, 河原 祥朗, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A356 - A356   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 膵癌の分子異常と個別化治療 切除不能進行膵癌治療において生殖細胞BRCA病的変異は体細胞CGP結果によらず白金製剤治療効果予測因子となる

    堀口 繁, 加藤 博也, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 松本 和幸, 堤 康一郎, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A87 - A87   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 神経内分泌腫瘍の新しい治療戦略 膵消化管神経内分泌腫瘍肝転移に対するPRRTの治療効果予測因子についての検討

    堀口 繁, 加藤 博也, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 松本 和幸, 堤 康一郎, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A108 - A108   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 神経線維腫症の消化管合併症に関する検討

    本田 真奈美, 岩室 雅也, 山崎 泰史, 田中 健大, 川野 誠司, 平岡 佐規子, 河原 祥朗, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A349 - A349   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Satellite double-stranded RNA induces mesenchymal transition in pancreatic cancer by regulating alternative splicing. 査読 国際誌

    Takuma Iwata, Takahiro Kishikawa, Takahiro Seimiya, Genso Notoya, Tatsunori Suzuki, Chikako Shibata, Yu Miyakawa, Nariaki Odawara, Kazuyoshi Funato, Eri Tanaka, Mari Yamagami, Kazuma Sekiba, Motoyuki Otsuka, Kazuhiko Koike, Mitsuhiro Fujishiro

    The Journal of biological chemistry   300 ( 3 )   105742 - 105742   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Human satellite II (HSATII), composed of tandem repeats in pericentromeric regions, is aberrantly transcribed in epithelial cancers, particularly pancreatic cancer. Dysregulation of repetitive elements in cancer tissues can facilitate incidental dsRNA formation; however, it remains controversial whether dsRNAs play tumor-promoting or tumor-suppressing roles during cancer progression. Therefore, we focused on the double-stranded formation of HSATII RNA and explored its molecular function. The overexpression of double-stranded HSATII (dsHSATII) RNA promoted mesenchymal-like morphological changes and enhanced the invasiveness of pancreatic cancer cells. We identified an RNA-binding protein, spermatid perinuclear RNA-binding protein (STRBP), which preferentially binds to dsHSATII RNA rather than single-stranded HSATII RNA. The mesenchymal transition of dsHSATII-expressing cells was rescued by STRBP overexpression. Mechanistically, STRBP is involved in the alternative splicing of genes associated with epithelial-mesenchymal transition (EMT). We also confirmed that isoform switching of CLSTN1, driven by dsHSATII overexpression or STRBP depletion, induced EMT-like morphological changes. These findings reveal a novel tumor-promoting function of dsHSATII RNA, inducing EMT-like changes and cell invasiveness, thus enhancing our understanding of the biological significance of aberrant expression of satellite arrays in malignant tumors.

    DOI: 10.1016/j.jbc.2024.105742

    PubMed

    researchmap

  • 大腸鋸歯状病変の病態解明と診療戦略 Serrated polyposis syndromeの臨床病理学的特徴とその発癌ポテンシャルの検討

    平井 亮佑, 衣笠 秀明, 平岡 佐規子, 田中 健大, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A215 - A215   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • AIを用いた消化器疾患の診断・治療への応用 内視鏡画像を用いた早期胃癌の深達度診断支援プログラムの性能

    平田 翔一郎, 濱田 健太, 河原 祥朗, 倉岡 紗樹子, 内田 大輔, 河野 吉泰, 岩室 雅也, 川野 誠司, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A36 - A36   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 免疫関連有害事象による胃炎の5例

    岩室 雅也, 田中 健大, 平田 翔一郎, 河野 吉泰, 川野 誠司, 河原 祥朗, 大塚 基之

    Gastroenterological Endoscopy   66 ( 3 )   266 - 272   2024年3月

  • 経口胆道鏡検査におけるAIを用いた色素内視鏡画像への疑似変換

    佐藤 亮介, 松本 和幸, 冨谷 昌弘, 谷本 太郁由, 大戸 彰三, 原田 圭, 服部 直, 小幡 泰介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 藤井 佑樹, 内田 大輔, 衣笠 秀明, 堤 康一郎, 堀口 繁, 加藤 博也, 河原 祥朗, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A356 - A356   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 大腸鋸歯状病変の病態解明と診療戦略 Serrated polyposis syndromeの臨床病理学的特徴とその発癌ポテンシャルの検討

    平井 亮佑, 衣笠 秀明, 平岡 佐規子, 田中 健大, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A215 - A215   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Long-term monitoring of gastric mucosa-associated lymphoid tissue lymphoma in patients with extra copies of the MALT1 gene. 査読 国際誌

    Masaya Iwamuro, Ryuta Takenaka, Koji Miyahara, Shotaro Okanoue, Masao Yoshioka, Chihiro Sakaguchi, Kumiko Yamamoto, Yoshinari Kawai, Tatsuya Toyokawa, Takehiro Tanaka, Motoyuki Otsuka

    Scientific reports   14 ( 1 )   4953 - 4953   2024年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The objective of this study was to clarify the long-term prognosis of patients with gastric mucosa-associated lymphoid tissue (MALT) lymphoma with additional copies of MALT1. In this multicenter retrospective study, we enrolled 145 patients with gastric MALT lymphoma who underwent fluorescence in situ hybridization (FISH) analysis to detect t(11;18) translocation. The patient cohort was divided into three groups: Group A (n = 87), comprising individuals devoid of the t(11;18) translocation or extra MALT1 copies; Group B (n = 27), encompassing patients characterized by the presence of the t(11;18) translocation; and Group C (n = 31), including patients with extra MALT1 copies. The clinical outcomes in each cohort were collected. Over the course of a mean follow-up of 8.5 ± 4.2 years, one patient died of progressive MALT lymphoma, while 15 patients died due to etiologies unrelated to lymphoma. The progression or relapse of MALT lymphoma was observed in 11 patients: three in Group A, two in Group B, and six in Group C. In Groups A, B, and C, the 10-year overall survival rates were 82.5%, 93.8%, and 86.4%, respectively, and the 10-year event-free survival rates were 96.1%, 96.0%, and 82.9%, respectively. The event-free survival rate in Group C was significantly lower than that in Group A. However, no differences were observed in the 10-year event-free survival rates among individuals limited to stage I or II1 disease (equivalent to excluding patients with stage IV disease in this study, as there were no patients with stage II2), with rates of 98.6%, 95.8%, and 92.3% for Groups A, B, and C, respectively. In conclusion, the presence of extra copies of MALT1 was identified as an inferior prognostic determinant of event-free survival. Consequently, trisomy/tetrasomy 18 may serve as an indicator of progression and refractoriness to therapeutic intervention in patients with gastric MALT lymphoma, particularly stage IV gastric MALT lymphoma.

    DOI: 10.1038/s41598-024-55663-9

    PubMed

    researchmap

  • Endoscopic and clinical features of gastric emphysema. 査読 国際誌

    Masaya Iwamuro, Ryuta Takenaka, Tatsuya Toyokawa, Masahide Kita, Takao Tsuzuki, Masao Yoshioka, Tatsuhiro Gotoda, Shotaro Okanoue, Minoru Matsubara, Chihiro Sakaguchi, Motoyuki Otsuka

    Scientific reports   14 ( 1 )   2202 - 2202   2024年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Gastric emphysema is characterized by the presence of intramural gas in the stomach without bacterial infection. Due to its rarity, most reports on gastric emphysema have been limited to single-case studies, and this condition's clinical and endoscopic features have not been thoroughly investigated. In this study, we analyzed 45 patients with gastric emphysema from 10 institutions and examined their characteristics, endoscopic features, and outcomes. The mean age at diagnosis of gastric emphysema in our study population (35 males and 10 females) was 68.6 years (range, 14-95 years). The top five underlying conditions associated with gastric emphysema were the placement of a nasogastric tube (26.7%), diabetes mellitus (20.0%), post-percutaneous endoscopic gastrostomy (17.8%), malignant neoplasms (17.8%), and renal failure (15.6%). Among the 45 patients, 42 were managed conservatively with fasting and administration of proton pump inhibitors. Unfortunately, seven patients died within 30 days of diagnosis, and 35 patients experienced favorable recoveries. The resolution of gastric emphysema was confirmed in 30 patients through computed tomography (CT) scans, with a mean duration of 17.1 ± 34.9 days (mean ± standard deviation [SD], range: 1-180 days) from the time of diagnosis to the disappearance of the gastric intramural gas. There were no instances of recurrence. Endoscopic evaluation was possible in 18 patients and revealed that gastric emphysema presented with features such as redness, erosion, coarse mucosa, and ulcers, with fewer mucosal injuries on the anterior wall (72.2%), a clear demarcation between areas of mucosal injury and intact mucosa (61.1%), and predominantly longitudinal mucosal injuries on the stomach folds (50.0%). This study is the first English-language report to analyze endoscopic findings in patients with gastric emphysema.

    DOI: 10.1038/s41598-024-52633-z

    PubMed

    researchmap

  • Anti-PD-1 Autoantibody Predicts Survival of Patients With Hepatocellular Carcinoma Receiving Atezolizumab/Bevacizumab 国際誌

    Yuki Sasaki, Kazuyuki Matsumoto, Akinobu Takaki, Takuya Adachi, Masahiro Takahara, Keita Ozato, Yasuto Takeuchi, Masahiko Sue, Nozomi Miyake, Nozomu Wada, Hideki Onishi, Hidenori Shiraha, Takashi Oda, Koichiro Tsutsumi, Kazuhiro Nouso, Kazuya Kariyama, Hiroaki Hagihara, Akio Moriya, Motoyuki Otsuka

    Gastro Hep Advances   3 ( 8 )   1138 - 1147   2024年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.gastha.2024.07.018

    Scopus

    PubMed

    researchmap

  • Serum level of full-length connective tissue growth factor reflects liver fibrosis stage in patients with Fontan-associated liver disease. 査読 国際誌

    Tomomi Kogiso, Kayo Takayanagi, Tsutomu Ishizuka, Motoyuki Otsuka, Kei Inai, Yuri Ogasawara, Kentaro Horiuchi, Makiko Taniai, Katsutoshi Tokushige

    PloS one   19 ( 1 )   e0296375   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Chronic liver disease leads to liver fibrosis, and an accurate diagnosis of the fibrosis stage is crucial for medical management. Connective tissue growth factor (CTGF) is produced by endothelial cells and platelets and plays a central role in inducing fibrosis in various organs. In the present study, we tested the validity of measuring the serum levels of two types of CTGF to estimate the biopsy-confirmed liver fibrosis stage. METHODS: We used two detection antibodies targeting the N- and C-terminal of CTGF to measure the serum levels of two forms of CTGF consisting of its full length and its N-terminal fragment. We analyzed the level of CTGF (via enzyme-linked immunosorbent assay) and the liver fibrosis stage in 38 patients with Fontan-associated liver disease (FALD) (26 cases of which were diagnosed pathologically). Correlations were determined by multivariate analysis and the area under the receiver operating characteristic curve. The 65 patients with nonalcoholic fatty liver disease (NAFLD) were included as a disease control group for examination. RESULTS: Full-length CTGF was significantly inversely correlated with liver fibrosis in patients with FALD. Although the platelet count was also associated with the liver fibrosis stage, full-length CTGF was more closely correlated with the fibrosis stage. Furthermore, the level of full-length CTGF was inversely associated with high central venous pressure. Conversely, the serum level of CTGF was not correlated with the fibrosis stage in NAFLD. CONCLUSION: The serum level of full-length CTGF may be useful for estimating the liver fibrosis stage in patients with FALD.

    DOI: 10.1371/journal.pone.0296375

    PubMed

    researchmap

  • [Small intestinal perforation manifesting as post-transplant lymphoproliferative disorder occurring 23 years after living lung transplantation: a case report].

    Daisuke Kametaka, Masaya Iwamuro, Shoko Inoo, Seiji Kawano, Takehiro Tanaka, Yoshiro Kawahara, Motoyuki Otsuka

    Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology   121 ( 11 )   896 - 903   2024年

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)  

    A Japanese female patient underwent a living lung transplant at age 29 and has been on immunomodulatory drug therapy since then. At age 52, she presented with sudden hematochezia. Despite abdominal computed tomography scan, esophagogastroduodenoscopy, and colonoscopy, no definitive source of bleeding was identified. Considering the possibility of small bowel bleeding, video capsule endoscopy was performed, which revealed a suspected ulcerative lesion in the jejunum. Subsequent per-oral double-balloon endoscopy confirmed the presence of an ulcerative lesion in the jejunum. A potential pathological diagnosis of post-transplant lymphoproliferative disorder (PTLD) was considered based on endoscopic biopsy specimens from the jejunal lesion. However, before the pathologic biopsy results were available, the patient experienced small intestinal perforation, necessitating emergency partial resection. Pathologic examination revealed a dense proliferation of medium-to-large atypical lymphocytes with neutrophilic infiltration in the perforated area of the small intestinal wall. Immunostaining showed lymphoid cells positive for CD20 but negative for CD3. Epstein-Barr virus (EBV) -encoded RNA was detected by in situ hybridization, and Ki-67 staining demonstrated a higher percentage of positive cells. Consequently, an EBV-positive diffuse large B-cell lymphoma, developed as PTLD, was diagnosed. Complete remission was achieved with a reduced immunomodulatory drug dosage and rituximab therapy. She has been alive for 8 months postoperatively without recurrence. This case suggests that PTLD should be considered in assessing patients presenting with abdominal symptoms following organ transplantation.

    DOI: 10.11405/nisshoshi.121.896

    PubMed

    researchmap

  • Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy. 国際誌

    Issei Saeki, Shigeo Shimose, Tetsu Tomonari, Takanori Ito, Joji Tani, Yasuto Takeuchi, Naoki Yoshioka, Takehito Naito, Mamiko Takeuchi, Satoru Kakizaki, Takeshi Hatanaka, Kyo Sasaki, Tetsuya Yasunaka, Masahiro Sakata, Hideki Iwamoto, Satoshi Itano, Tomotake Shirono, Norikazu Tanabe, Takafumi Yamamoto, Yuki Kanayama, Atsushi Naganuma, Sohji Nishina, Motoyuki Otsuka, Hideki Kobara, Hiroki Kawashima, Tetsuji Takayama, Takumi Kawaguchi, Takahiro Yamasaki, Taro Takami

    PloS one   19 ( 9 )   e0311084   2024年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Durvalumab plus tremelimumab (Durva/Treme) combined immunotherapy is the first-line therapy recommended for unresectable hepatocellular carcinoma (HCC). Since sequential therapy is more effective in improving prognosis, tumor markers have been used as predictive biomarkers for response to systemic therapy. This study aimed to investigate the predictive ability of objective response (OR) by tumor markers for Durva/Treme therapy against HCC. In this multicenter study, 110 patients with HCC who received Durva/Treme therapy were retrospectively enrolled. The OR rate was 15.5%. To aid early decision-making regarding OR, we evaluated the predictors contributing to OR in two steps: before (first step) and 4 weeks after (second step) treatment induction. Changes in tumor markers (alpha-fetoprotein [AFP] and des-gamma-carboxy prothrombin [DCP]) from baseline to 4 weeks after treatment (ΔAFP/ΔDCP) were included as the input factors. In the first step, multivariable analysis identified only the baseline AFP level (odds ratio 3.497, p = 0.029) as a predictor of OR. Patients with AFP ≥ 400 ng/mL had a significantly higher OR rate than those with < 400 ng/mL (28.2 vs. 8.5%, p = 0.011), and there was no significant difference in progression-free survival (PFS) between the two groups. When AFP/DCP response was defined as a ≥10% reduction from baseline, multivariable analysis showed that AFP response (odds ratio 6.023, p = 0.042) and DCP response (odds ratio 11.657, p = 0.006) were both independent predictors of OR in the second step. The PFS of patients with AFP or DCP response was significantly longer than that of patients without AFP or DCP response. The study demonstrated that the use of AFP and DCP can predict the OR of patients with HCC receiving Durva/Treme therapy.

    DOI: 10.1371/journal.pone.0311084

    PubMed

    researchmap

  • Prospective observational study of zinc deficiency symptoms during first-line chemotherapy for gastric and colorectal cancer. 国際誌

    Chihiro Sakaguchi, Tomohiro Nishina, Yoshiyasu Kono, Kaori Hino, Akinori Asagi, Yoshinori Ohno, Takeshi Kajiwara, Seijin Nadano, Natsumi Yamashita, Mikiko Tohyama, Ichinosuke Hyodo, Hiroyuki Okada, Motoyuki Otsuka

    Journal of gastrointestinal oncology   14 ( 6 )   2384 - 2394   2023年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Zinc deficiency during long-term chemotherapy and its related symptoms, including skin rash, taste disorders, and oral mucositis, have not been sufficiently investigated. METHODS: This prospective observational study enrolled patients with gastric and colorectal cancer who underwent standard first-line chemotherapy. According to the Practice Guidelines for Zinc Deficiency, zinc deficiency is defined as a serum level of <60 µg/dL. Serum zinc levels were measured before and after (1, 3, and 6 months) chemotherapy, and symptoms were assessed using the Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events version 1.0. Repeated measures were analyzed using a generalized linear mixed model. RESULTS: Of the 61 enrolled patients, 48 who underwent standard first-line chemotherapy with fluoropyrimidine plus oxaliplatin were analyzed. Zinc deficiency was observed in 18 patients (38%) before chemotherapy. The least-squares means of serum zinc levels significantly decreased at 3 and 6 months of chemotherapy in 30 patients without zinc deficiency at the start of chemotherapy (both P<0.01) but not in 18 with zinc deficiency at the beginning. Changes in serum zinc levels during chemotherapy negatively correlated with changes in taste, rash, and itching (all P<0.04) in patients without zinc deficiency before treatment initiation. CONCLUSIONS: Serum zinc levels decreased during chemotherapy in zinc-non-deficient patients at the beginning of chemotherapy and correlated with taste changes, skin rash, and itching. Therefore, investigating whether zinc supplementation ameliorates these symptoms is necessary.

    DOI: 10.21037/jgo-23-517

    PubMed

    researchmap

  • A small molecule iCDM-34 identified by in silico screening suppresses HBV DNA through activation of aryl hydrocarbon receptor. 査読 国際誌

    Yutaka Furutani, Yoshinori Hirano, Mariko Toguchi, Shoko Higuchi, Xian-Yang Qin, Kaori Yanaka, Yumi Sato-Shiozaki, Nobuaki Takahashi, Marina Sakai, Pornparn Kongpracha, Takehiro Suzuki, Naoshi Dohmae, Mutsuko Kukimoto-Niino, Mikako Shirouzu, Shushi Nagamori, Harukazu Suzuki, Kaoru Kobayashi, Takahiro Masaki, Hiroo Koyama, Kazuma Sekiba, Motoyuki Otsuka, Kazuhiko Koike, Michinori Kohara, Soichi Kojima, Hideaki Kakeya, Tomokazu Matsuura

    Cell Death Discovery   9 ( 1 )   467 - 467   2023年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    IFN-alpha have been reported to suppress hepatitis B virus (HBV) cccDNA via APOBEC3 cytidine deaminase activity through interferon signaling. To develop a novel anti-HBV drug for a functional cure, we performed in silico screening of the binding compounds fitting the steric structure of the IFN-alpha-binding pocket in IFNAR2. We identified 37 compounds and named them in silico cccDNA modulator (iCDM)-1-37. We found that iCDM-34, a new small molecule with a pyrazole moiety, showed anti-HCV and anti-HBV activities. We measured the anti-HBV activity of iCDM-34 dependent on or independent of entecavir (ETV). iCDM-34 suppressed HBV DNA, pgRNA, HBsAg, and HBeAg, and also clearly exhibited additive inhibitory effects on the suppression of HBV DNA with ETV. We confirmed metabolic stability of iCDM-34 was stable in human liver microsomal fraction. Furthermore, anti-HBV activity in human hepatocyte-chimeric mice revealed that iCDM-34 was not effective as a single reagent, but when combined with ETV, it suppressed HBV DNA compared to ETV alone. Phosphoproteome and Western blotting analysis showed that iCDM-34 did not activate IFN-signaling. The transcriptome analysis of interferon-stimulated genes revealed no increase in expression, whereas downstream factors of aryl hydrocarbon receptor (AhR) showed increased levels of the expression. CDK1/2 and phospho-SAMHD1 levels decreased under iCDM-34 treatment. In addition, AhR knockdown inhibited anti-HCV activity of iCDM-34 in HCV replicon cells. These results suggest that iCDM-34 decreases the phosphorylation of SAMHD1 through CDK1/2, and suppresses HCV replicon RNA, HBV DNA, and pgRNA formation.

    DOI: 10.1038/s41420-023-01755-w

    PubMed

    researchmap

  • Successful removal of a proximally migrated pancreatic stent using a novel device delivery system. 査読 国際誌

    Akihiro Matsumi, Kazuyuki Matsumoto, Daisuke Uchida, Shigeru Horiguchi, Koichiro Tsutsumi, Hironari Kato, Motoyuki Otsuka

    Endoscopy   55 ( S 01 )   E641-E642   2023年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1055/a-2063-3408

    PubMed

    researchmap

  • Usefulness of the artificial intelligence-mediated virtual chromoendoscopy in peroral cholangioscopy. 査読 国際誌

    Ryosuke Sato, Kazuyuki Matsumoto, Hideaki Kinugasa, Daisuke Uchida, Shigeru Horiguchi, Hironari Kato, Motoyuki Otsuka

    Endoscopy   55 ( S 01 )   E971-E972   2023年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1055/a-2142-4555

    PubMed

    researchmap

  • 高齢者におけるステント治療の現状と工夫 高齢者の急性胆嚢炎におけるETGBDとEUS-GBDの比較検討

    服部 直, 宮本 和也, 松本 和幸, 加藤 博也, 大塚 基之

    日本消化器病学会中国支部例会・日本消化器内視鏡学会中国支部例会プログラム・抄録集   120回・131回   62 - 62   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 膵神経内分泌腫瘍の治療中にうっ血性左側結腸炎を発症した1例

    佐藤 亮介, 堀口 繁, 小幡 泰介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 内田 大輔, 松本 和幸, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器病学会中国支部例会・日本消化器内視鏡学会中国支部例会プログラム・抄録集   120回・131回   84 - 84   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • ロボット支援下膵頭十二指腸切除術後の捻転を伴う輸入脚症候群に対して内視鏡的整復を行った1例

    原田 圭, 藤井 佑樹, 小幡 泰介, 佐藤 亮介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 山崎 辰洋, 内田 大輔, 松本 和幸, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器病学会中国支部例会・日本消化器内視鏡学会中国支部例会プログラム・抄録集   120回・131回   112 - 112   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 短期間で急速に進行し、根治外科切除を行うも遠隔転移再発を来した十二指腸癌の一例

    渋谷 香苗, 河野 吉泰, 神尾 知宏, 平田 翔一郎, 倉岡 紗樹子, 稲生 祥子, 里見 拓也, 松枝 克典, 濱田 健太, 岩室 雅也, 川野 誠司, 河原 祥朗, 高木 弘誠, 楳田 祐三, 田中 健大, 大塚 基之

    日本消化器病学会中国支部例会・日本消化器内視鏡学会中国支部例会プログラム・抄録集   120回・131回   75 - 75   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 特発性肺線維症に対する肺移植後に重症膵炎を発症し、診断に苦慮した膵頭部癌の一例

    矢杉 賢吾, 堀口 しげる, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 藤井 祐樹, 山崎 辰洋, 内田 大輔, 松本 和幸, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器病学会中国支部例会・日本消化器内視鏡学会中国支部例会プログラム・抄録集   120回・131回   85 - 85   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 消化器診療の先端診断と治療の新展開 下咽頭表在癌スクリーニングにおける唾液中DCC遺伝子メチル化解析の有用性

    平井 亮佑, 衣笠 秀明, 大塚 基之

    日本消化器病学会中国支部例会・日本消化器内視鏡学会中国支部例会プログラム・抄録集   120回・131回   45 - 45   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding. 国際誌

    Hiroyuki Terasawa, Kazuyuki Matsumoto, Takehiro Tanaka, Takeshi Tomoda, Taiji Ogawa, Yuki Ishihara, Tatsuya Kikuchi, Taisuke Obata, Takashi Oda, Akihiro Matsumi, Kazuya Miyamoto, Kosaku Morimoto, Yuki Fujii, Tatsuhiro Yamazaki, Daisuke Uchida, Shigeru Horiguchi, Koichiro Tsutsumi, Hironari Kato, Motoyuki Otsuka

    Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]   23 ( 8 )   988 - 995   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: EUS-FNA/B for pancreatic ductal adenocarcinoma (PDAC) is generally considered to be safe; however, while the incidence is low, there are occurrences of complications. Among these complications, there are serious ones like needle tract seeding (NTS), and it is not known than which types of tumors have the risks of EUS-FNA/B complications. This study aimed to evaluate the risk of EUS-FNA/B complications in patients with PDAC, focusing on morphological features. METHODS: Overall, 442 patients who underwent EUS-FNA/B for solid pancreatic masses between January 2018 and May 2022 in four institutions were retrospectively surveyed. Finally, 361 patients histopathologically diagnosed with PDAC were analyzed. Among these patients, 79 tumors with cysts or necrotic components were compared with 282 tumors without cysts or necrotic components. The incidence and risk of EUS-FNA/B complications including NTS were evaluated. RESULTS: There were 9 (2.4 %) of total EUS-FNA/B complications and 3 (0.8 %) of NTS. The incidence of total complication rate and NTS in tumors with cysts or necrotic components were significantly higher than in those without cysts or necrotic components (total complication 6.3 % vs. 1.4 %, p = 0.026, NTS 3.7 % vs. 0 %, p = 0.01). The transgastric route of puncture (OR: 93.3, 95 % CI: 3.81-2284.23) and the existence of cysts or necrotic components (OR: 7.3, 95 % CI: 1.47-36.19) were risk factors for EUS-FNA/B complications identified by the multivariate analysis. CONCLUSIONS: We should pay attention to the risks of EUS-FNA/B complications, including NTS, when the tumor has cysts or necrotic components.

    DOI: 10.1016/j.pan.2023.10.018

    PubMed

    researchmap

  • Optimal Bowel Preparation Method to Visualize the Distal Ileum via Small Bowel Capsule Endoscopy. 国際誌

    Daisuke Kametaka, Mamoru Ito, Seiji Kawano, Shuhei Ishiyama, Akiko Fujiwara, Junichirou Nasu, Masao Yoshioka, Junji Shiode, Kazuhide Yamamoto, Masaya Iwamuro, Yoshiro Kawahara, Hiroyuki Okada, Motoyuki Otsuka

    Diagnostics (Basel, Switzerland)   13 ( 20 )   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Small bowel capsule endoscopy (SBCE) is a convenient and minimally invasive method widely used to evaluate the small intestine. However, especially in the distal ileum, visualization of the intestinal mucosa is frequently hampered by the remaining intestinal contents, making it difficult to detect critical lesions. Although several studies have reported on the efficacy of bowel preparation before SBCE, no standardized protocol has been established. Herein, we determined the optimal preparation method for better visualization of the distal ileum using SBCE. We retrospectively analyzed 259 consecutive patients who had undergone SBCE between July 2009 and December 2019, divided into three groups: Group A (no preparation except overnight fasting), Group B (ingestion of 1-2 L polyethylene glycol 4 h before colonoscopy after overnight fasting and performing SBCE immediately after colonoscopy), and Group C (ingestion of 0.9 L magnesium citrate [MC] before SBCE after overnight fasting). The visibility of the intestinal mucosa in the first 10 min and at the last 10 min during the period of observation of the distal ileum was examined using a scoring system and compared. The visibility of the images captured by SBCE was assessed based on the scoring of the degree of bile/chyme staining, residual fluid and debris, brightness, bubble reduction, and visualized mucosa. The status of intestinal collapse was also assessed. In the first 10 min of observation of the distal ileum, no significant differences were detected among the groups. In the last 10 min, significantly better images were acquired in Group C in terms of bile/chyme staining, brightness, bubble reduction, and visualized mucosa. Bowel preparation using a low-dose MC solution 2 h before SBCE provided significantly higher-quality images of the distal ileum. Further optimization, such as the timing of initiating the preparation, is necessary to determine the optimal regimen for bowel preparation prior to SBCE.

    DOI: 10.3390/diagnostics13203269

    PubMed

    researchmap

  • Idiopathic Gastric Antral Ulcers.

    Masaya Iwamuro, Takehiro Tanaka, Seiji Kawano, Yoshiro Kawahara, Motoyuki Otsuka

    Internal medicine (Tokyo, Japan)   63 ( 10 )   1367 - 1371   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    A Japanese woman presented with gastric antral ulcers accompanied by erosion and edema, demonstrating a chronic pattern of improvement and recurrence for more than six years. The patient had no relevant treatment history, and Helicobacter pylori infection was ruled out. Other potential etiologies contributing to gastric ulcers were eliminated on the basis of endoscopic biopsy and blood laboratory findings. Consequently, the patient was diagnosed with idiopathic gastric antral ulcer. This disease is often overlooked, and the chronological endoscopic images provided in this report can be used as a reference.

    DOI: 10.2169/internalmedicine.2554-23

    PubMed

    researchmap

  • Interventional EUSを用いた診療戦略-最適な低侵襲医療を目指して 小病変かつ低悪性度の膵神経内分泌腫瘍に対するEUSガイド下低侵襲治療

    松本 和幸, 加藤 博也, 大塚 基之

    Gastroenterological Endoscopy   65 ( Suppl.2 )   1838 - 1838   2023年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • AIを用いた経口胆道鏡検査の良悪性診断支援システムの開発

    佐藤 亮介, 松本 和幸, 加藤 博也, 河原 祥朗, 大塚 基之

    Gastroenterological Endoscopy   65 ( Suppl.2 )   2028 - 2028   2023年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • Endoscopic Manifestations and Clinical Characteristics of Localized Gastric Light-Chain Amyloidosis.

    Masaya Iwamuro, Shouichi Tanaka, Tatsuya Toyokawa, Mamoru Nishimura, Takao Tsuzuki, Koji Miyahara, Shin Negishi, Shogen Ohya, Takehiro Tanaka, Motoyuki Otsuka

    Acta medica Okayama   77 ( 5 )   545 - 552   2023年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    To determine the endoscopic and clinical features of localized gastric amyloid light-chain (AL) amyloidosis, we retrospectively examined the characteristics of nine patients (eight men and one woman) encountered by the hospitals in our network. Lesions were predominantly flat and depressed with surface vascular dilatation (n=5); others were characterized by subepithelial lesions (n=2), mucosal color change (n=1), and a mass-like morphology with swollen mucosal folds (n=1). Colonoscopy (n=7), video capsule enteroscopy (n=2), serum (n=5) and urine immunoelectrophoresis (n=4), and bone marrow examination (n=3) were performed to exclude involvement of organs other than the stomach. As treatment for gastric lesions of AL amyloidosis, one patient each underwent endoscopic submucosal dissection (n=1) and argon plasma coagulation (n=1), while the remaining seven patients underwent no specific treatment. During a mean follow-up of 4.2 years, one patient died 3.2 years after diagnosis, but the cause of death, which occurred in another hospital, was unknown. The remaining eight patients were alive at the last visit. In conclusion, although localized gastric AL amyloidosis can show various macroscopic features on esophagogastroduodenoscopy, flat, depressed lesions with vascular dilatation on the surface are predominant.

    DOI: 10.18926/AMO/65978

    PubMed

    researchmap

  • 高齢者の食道表在癌・早期胃癌に対する内視鏡治療の適応と問題点 後期高齢表在食道癌患者に対する内視鏡治療後長期成績の検討

    松枝 克典, 川野 誠司, 大塚 基之

    日本消化器病学会雑誌   120 ( 臨増大会 )   A586 - A586   2023年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 消化管領域における希少疾患に対する内視鏡診療 消化管希少疾患 gastric adenocarcinoma and proximal polyposis of the stomach(GAPPS)の2家系の報告

    平井 亮佑, 川野 誠司, 大塚 基之

    Gastroenterological Endoscopy   65 ( Suppl.2 )   1906 - 1906   2023年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • The efficacy of non-anesthesiologist-administered propofol sedation with a target-controlled infusion system during double-balloon endoscopic retrograde cholangiopancreatography. 国際誌

    Kazuya Miyamoto, Kazuyuki Matsumoto, Taisuke Obata, Ryosuke Sato, Akihiro Matsumi, Kosaku Morimoto, Taiji Ogawa, Hiroyuki Terasawa, Yuki Fujii, Tatsuhiro Yamazaki, Daisuke Uchida, Shigeru Horiguchi, Koichiro Tsutsumi, Hironari Kato, Motoyuki Otsuka

    BMC gastroenterology   23 ( 1 )   296 - 296   2023年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The sedation method used during double-balloon endoscopic retrograde cholangiopancreatography (DB-ERCP) differs among countries and/or facilities, and there is no established method. This study aimed to evaluate the efficacy of non-anesthesiologist-administered propofol (NAAP) sedation using a target-controlled infusion (TCI) system during DB-ERCP. METHODS: This retrospective study was conducted between May 2017 and December 2020 at an academic center. One hundred and fifty-six consecutive patients who underwent DB-ERCP were sedated by gastroenterologists using diazepam (n = 77) or propofol with a TCI system (n = 79), depending on the period. The primary endpoint was a comparison of poor sedation rates between the two groups. Poor sedation was defined as a condition requiring the use of other sedative agents or discontinuation of the procedure. Secondary endpoints were sedation-related adverse events and risk factors for poor sedation. RESULTS: Poor sedation occurred significantly more often in the diazepam sedation group (diazepam sedation, n = 12 [16%] vs. propofol sedation, n = 1 [1%]; P = 0.001). Vigorous body movements (3 or 4) (diazepam sedation, n = 40 [52%] vs. propofol sedation, n = 28 [35%]; P = 0.038) and hypoxemia (< 85%) (diazepam sedation, n = 7 [9%] vs. propofol sedation, n = 1 [1%]; P = 0.027) occurred significantly more often in the diazepam sedation group. In the multivariate analysis, age < 70 years old (OR, 10.26; 95% CI, 1.57-66.98; P = 0.015), BMI ≥ 25 kg/m2 (OR, 11.96; 95% CI, 1.67-85.69; P = 0.014), and propofol sedation (OR, 0.06; 95% CI, 0.01-0.58; P = 0.015) were associated factors for poor sedation. CONCLUSIONS: NAAP sedation with the TCI system during DB-ERCP was safer and more effective than diazepam sedation.

    DOI: 10.1186/s12876-023-02936-8

    PubMed

    researchmap

  • 先天性胆道拡張症術後の肝内胆管狭窄に対し内視鏡的胆道拡張術が有効であった一例

    宮本 和也, 加藤 博也, 小幡 泰介, 佐藤 亮介, 松三 明宏, 森本 光作, 藤井 佑樹, 山崎 辰洋, 内田 大輔, 松本 和幸, 堀口 繁, 堤 康一郎, 大塚 基之

    日本膵・胆管合流異常研究会プロシーディングス   46   76 - 76   2023年9月

  • IBD診療におけるtreat to targetを考える Treat to targetを意識したクローン病におけるsurrogate markerの組み合わせ

    井口 俊博, 平岡 佐規子, 青山 祐樹, 竹井 健介, 井川 翔子, 高原 政宏, 大塚 基之

    日本大腸肛門病学会雑誌   76 ( 9 )   A51 - A51   2023年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本大腸肛門病学会  

    researchmap

  • 胆膵癌ゲノムパネル検査における検査法についての検討(Investigation of test methods for pancreatobiliary cancer genomic panel test)

    堀口 繁, 加藤 博也, 松本 和幸, 大塚 基之

    日本癌学会総会記事   82回   828 - 828   2023年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    researchmap

  • Biological Roles of Hepatitis B Viral X Protein in the Viral Replication and Hepatocarcinogenesis.

    Motoyuki Otsuka

    Acta medica Okayama   77 ( 4 )   341 - 345   2023年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatitis B virus is a pathogenic virus that infects 300 million people worldwide and causes chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Hepatitis B virus encodes four proteins. Among them, the HBx protein plays a central role in the HBV pathogenesis. Because the HBx protein is considered to play a central role in the induction of viral replication and hepatocarcinogenesis, the regulation of its function could be a key factor in the development of new interventions against hepatitis B. In this review, HBx protein-related viral replication and hepatocarcinogenesis mechanisms are described, with a focus on the recently reported viral replication mechanisms related to degradation of the Smc5/6 protein complex. We also discuss our recent discovery of a compound that inhibits HBx protein-induced degradation of the Smc5/6 protein complex, and that exerts inhibitory effects on both viral replication and hepatocarcinogenesis. Finally, prospects for future research on the HBx protein are described.

    DOI: 10.18926/AMO/65739

    PubMed

    researchmap

  • 【胃良性疾患の近未来】[薬剤関連疾患]White globe appearance(WGA)

    岩室 雅也, 田中 健大, 大塚 基之

    消化器内視鏡   35 ( 8 )   1072 - 1074   2023年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)東京医学社  

    researchmap

  • 「術後胆管炎の診断と治療の現状」 再発リスク因子からみた術後良性胆管空腸吻合部狭窄に対する最適な内視鏡治療戦略

    松三 明宏, 松本 和幸, 大塚 基之

    胆道   37 ( 3 )   417 - 417   2023年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本胆道学会  

    researchmap

  • 「難治性胆汁漏に対する治療」 重症度からみた術後胆汁漏に対する内視鏡治療成績

    小幡 泰介, 松本 和幸, 大塚 基之

    胆道   37 ( 3 )   423 - 423   2023年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本胆道学会  

    researchmap

  • Oxidative stress-related markers as prognostic factors for patients with primary sclerosing cholangitis in Japan. 査読 国際誌

    Atsushi Oyama, Akinobu Takaki, Takuya Adachi, Nozomu Wada, Yasuto Takeuchi, Hideki Onishi, Hidenori Shiraha, Hiroyuki Okada, Motoyuki Otsuka

    Hepatology international   17 ( 5 )   1215 - 1224   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/PURPOSE: Primary sclerosing cholangitis (PSC) is a rare chronic liver disease. The mechanisms and prediction of PSC progression are unclear. Recent investigations have shown that general conditions, such as oxidative stress, affect the course of chronic diseases. We investigated the clinical course and oxidative stress-related condition of PSC to determine prognostic factors. METHODS: We recruited 58 patients with PSC (mean age; 37.4 years, mean observation period; 1382 days) who visited our department from 2003 to 2021. Clinical characteristics were investigated to define prognostic factors. Oxidative stress status was evaluated using two types of markers: an oxidative stress marker (serum reactive oxygen metabolite; dROM) and an antioxidant marker (serum OXY adsorbent test; OXY). RESULTS: The revised Mayo risk, Child-Pugh, model for end-stage liver disease-sodium (MELD-Na) scores or fibrosis-related FIB-4 index significantly predicted poor overall survival. High intestinal immunoglobulin A (IgA) levels predicted poor survival. Among patients with high and intermediate revised Mayo risk scores, those with physiologically high dROM levels showed better survival than those with lower dROM levels. In this population, dROM was negatively correlated with AST and IgA, which are both correlated with survival. CONCLUSIONS: High and intermediate revised Mayo risk score group predicted a poor clinical course in PSC. Additionally, the Child-Pugh score, MELD-Na score, FIB-4 index, and serum IgA were significantly correlated with survival. In patients with high and intermediate revised Mayo risk scores, physiologically high oxidative stress status correlated with low IgA levels and a good prognosis.

    DOI: 10.1007/s12072-023-10557-2

    PubMed

    researchmap

  • Review of oral and pharyngolaryngeal benign lesions detected during esophagogastroduodenoscopy. 査読 国際誌

    Masaya Iwamuro, Kenta Hamada, Seiji Kawano, Yoshiro Kawahara, Motoyuki Otsuka

    World journal of gastrointestinal endoscopy   15 ( 7 )   496 - 509   2023年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Recent advancements in endoscopy equipment have facilitated endoscopists' detection of neoplasms in the oral cavity and pharyngolaryngeal regions. In particular, image-enhanced endoscopy using narrow band imaging or blue laser imaging play an integral role in the endoscopic diagnosis of oral and pharyngolaryngeal cancers. Despite these advancements, limited studies have focused on benign lesions that can be observed during esophagogastroduodenoscopy in the oral and pharyngolaryngeal regions. Therefore, this mini-review aimed to provide essential information on such benign lesions, along with representative endoscopic images of dental caries, cleft palate, palatal torus, bifid uvula, compression by cervical osteophytes, tonsil hyperplasia, black hairy tongue, oral candidiasis, oral and pharyngolaryngeal ulcers, pharyngeal melanosis, oral tattoos associated with dental alloys, retention cysts, papilloma, radiation-induced changes, skin flaps, vocal cord paresis, and vocal fold leukoplakia. Whilst it is imperative to seek consultation from otolaryngologists or dentists in instances where the diagnosis cannot be definitively ascertained by endoscopists, the merits of attaining foundational expertise pertaining to oral and pharyngolaryngeal lesions are unequivocal. This article will be a valuable resource for endoscopists seeking to enhance their understanding of oral and pharyngolaryngeal lesions.

    DOI: 10.4253/wjge.v15.i7.496

    PubMed

    researchmap

  • 当院における術後膵空腸吻合部狭窄に対する内視鏡治療成績の検討

    森本 光作, 山崎 辰洋, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 宮本 和也, 寺澤 裕之, 藤井 佑樹, 内田 大輔, 松本 和幸, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    膵臓   38 ( 3 )   A337 - A337   2023年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本膵臓学会  

    researchmap

  • 結節を有するIPMNの良悪性診断における新規TIC解析プログラムを用いた造影EUSの有用性

    宮本 和也, 松本 和幸, 内田 大輔, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 森本 光作, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    膵臓   38 ( 3 )   A345 - A345   2023年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本膵臓学会  

    researchmap

  • 結節を有するIPMNの良悪性診断における新規TIC解析プログラムを用いた造影EUSの有用性

    宮本 和也, 松本 和幸, 内田 大輔, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 森本 光作, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    膵臓   38 ( 3 )   A345 - A345   2023年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本膵臓学会  

    researchmap

  • 当院における術後膵空腸吻合部狭窄に対する内視鏡治療成績の検討

    森本 光作, 山崎 辰洋, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 宮本 和也, 寺澤 裕之, 藤井 佑樹, 内田 大輔, 松本 和幸, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    膵臓   38 ( 3 )   A337 - A337   2023年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本膵臓学会  

    researchmap

  • 高齢者における膵癌術前化学療法の有効性と安全性の検討

    藤井 佑樹, 堀口 繁, 佐藤 亮介, 小幡 泰介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 山崎 辰洋, 内田 大輔, 松本 和幸, 堤 康一郎, 加藤 博也, 大塚 基之

    膵臓   38 ( 3 )   A316 - A316   2023年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本膵臓学会  

    researchmap

  • Endoscopic evaluation by the Kyoto classification of gastritis combined with serum anti-Helicobacter pylori antibody testing reliably risk-stratifies subjects in a population-based gastric cancer screening program. 査読

    Ryosuke Hirai, Mami Hirai, Motoyuki Otsuka, Toshiharu Mitsuhashi, Yuichi Shimodate, Hirokazu Mouri, Kazuhiro Matsueda, Hiroshi Yamamoto, Motowo Mizuno

    Journal of gastroenterology   58 ( 9 )   848 - 855   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: We previously demonstrated that the Kyoto classification of gastritis was useful for judging the status of Helicobacter pylori infection in a population-based screening program, and that adding H. pylori antibody test improved its accuracy (UMIN000028629). Here, we tested whether our endoscopic diagnosis of H. pylori infection status reliably estimated gastric cancer risk in the program. METHODS: Data were collected from1345 subjects who underwent endoscopic follow-up 4 years after the end of the registration. We analyzed the association of three diagnostic methods of H. pylori infection with gastric cancer detection: (1) endoscopic diagnosis based on the Kyoto classification of gastritis; (2) serum diagnosis according to the ABC method (H. pylori antibody and pepsinogen I and II); and (3) endoscopic diagnosis together with H. pylori antibody test. RESULTS: During the follow-up, 19 cases of gastric cancer were detected. By Kaplan-Meier analysis, the detection rates of cancer were significantly higher in the past or current H. pylori infection groups than in the never-infected group with all 3 methods. By the Cox proportional hazards model, the hazard ratio for cancer detection was highest in evaluation with the combined endoscopic diagnosis and the antibody test (method 3; hazard ratio 22.6, 95% confidence interval 2.99-171) among the three methods (the endoscopic diagnosis (method 1); 11.3, 2.58-49.8, and the ABC method (method 2); 7.52, 2.49-22.7). CONCLUSIONS: Endoscopic evaluation of H. pylori status with the Kyoto classification of gastritis, especially combined with serum anti-Helicobacter pylori antibody testing, reliably risk-stratified subjects in a population-based gastric cancer screening program.

    DOI: 10.1007/s00535-023-02010-w

    PubMed

    researchmap

  • Update in Molecular Aspects and Diagnosis of Autoimmune Gastritis. 査読 国際誌

    Masaya Iwamuro, Takehiro Tanaka, Motoyuki Otsuka

    Current issues in molecular biology   45 ( 7 )   5263 - 5275   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Recent studies have advanced our understanding of the pathophysiology of autoimmune gastritis, particularly its molecular aspects. The most noteworthy recent advancement lies in the identification of several candidate genes implicated in the pathogenesis of pernicious anemia through genome-wide association studies. These genes include PTPN22, PNPT1, HLA-DQB1, and IL2RA. Recent studies have also directed attention towards other genes such as ATP4A, ATP4B, AIRE, SLC26A7, SLC26A9, and BACH2 polymorphism. In-depth investigations have been conducted on lymphocytes and cytokines, including T helper 17 cells, interleukin (IL)-17A, IL-17E, IL-17F, IL-21, IL-19, tumor necrosis factor-α, IL-15, transforming growth factor-β1, IL-13, and diminished levels of IL-27. Animal studies have explored the involvement of roseolovirus and H. pylori in relation to the onset of the disease and the process of carcinogenesis, respectively. Recent studies have comprehensively examined the involvement of autoantibodies, serum pepsinogen, and esophagogastroduodenoscopy in the diagnosis of autoimmune gastritis. The current focus lies on individuals demonstrating atypical presentations of the disease, including those diagnosed in childhood, those yielding negative results for autoantibodies, and those lacking the typical endoscopic characteristics of mucosal atrophy. Here, we discuss the recent developments in this field, focusing on genetic predisposition, epigenetic modifications, lymphocytes, cytokines, oxidative stress, infectious agents, proteins, microRNAs, autoantibodies, serum pepsinogen, gastrin, esophagogastroduodenoscopy and microscopic findings, and the risk of gastric neoplasm.

    DOI: 10.3390/cimb45070334

    PubMed

    researchmap

  • 肝内結石に対して内視鏡用イントロデューサーEndoSheatherが有用であった1例

    佐藤 亮介, 藤井 佑樹, 小幡 泰介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 山崎 辰洋, 内田 大輔, 松本 和幸, 堤 康一郎, 堀口 繁, 加藤 博也, 大塚 基之

    日本消化器内視鏡学会中国支部例会   130回   83 - 83   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器内視鏡学会-中国支部  

    researchmap

  • 悪性輸入脚症候群に対して超音波内視鏡下消化管ドレナージが有効であった1例

    森本 光作, 松本 和幸, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 宮本 和也, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 内田 大輔, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器内視鏡学会中国支部例会   130回   83 - 83   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器内視鏡学会-中国支部  

    researchmap

  • EUS関連手技の言語化した教育法

    松本 和幸, 加藤 博也, 堤 康一郎, 大塚 基之

    日本消化器病学会四国支部例会プログラム・抄録集   119回   37 - 37   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-四国支部  

    researchmap

  • 長期経過を追えた膵Intraductal oncocytic papillary neoplasm(IOPN)の1例

    藤井 佑樹, 佐藤 亮介, 小幡 泰介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 山崎 辰洋, 内田 大輔, 松本 和幸, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器病学会中国支部例会プログラム・抄録集   119回   67 - 67   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 進行胆道癌に対するゲムシタビン・シスプラチン・S-1併用療法の治療成績についての検討

    小幡 泰介, 松本 和幸, 佐藤 亮介, 菊池 達也, 織田 崇志, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 内田 大輔, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器病学会中国支部例会プログラム・抄録集   119回   65 - 65   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 肝内結石に対して内視鏡用イントロデューサーEndoSheatherが有用であった1例

    佐藤 亮介, 藤井 佑樹, 小幡 泰介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 山崎 辰洋, 内田 大輔, 松本 和幸, 堤 康一郎, 堀口 繁, 加藤 博也, 大塚 基之

    日本消化器内視鏡学会中国支部例会   130回   83 - 83   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器内視鏡学会-中国支部  

    researchmap

  • 長期経過を追えた膵Intraductal oncocytic papillary neoplasm(IOPN)の1例

    藤井 佑樹, 佐藤 亮介, 小幡 泰介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 山崎 辰洋, 内田 大輔, 松本 和幸, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器病学会中国支部例会プログラム・抄録集   119回   67 - 67   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 進行胆道癌に対するゲムシタビン・シスプラチン・S-1併用療法の治療成績についての検討

    小幡 泰介, 松本 和幸, 佐藤 亮介, 菊池 達也, 織田 崇志, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 内田 大輔, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器病学会中国支部例会プログラム・抄録集   119回   65 - 65   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 悪性輸入脚症候群に対して超音波内視鏡下消化管ドレナージが有効であった1例

    森本 光作, 松本 和幸, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 宮本 和也, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 内田 大輔, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器内視鏡学会中国支部例会   130回   83 - 83   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器内視鏡学会-中国支部  

    researchmap

  • Helicobacter pylori除菌により寛解し、長期間経過後に再発した胃MALTリンパ腫の一例

    稲生 祥子, 岩室 雅也, 平田 翔一郎, 平井 亮佑, 倉岡 紗樹子, 小橋 真由, 岡上 昇太郎, 里見 拓也, 松枝 克典, 濱田 健太, 河野 吉泰, 川野 誠司, 河原 祥朗, 大塚 基之

    日本消化器病学会中国支部例会プログラム・抄録集   119回   71 - 71   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 免疫関連有害事象(irAE:immune-related adverse events)による胃炎の5例

    岩室 雅也, 田中 健大, 平田 翔一郎, 河野 吉泰, 川野 誠司, 河原 祥朗, 大塚 基之

    日本消化器病学会中国支部例会プログラム・抄録集   119回   70 - 70   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 内反性増殖を示した十二指腸腺癌に対してUnderwater EMRにて切除し得た1例

    松枝 克典, 川野 誠司, 平田 翔一郎, 岡上 昇太郎, 里見 拓也, 稲生 祥子, 濱田 健太, 河野 吉泰, 岩室 雅也, 河原 祥朗, 田中 健大, 大塚 基之

    日本消化器内視鏡学会中国支部例会   130回   76 - 76   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器内視鏡学会-中国支部  

    researchmap

  • 肝生検により診断された播種性bacillus Calmette-Guerin(BCG)症の1例

    伊木 道子, 竹内 康人, 須江 真彦, 三宅 望, 足立 卓哉, 和田 望, 大西 秀樹, 白羽 秀則, 高木 章乃夫, 大塚 基之

    日本消化器病学会中国支部例会プログラム・抄録集   119回   62 - 62   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 血流豊富な粘膜下腫瘍の形態を呈した上行結腸血管周囲類上皮細胞腫の1例

    青山 祐樹, 井口 俊博, 平岡 佐規子, 豊澤 惇希, 竹井 健介, 井川 翔子, 山崎 泰史, 衣笠 秀明, 高原 政宏, 庄司 良平, 近藤 喜太, 柳井 広之, 大塚 基之

    日本消化器内視鏡学会中国支部例会   130回   81 - 81   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器内視鏡学会-中国支部  

    researchmap

  • 免疫関連有害事象(irAE:immune-related adverse events)による胃炎の5例

    岩室 雅也, 田中 健大, 平田 翔一郎, 河野 吉泰, 川野 誠司, 河原 祥朗, 大塚 基之

    日本消化器病学会中国支部例会プログラム・抄録集   119回   70 - 70   2023年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • Collagenous Colitis in a Patient With Gastric Cancer Who Underwent Chemotherapy. 査読 国際誌

    Masaya Iwamuro, Takehiro Tanaka, Shunsuke Kagawa, Shoko Inoo, Motoyuki Otsuka

    Cureus   15 ( 5 )   e39466   2023年5月

     詳細を見る

    記述言語:英語  

    Herein, we present a case of collagenous colitis in a patient who underwent chemotherapy for gastric cancer, comprising five cycles of S-1 plus oxaliplatin and trastuzumab, followed by five cycles of paclitaxel and ramucirumab and seven cycles of nivolumab. The subsequent initiation of trastuzumab deruxtecan chemotherapy led to the development of grade 3 diarrhea after the second cycle of treatment. Collagenous colitis was diagnosed via colonoscopy and biopsy. The patient's diarrhea improved following the cessation of lansoprazole. This case highlights the importance of considering collagenous colitis as a differential diagnosis, in addition to chemotherapy-induced colitis and immune-related adverse event (irAE) colitis, in patients with similar clinical presentations.

    DOI: 10.7759/cureus.39466

    PubMed

    researchmap

  • 選択的胆管seekingのためのデバイス選択

    小幡 泰介, 内田 大輔, 加藤 博也, 佐藤 亮介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 松本 和幸, 堀口 繁, 堤 康一郎, 大塚 基之

    Gastroenterological Endoscopy   65 ( Suppl.1 )   971 - 971   2023年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • 選択的胆管seekingのためのデバイス選択

    小幡 泰介, 内田 大輔, 加藤 博也, 佐藤 亮介, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 松本 和幸, 堀口 繁, 堤 康一郎, 大塚 基之

    Gastroenterological Endoscopy   65 ( Suppl.1 )   971 - 971   2023年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • EUS-HGSにおけるダブルガイドワイヤー法の有用性

    松三 明宏, 藤井 佑樹, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 宮本 和也, 森本 光作, 寺澤 裕之, 山崎 辰洋, 内田 大輔, 松本 和幸, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器病学会雑誌   120 ( 臨増総会 )   A321 - A321   2023年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 後期高齢者におけるIPMNの治療移行割合についての検討

    宮本 和也, 松本 和幸, 小幡 泰介, 佐藤 亮介, 織田 崇志, 菊池 達也, 松三 明宏, 森本 光作, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 内田 大輔, 堀口 繁, 堤 康一郎, 加藤 博也, 大塚 基之

    日本消化器病学会雑誌   120 ( 臨増総会 )   A378 - A378   2023年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 胆嚢オルガノイドを用いた発癌モデルより同定したmiR-34a-5p補充による胆嚢癌治療の開発

    織田 崇志, 堤 康一郎, 小幡 泰介, 菊池 達也, 松三 明宏, 宮本 和也, 森本 光作, 寺澤 裕之, 藤井 佑樹, 山崎 辰洋, 赤穂 宗一郎, 内田 大輔, 松本 和幸, 堀口 繁, 加藤 博也, 大塚 基之

    日本消化器病学会雑誌   120 ( 臨増総会 )   A328 - A328   2023年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Optimal liver drainage rate for survival in patients with unresectable malignant hilar biliary obstruction using 3D-image volume analyzer. 国際誌

    Kosaku Morimoto, Kazuyuki Matsumoto, Taisuke Obata, Takashi Oda, Kazuya Miyamoto, Akihiro Matsumi, Hiroyuki Terasawa, Yuki Fujii, Tatsuhiro Yamazaki, Shigeru Horiguchi, Koichiro Tsutsumi, Hironari Kato, Motoyuki Otsuka

    Therapeutic advances in gastroenterology   16   17562848231206980 - 17562848231206980   2023年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Drainage exceeding 50% of total liver volume is a beneficial prognostic factor in patients with unresectable malignant hilar biliary obstruction (UMHBO). However, it is unclear what threshold percentage of total liver volume drained ('liver drainage rate') significantly improves survival in patients with UMHBO who received systemic chemotherapy. OBJECTIVES: We aimed to assess the optimal liver drainage rate that improves survival in patients with UMHBO receiving chemotherapy using a three-dimensional (3D)-image volume analyzer. DESIGN: This study was a single-center retrospective cohort study. METHODS: Data from 90 patients with UMHBO who received chemotherapy after endoscopic biliary drainage using metal stents at Okayama University Hospital from January 2003 to December 2020 were reviewed. The liver drainage rate was calculated by dividing the drained liver volume by the total liver volume using a 3D-image volume analyzer. The primary endpoint was overall survival by liver drainage rate. The secondary endpoints were time to recurrent biliary obstruction (TRBO) and prognostic factors. RESULTS: The median total liver volume was 1172 (range: 673-2032) mL, and the median liver drainage rate was 83% (range: 50-100). Overall survival was 376 (95% CI: 271-450) days, and patients with >80% drainage (n = 67) had significantly longer survival than those with <80% drainage (n = 23) (450 days versus 224 days, p = 0.0033, log-rank test). TRBO was 201 (95% CI: 155-327) days and did not differ significantly by liver drainage rate. Multivariate Cox proportional hazards regression analysis revealed >80% liver drainage [hazard ratio (HR): 0.35, 95% CI: 0.20-0.62, p = 0.0003] and hilar cholangiocarcinoma (HR: 0.30, 95% CI: 0.17-0.50, p < 0.0001) as significant prognostic factors. CONCLUSION: In patients with UMHBO scheduled for chemotherapy, >80% drainage is associated with improved survival. Further prospective multicenter studies are needed to verify the results of this study. TRAIL REGISTRATION: Okayama University Hospital, IRB number: 2108-011.

    DOI: 10.1177/17562848231206980

    PubMed

    researchmap

  • Smaller extracellular vesicles are released from pancreatic cancer cells by the alteration of the lipid composition under low glucose conditions. 査読 国際誌

    Chikako Shibata, Motoyuki Otsuka, Takahiro Seimiya, Kazunaga Ishigaki, Yu Miyakawa, Takahiro Kishikawa, Mitsuhiro Fujishiro

    Biochemical and biophysical research communications   637   314 - 321   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Extracellular vesicles (EVs) released from cells into the blood facilitate intercellular communication and serve as new biomarkers to understand the pathophysiology of several conditions. Although the importance of the cargo inside EVs has been extensively studied, the sizes of EVs that vary with different types of cancers are relatively poorly explored. Here, we show that pancreatic cancer cell-derived EVs are significantly smaller than non-cancer cell-derived EVs. The smaller size distribution of these EVs was confirmed by specifically isolating and examining tumor-derived EVs from the heterogeneous EV population isolated from the sera of patients with pancreatic ductal adenocarcinoma. In vitro analyses mimicking tumor microenvironment conditions revealed that low glucose conditions reduced the size distribution and increased the level of unsaturated fatty acids in the tumor-derived EVs. Because the lipid composition defines the fluidity of the membrane, the results suggest that the alterations in the size of EVs could be due to the alteration of the fluidity and stability of the membrane covering the EVs. Furthermore, the uptake of smaller EVs by recipient cells was increased, which may lead to enhanced functional results. These results provide fundamental insights into the factors defining the size of EVs, which may be important for developing cancer screening methods and understanding cancer-related pathophysiology.

    DOI: 10.1016/j.bbrc.2022.11.040

    PubMed

    researchmap

  • HNF1B-driven three-dimensional chromatin structure for molecular classification in pancreatic cancers. 査読 国際誌

    Hiroyuki Kato, Keisuke Tateishi, Dosuke Iwadate, Keisuke Yamamoto, Hiroaki Fujiwara, Takuma Nakatsuka, Yotaro Kudo, Yoku Hayakawa, Hideaki Ijichi, Motoyuki Otsuka, Takahiro Kishikawa, Ryota Takahashi, Koji Miyabayashi, Yousuke Nakai, Yoshihiro Hirata, Atsushi Toyoda, Shinichi Morishita, Mitsuhiro Fujishiro

    Cancer science   114 ( 4 )   1672 - 1685   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The molecular subtypes of pancreatic cancer (PC), either classical/progenitor-like or basal/squamous-like, are currently a major topic of research because of their direct association with clinical outcomes. Some transcription factors (TFs) have been reported to be associated with these subtypes. However, the mechanisms by which these molecular signatures of PCs are established remain unknown. Epigenetic regulatory processes, supported by dynamic changes in the chromatin structure, are essential for transcriptional profiles. Previously, we reported the importance of open chromatin profiles in the biological features and transcriptional status of PCs. Here, we aimed to analyze the relationships between three-dimensional (3D) genome structures and the molecular subtypes of human PCs using Hi-C analysis. We observed a correlation of the specific elements of 3D genome modules, including compartments, topologically associating domains, and enhancer-promoter loops, with the expression of related genes. We focused on HNF1B, a TF that is implicated in the progenitor subtype. Forced expression of HNF1B in squamous-type PC organoids induced the upregulation and downregulation of genes associated with progenitor and squamous subtypes, respectively. Long-range genomic interactions induced by HNF1B were accompanied by compartment modulation and H3K27ac redistribution. We also found that these HNF1B-induced changes in subtype-related gene expression required an intrinsically disordered region, suggesting a possible involvement of phase separation in compartment modulation. Thus, mapping of 3D structural changes induced by TFs, such as HNF1B, may become a useful resource for further understanding the molecular features of PCs.

    DOI: 10.1111/cas.15690

    PubMed

    researchmap

  • The RNA-Binding Protein ELAVL1 Regulates Hepatitis B Virus Replication and Growth of Hepatocellular Carcinoma Cells. 査読 国際誌

    Hiroaki Kanzaki, Tetsuhiro Chiba, Tatsuya Kaneko, Junjie Ao, Motoyasu Kan, Ryosuke Muroyama, Shingo Nakamoto, Tatsuo Kanda, Hitoshi Maruyama, Jun Kato, Yoh Zen, Ai Kotani, Kazuma Sekiba, Motoyuki Otsuka, Masayuki Ohtsuka, Naoya Kato

    International journal of molecular sciences   23 ( 14 )   2022年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Previous RNA immunoprecipitation followed by proteomic approaches successfully demonstrated that Embryonic Lethal, Abnormal Vision, Drosophila-Like 1 (ELAVL1) interacts with hepatitis B virus (HBV)-derived RNAs. Although ELAVL family proteins stabilize AU-rich element (ARE)-containing mRNAs, their role in HBV transcription remains unclear. This study conducted loss-of-function assays of ELAVL1 for inducible HBV-replicating HepAD38 cells and HBx-overexpressed HepG2 cells. In addition, clinicopathological analyses in primary hepatocellular carcinoma (HCC) surgical samples were also conducted. Lentivirus-mediated short hairpin RNA knockdown of ELAVL1 resulted in a decrease in both viral RNA transcription and production of viral proteins, including HBs and HBx, probably due to RNA stabilization by ELAVL1. Cell growth of HepAD38 cells was more significantly impaired in ELAVL1-knockdown than those in the control group, with or without HBV replication, indicating that ELAVL1 is involved in proliferation by factors other than HBV-derived RNAs. Immunohistochemical analyses of 77 paired HCC surgical specimens demonstrated that diffuse ELAVL1 expression was detected more frequently in HCC tissues (61.0%) than in non-tumor tissues (27.3%). In addition, the abundant expression of ELAVL1 tended to affect postoperative recurrence in HBV-related HCC patients. In conclusion, ELAVL1 contributes not only to HBV replication but also to HCC cell growth. It may be a potent therapeutic target for HBV-related HCC treatment.

    DOI: 10.3390/ijms23147878

    PubMed

    researchmap

  • Hepatitis B virus-associated hepatocellular carcinoma with Smc5/6 complex deficiency is susceptible to PARP inhibitors. 査読 国際誌

    Kazuyoshi Funato, Motoyuki Otsuka, Kazuma Sekiba, Yu Miyakawa, Takahiro Seimiya, Chikako Shibata, Takahiro Kishikawa, Mitsuhiro Fujishiro

    Biochemical and biophysical research communications   607   89 - 95   2022年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DNA repair processes represent attractive synthetic lethal targets because many cancers exhibit impaired DNA repair pathways, which leads to dependence on specific repair proteins. The finding that poly (ADP-ribose) polymerase (PARP)-1 inhibitors are highly effective against cancers with deficient homologous recombination highlights the potential of this approach. In hepatitis B viral (HBV) infection, degradation of the structural maintenance of the chromosome 5/6 (Smc5/6) complex, which plays a key role in repairing double-stranded DNA breaks by homologous recombination, is induced by HBV regulatory protein X (HBx). Here, we hypothesized that a deficiency in the Smc5/6 complex in HBV-associated hepatocellular carcinoma (HCC) increases susceptibility to PARP inhibitors via a deficiency in homologous recombination. We confirmed impaired double-stranded DNA break repair in HBx-expressing HCC cells using a sensitive reporter to monitor homologous recombination. Treatment with a PARP inhibitor was significantly more effective against HBx-expressing HCC cells, and overexpression of Smc5/6 prevented these effects. Overall, our results suggest that homologous recombination deficiency in HBV-associated HCC leads to increased susceptibility to PARP inhibitors.

    DOI: 10.1016/j.bbrc.2022.03.137

    PubMed

    researchmap

  • Roles of circular RNAs in the pathogenesis and treatment of pancreatic cancer. 査読 国際誌

    Takahiro Seimiya, Motoyuki Otsuka, Mitsuhiro Fujishiro

    Frontiers in cell and developmental biology   10   1023332 - 1023332   2022年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Circular RNAs are single-stranded RNAs with a covalently closed structure formed by the process of back-splicing. Aberrant expression of circular RNAs contributes to the pathogenesis of a wide range of cancers. Pancreatic cancer is one of the most lethal cancers due to diagnostic difficulties and limited therapeutic options. Circular RNAs are emerging as novel diagnostic biomarkers and therapeutic targets for pancreatic cancer. Moreover, recent advances in the therapeutic application of engineered circular RNAs have provided a promising approach to overcoming pancreatic cancer. This review discusses the roles of circular RNAs in the pathogenesis of pancreatic cancer and in potential treatment applications and their usefulness as diagnostic biomarkers.

    DOI: 10.3389/fcell.2022.1023332

    PubMed

    researchmap

  • Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. 国際誌

    Motoyuki Otsuka

    Hepatology research : the official journal of the Japan Society of Hepatology   51 ( 10 )   1013 - 1025   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary pro- vides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan.

    DOI: 10.1111/hepr.13688

    PubMed

    researchmap

  • Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020.

    Motoyuki Otsuka

    Journal of gastroenterology   56 ( 11 )   951 - 963   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Nonalcoholic fatty liver disease (NAFLD) has become a serious public health issue not only in Western countries but also in Japan. Within the wide spectrum of NAFLD, nonalcoholic steatohepatitis (NASH) is a progressive form of disease that often develops into liver cirrhosis and increases the risk of hepatocellular carcinoma (HCC). While a definite diagnosis of NASH requires liver biopsy to confirm the presence of hepatocyte ballooning, hepatic fibrosis is the most important prognostic factor in NAFLD. With so many NAFLD patients, it is essential to have an effective screening method for NAFLD with hepatic fibrosis. As HCC with non-viral liver disease has increased markedly in Japan, effective screening and surveillance of HCC are also urgently needed. The most common death etiology in NAFLD patients is cardiovascular disease (CVD) event. Gastroenterologists must, therefore, pay close attention to CVD when examining NAFLD patients. In the updated guidelines, we propose screening and follow-up methods for hepatic fibrosis, HCC, and CVD in NAFLD patients. Several drug trials are ongoing for NAFLD/NASH therapy, however, there is currently no specific drug therapy for NAFLD/NASH. In addition to vitamin E and thiazolidinedione derivatives, recent trials have focused on sodium glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues, and effective therapies are expected to be developed. These practical guidelines for NAFLD/NASH were established by the Japanese Society of Gastroenterology in conjunction with the Japan Society of Hepatology. Clinical evidence reported internationally between 1983 and October 2018 was collected, and each clinical and background question was evaluated using the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system. This English summary provides the core essentials of these clinical practice guidelines, which include the definition and concept, screening systems for hepatic fibrosis, HCC and CVD, and current therapies for NAFLD/NASH in Japan.

    DOI: 10.1007/s00535-021-01796-x

    PubMed

    researchmap

  • Humanized virus-suppressing factor inhibits hepatitis B virus infection by targeting viral cell entry. 査読 国際誌

    Yu Miyakawa, Motoyuki Otsuka, Kazuma Sekiba, Kazuyoshi Funato, Kazuhiko Koike

    Heliyon   7 ( 7 )   e07586   2021年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Although nucleos(t)ide analogs and interferons suppress hepatitis B virus (HBV) replication, they must be taken continuously and have a low response rate. Therefore, therapeutics for HBV with novel modes of action are needed. Humanized virus-suppressing factor (hzVSF) is a monoclonal antibody against vimentin that exhibits broad-spectrum antiviral activity. Here, hzVSF significantly inhibited HBV infection. Although hzVSF inhibited HBV RNA production, it did not affect viral transcription from minicircle DNA mimicking covalently closed circular DNA. Additionally, hzVSF did not inhibit viral protein or DNA release from infected cells. Rather, hzVSF inhibited the cell entry of viral preS1 peptides, possibly by altering intracellular vimentin localization, which is important for HBV cell entry. These results suggest that hzVSF has therapeutic potential for HBV infection with a novel mode of action.

    DOI: 10.1016/j.heliyon.2021.e07586

    PubMed

    researchmap

  • Potential of HBx Gene for Hepatocarcinogenesis in Noncirrhotic Liver. 査読 国際誌

    Kazuma Sekiba, Motoyuki Otsuka, Kazuhiko Koike

    Seminars in liver disease   41 ( 2 )   142 - 149   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Current treatments for hepatitis B virus (HBV) using nucleos(t)ide analogs cannot eliminate the risk of hepatocellular carcinoma (HCC) development. As HBV-associated HCC can develop even in the absence of liver cirrhosis, HBV is regarded to possess direct oncogenic potential. HBV regulatory protein X (HBx) has been identified as a primary mediator of HBV-mediated hepatocarcinogenesis. A fragment of the HBV genome that contains the coding region of HBx is commonly integrated into the host genome, resulting in the production of aberrant proteins and subsequent hepatocarcinogenesis. Besides, HBx interferes with the host DNA or deoxyribonucleic acid damage repair pathways, signal transduction, epigenetic regulation of gene expression, and cancer immunity, thereby promoting carcinogenesis in the noncirrhotic liver. However, numerous molecules and pathways have been implicated in the development of HBx-associated HCC, suggesting that the mechanisms underlying HBx-mediated hepatocarcinogenesis remain to be elucidated.

    DOI: 10.1055/s-0041-1723033

    PubMed

    researchmap

  • Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma. 査読

    Takuma Nakatsuka, Hayato Nakagawa, Yuki Hayata, Taijiro Wake, Tomoharu Yamada, Mizuki Nishibatake Kinoshita, Ryo Nakagomi, Masaya Sato, Tatsuya Minami, Koji Uchino, Kenichiro Enooku, Yotaro Kudo, Yasuo Tanaka, Takahiro Kishikawa, Motoyuki Otsuka, Ryosuke Tateishi, Kazuhiko Koike

    Journal of gastroenterology   56 ( 5 )   456 - 469   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Liquid biopsies, particularly those involving circulating tumor DNA (ctDNA), are rapidly emerging as a non-invasive alternative to tumor biopsies. However, clinical applications of ctDNA analysis in hepatocellular carcinoma (HCC) have not been fully elucidated. METHODS: We measured the amount of plasma-derived cell-free DNA (cfDNA) in HCC patients before (n = 100) and a few days after treatment (n = 87), including radiofrequency ablation, transarterial chemoembolization, and molecular-targeted agents (MTAs), and prospectively analyzed their associations with clinical parameters and prognosis. TERT promoter mutations in cfDNA were analyzed using droplet digital PCR. Furthermore, we performed a comprehensive mutational analysis of post-treatment cfDNA via targeted ultra-deep sequencing (22,000× coverage) in a panel of 275 cancer-related genes in selected patients. RESULTS: Plasma cfDNA levels increased significantly according to HCC clinical stage, and a high cfDNA level was independently associated with a poor prognosis. TERT promoter mutations were detected in 45% of all cases but were not associated with any clinical characteristics. cfDNA levels increased significantly a few days after treatment, and a greater increase in post-treatment cfDNA levels was associated with a greater therapeutic response to MTAs. The detection rate of TERT mutations increased to 57% using post-treatment cfDNA, suggesting that the ctDNA was enriched. Targeted ultra-deep sequencing using post-treatment cfDNA after administering lenvatinib successfully detected various gene mutations and obtained promising results in lenvatinib-responsive cases. CONCLUSIONS: Post-treatment cfDNA analysis may facilitate the construction of biomarkers for predicting MTA treatment effects.

    DOI: 10.1007/s00535-021-01773-4

    PubMed

    researchmap

  • Mutant KRAS drives metabolic reprogramming and autophagic flux in premalignant pancreatic cells. 査読 国際誌

    Tatsunori Suzuki, Takahiro Kishikawa, Tatsuyuki Sato, Norihiko Takeda, Yuki Sugiura, Takahiro Seimiya, Kazuma Sekiba, Motoko Ohno, Takuma Iwata, Rei Ishibashi, Motoyuki Otsuka, Kazuhiko Koike

    Cancer gene therapy   29 ( 5 )   505 - 518   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Mutational activation of the KRAS gene occurs in almost all pancreatic ductal adenocarcinoma (PDAC) and is the earliest molecular event in their carcinogenesis. Evidence has accumulated of the metabolic reprogramming in PDAC, such as amino acid homeostasis and autophagic flux. However, the biological effects of KRAS mutation on metabolic reprogramming at the earlier stages of PDAC carcinogenesis are unclear. Here we report dynamic metabolic reprogramming in immortalized human non-cancerous pancreatic ductal epithelial cells, in which a KRAS mutation was induced by gene-editing, which may mimic early pancreatic carcinogenesis. Similar to the cases of PDAC, KRAS gene mutation increased the dependency on glucose and glutamine for maintaining the intracellular redox balance. In addition, the intracellular levels of amino acids were significantly decreased because of active protein synthesis, and the cells required greater autophagic flux to maintain their viability. The lysosomal inhibitor chloroquine significantly inhibited cell proliferation. Therefore, metabolic reprogramming is an early event in carcinogenesis initiated by KRAS gene mutation, suggesting a rationale for the development of nutritional interventions that suppress or delay the development of PDAC.

    DOI: 10.1038/s41417-021-00326-4

    PubMed

    researchmap

  • The biological role of metabolic reprogramming in pancreatic cancer 国際誌

    Tatsunori Suzuki, Motoyuki Otsuka, Takahiro Seimiya, Takuma Iwata, Takahiro Kishikawa, Kazuhiko Koike

    MedComm   1 ( 3 )   302 - 310   2020年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Wiley  

    Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease and highly resistant to all forms of therapy. PDAC cells reprogram their metabolism extensively to promote their survival and growth. Reflecting the vital role of altered metabolism, experimental and clinical trials targeting the rewired metabolism are currently underway. In this review, we summarize the vital role of metabolic reprogramming in the development of PDAC and the future of novel therapeutic applications.

    DOI: 10.1002/mco2.37

    PubMed

    researchmap

  • The fatty-acid amide hydrolase inhibitor URB597 inhibits MICA/B shedding. 査読 国際誌

    Kazuma Sekiba, Motoyuki Otsuka, Takahiro Seimiya, Eri Tanaka, Kazuyoshi Funato, Yu Miyakawa, Kazuhiko Koike

    Scientific reports   10 ( 1 )   15556 - 15556   2020年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    MICA/B proteins are expressed on the surface of various types of stressed cells, including cancer cells. Cytotoxic lymphocytes expressing natural killer group 2D (NKG2D) receptor recognize MICA/B and eliminate the cells. However, cancer cells evade such immune recognition by inducing proteolytic shedding of MICA/B proteins. Therefore, preventing the shedding of MICA/B proteins could enhance antitumor immunity. Here, by screening a protease inhibitor library, we found that the fatty-acid amide hydrolase (FAAH) inhibitor, URB597, suppresses the shedding of MICA/B. URB597 significantly reduced the soluble MICA level in culture medium and increased the MICA level on the surface of cancer cells. The effect was indirect, being mediated by increased expression of tissue inhibitor of metalloproteinases 3 (TIMP3). Knockdown of TIMP3 expression reversed the effect of URB597, confirming that TIMP3 is required for the MICA shedding inhibition by URB597. In contrast, FAAH overexpression reduced TIMP3 expression and the cell-surface MICA level and increased the soluble MICA level. These results suggest that inhibition of FAAH could prevent human cancer cell evasion of immune-mediated clearance.

    DOI: 10.1038/s41598-020-72688-y

    PubMed

    researchmap

  • Extracellular vesicles secreted by HBV-infected cells modulate HBV persistence in hydrodynamic HBV transfection mouse model. 査読 国際誌

    Masatoshi Kakizaki, Yuichiro Yamamoto, Motoyuki Otsuka, Kouichi Kitamura, Masatoshi Ito, Hideki Derek Kawai, Masamichi Muramatsu, Tatehiro Kagawa, Ai Kotani

    The Journal of biological chemistry   295 ( 35 )   12449 - 12460   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatitis B, a viral infection that affects the liver, is thought to affect over 257 million people worldwide, and long-term infection can lead to life-threatening issues such as cirrhosis or liver cancer. Chronic hepatitis B develops by the interaction between hepatitis B virus (HBV) and host immune response. However, questions of how HBV-infected cells thwart immune system defenses remain unanswered. Extracellular vesicles (EVs) are used for cellular communication, carrying cargoes such as RNAs, proteins, and lipids and delivering them intracellularly after being endocytosed by target cells. HBV-infected liver cells secrete several types of EVs into body fluids such as complete and incomplete virions, and exosomes. We previously demonstrated that monocytes that incorporated EVs moved to immunoregulatory phenotypes via up-regulation of PD-L1, an immunocheckpoint molecule, and down-regulation of CD69, a leukocyte activation molecule. In this study, we transfected mice with HBV using hydrodynamic injection and studied the effects of EVs secreted by HBV-infected liver cells. EVs secreted from cells with HBV replication strongly suppressed the immune response, inhibiting the eradication of HBV-replicating cells in the mice transfected with HBV. EVs were systemically incorporated in multiple organs, including liver, bone marrow (BM), and intestine. Intriguingly, the BM cells that incorporated EVs acquired intestinal tropism and the dendritic cell populations in the intestine increased. These findings suggest that the EVs secreted by HBV-infected liver cells exert immunosuppressive functions, and that an association between the liver, bone marrow, and intestinal tract exists through EVs secreted from HBV-infected cells.

    DOI: 10.1074/jbc.RA120.014317

    PubMed

    researchmap

  • HBx increases EGFR expression by inhibiting miR129-5p function. 査読 国際誌

    Masanori Ochi, Motoyuki Otsuka, Reo Maruyama, Kazuhiko Koike

    Biochemical and biophysical research communications   529 ( 2 )   198 - 203   2020年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Despite the efficient suppression of hepatitis B virus (HBV) replication by nucelos(t)ide analogs, HBV RNA expression usually continues even during nucleots(t)ide analog therapy because episomal covalently closed circular DNA (ccDNA), which is the template for HBV RNA transcription, cannot be eliminated. Here, we found that the common sequences of all HBV RNAs and that encoding the X protein (HBx) have similarities with the sequences of a host cellular microRNA (miRNA), miR129-5p. HBx inhibits miR129-5p function, resulting in increased expression of ZBTB20, a target gene of miR129-5p. ZBTB20 activates transcription and increases cell-surface epidermal growth factor receptor (EGFR) levels, promoting the cell growth rate, and this effect was reversed through ZBTB20 knockdown. mir129-5p levels in Ago2-containing complexes were reduced by expression of HBx, suggesting that the viral RNA sequestered miR129-5p from Ago2-containing complexes. These results indicate the possibility that HBV RNA may maintain pathogenicity even through nucleos(t)ide analog therapy.

    DOI: 10.1016/j.bbrc.2020.06.018

    PubMed

    researchmap

  • B型肝炎根治を目指した創薬研究 宿主蛋白Smc5/6の発現回復によるHBV関連肝発癌制御の可能性

    關場 一磨, 大塚 基之, 小池 和彦

    日本消化器病学会雑誌   117 ( 臨増総会 )   A93 - A93   2020年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • Emerging Roles of Exosomal Circular RNAs in Cancer. 査読 国際誌

    Takahiro Seimiya, Motoyuki Otsuka, Takuma Iwata, Chikako Shibata, Eri Tanaka, Tatsunori Suzuki, Kazuhiko Koike

    Frontiers in cell and developmental biology   8   568366 - 568366   2020年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Circular RNA (circRNA) is a type of non-coding RNA that forms a covalently closed continuous loop. The expression pattern of circRNA varies among cell types and tissues, and many circRNAs are aberrantly expressed in various cancers. Aberrantly expressed circRNAs have been shown to play crucial roles in carcinogenesis, functioning as microRNA sponges or new templates for protein translation. Recent research has shown that circRNAs are enriched in exosomes. Exosomes are secretory vesicles that mediate intercellular communication through the delivery of cargo, including proteins, lipids, DNA, and RNA. Exosome-mediated crosstalk between cancer cells and the tumor microenvironment promotes the epithelial-mesenchymal transition, angiogenesis, and immune escape, and thus may contribute to cancer invasion and metastasis. In this review, we discuss the biological functions of exosomal circRNAs and their significance in cancer progression. Additionally, we discuss the potential clinical applications of exosomal circRNAs as biomarkers and in cancer therapy.

    DOI: 10.3389/fcell.2020.568366

    PubMed

    researchmap

  • Deletion of Histone Methyltransferase G9a Suppresses Mutant Kras-driven Pancreatic Carcinogenesis

    HIROYUKI KATO, KEISUKE TATEISHI, HIROAKI FUJIWARA, HIDEAKI IJICHI, KEISUKE YAMAMOTO, TAKUMA NAKATSUKA, MIWAKO KAKIUCHI, MAKOTO SANO, YOTARO KUDO, YOKU HAYAKAWA, HAYATO NAKAGAWA, YASUO TANAKA, MOTOYUKI OTSUKA, YOSHIHIRO HIRATA, MAKOTO TACHIBANA, YOICHI SHINKAI, KAZUHIKO KOIKE

    Cancer Genomics - Proteomics   17 ( 6 )   695 - 705   2020年

     詳細を見る

    掲載種別:研究論文(学術雑誌)   出版者・発行元:Anticancer Research USA Inc.  

    DOI: 10.21873/cgp.20224

    researchmap

  • Improved liver function in patients with cirrhosis due to chronic hepatitis C virus who achieve sustained virologic response is not accompanied by increased liver volume. 査読 国際誌

    Taijiro Wake, Ryosuke Tateishi, Tsuyoshi Fukumoto, Ryo Nakagomi, Mizuki Nishibatake Kinoshita, Takuma Nakatsuka, Masaya Sato, Tatsuya Minami, Koji Uchino, Kenichiro Enooku, Hayato Nakagawa, Hidetaka Fujinaga, Yoshinari Asaoka, Yasuo Tanaka, Motoyuki Otsuka, Kazuhiko Koike

    PloS one   15 ( 4 )   e0231836   2020年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Serum albumin level improves in patients with chronic hepatitis C virus (HCV) infection who achieve sustained virologic response (SVR) with antiviral therapy. However, it remains controversial whether liver volume increases along with SVR. METHODS: Patients with chronic HCV infection with a history of hepatocellular carcinoma (HCC) who achieved SVR with anti-HCV treatment from March 2003 to November 2017 were enrolled. Patients were followed up with periodic computed tomography (CT) scans to detect HCC recurrence. Patients who underwent treatment for HCC recurrence within 1 year after initiation of anti-HCV treatment were excluded. Laboratory data, including alanine aminotransferase (ALT) level, serum albumin level, and platelet count, were collected at baseline and timepoints after treatment initiation. Liver volume was evaluated at baseline and 24 and 48 weeks after treatment initiation using a CT volume analyzer. A linear mixed-effects model was applied to analyze the chronologic change in liver volume. The correlations between changes in ALT level, albumin level, and liver volume were also evaluated. RESULTS: Of 108 enrolled patients, 78 had cirrhosis. Serum albumin level continued to increase through 48 weeks after treatment initiation. A significant increase in liver volume was observed only in patients without cirrhosis (P = 0.005). There was a significant correlation between ALT level decrease and albumin level increase (P = 0.018). CONCLUSIONS: Improved liver albumin production with SVR was contributed by improved liver cell function rather than increased liver volume in patients with cirrhosis.

    DOI: 10.1371/journal.pone.0231836

    PubMed

    researchmap

  • Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System. 査読 国際誌

    Kazuma Sekiba, Motoyuki Otsuka, Kazuhiko Koike

    Journal of visualized experiments : JoVE   ( 154 )   2019年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    There is an urgent need for novel therapeutic agents for hepatitis B virus (HBV) infection. Although currently available nucleos(t)ide analogs potently inhibit viral replication, they have no direct effect on the expression of viral proteins transcribed from a viral covalently closed circular DNA (cccDNA). As high viral antigen load may play a role in this chronic and HBV-related carcinogenesis, the goal of HBV treatment is to eradicate viral proteins. HBV regulatory protein X (HBx) binds to the host DNA damage-binding protein 1 (DDB1) protein to degrade structural maintenance of chromosomes 5/6 (Smc5/6), resulting in activation of viral transcription from cccDNA. Here, using a split luciferase complementation assay system, we present a comprehensive compound screening system to identify inhibitors of the HBx-DDB1 interaction. Our protocol enables easy detection of interaction dynamics in real time within living cells. This technique may become a key assay to discover novel therapeutic agents for treatment of HBV infection.

    DOI: 10.3791/60652

    PubMed

    researchmap

  • Detection of circulating colorectal cancer cells by a custom microfluid system before and after endoscopic metallic stent placement. 査読 国際誌

    Rei Ishibashi, Shuntaro Yoshida, Nariaki Odawara, Takahiro Kishikawa, Ryo Kondo, Ayako Nakada, Ryunosuke Hakuta, Naminatsu Takahara, Eri Tanaka, Kazuma Sekiba, Takahiro Seimiya, Takashi Ohnaga, Motoyuki Otsuka, Kazuhiko Koike

    Oncology letters   18 ( 6 )   6397 - 6404   2019年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Although the detection of circulating tumor cells (CTCs) should be crucial for future personalized medicine, no efficient and flexible methods have been established. The current study established a polymeric custom-made chip for capturing CTCs with a high efficiency and flexibility. As an example of clinical application, the effects of self-expandable metallic stent (SEMS) placement on the release of cancer cells into the blood of patients with colorectal cancer and bowel obstruction were analyzed. This was assessed as the placement of SEMS may cause mechanical damage and physical force to malignant tissue, increasing the risk of cancer cell release into the bloodstream. The present study examined the number of CTCs using a custom-made chip, before, at 24 h after and at 4 days after SEMS placement in patients with colorectal cancer. The results revealed that, among the 13 patients examined, the number of CTCs was increased in three cases at 24 h after SEMS placement. However, this increase was temporary. The number of CTCs also decreased at 4 days after stent placement in most cases. The CTC chip of the current study detected the number of CD133-positive cancer stem-like cells, which did not change, even in the patient whose total number of CTCs temporarily increased. The results indicated that this custom-made microfluid system can efficiently and flexibly detect CTCs, demonstrating its potential for obtaining information during the management of patients with cancer.

    DOI: 10.3892/ol.2019.11047

    PubMed

    researchmap

  • Inhibition of HBV Transcription From cccDNA With Nitazoxanide by Targeting the HBx-DDB1 Interaction. 査読 国際誌

    Kazuma Sekiba, Motoyuki Otsuka, Motoko Ohno, Mari Yamagami, Takahiro Kishikawa, Tatsunori Suzuki, Rei Ishibashi, Takahiro Seimiya, Eri Tanaka, Kazuhiko Koike

    Cellular and molecular gastroenterology and hepatology   7 ( 2 )   297 - 312   2019年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Elsevier {BV}  

    BACKGROUND & AIMS: Hepatitis B virus (HBV) infection is a major health concern worldwide. Although currently used nucleos(t)ide analogs efficiently inhibit viral replication, viral proteins transcribed from the episomal viral covalently closed circular DNA (cccDNA) minichromosome continue to be expressed long-term. Because high viral RNA or antigen loads may play a biological role during this chronicity, the elimination of viral products is an ultimate goal of HBV treatment. HBV regulatory protein X (HBx) was recently found to promote transcription of cccDNA with degradation of Smc5/6 through the interaction of HBx with the host protein DDB1. Here, this protein-protein interaction was considered as a new molecular target of HBV treatment. METHODS: To identify candidate compounds that target the HBx-DDB1 interaction, a newly constructed split luciferase assay system was applied to comprehensive compound screening. The effects of the identified compounds on HBV transcription and cccDNA maintenance were determined using HBV minicircle DNA, which mimics HBV cccDNA, and the natural HBV infection model of human primary hepatocytes. RESULTS: We show that nitazoxanide (NTZ), a thiazolide anti-infective agent that has been approved by the FDA for protozoan enteritis, efficiently inhibits the HBx-DDB1 protein interaction. NTZ significantly restores Smc5 protein levels and suppresses viral transcription and viral protein production in the HBV minicircle system and in human primary hepatocytes naturally infected with HBV. CONCLUSIONS: These results indicate that NTZ, which targets an HBV-related viral-host protein interaction, may be a promising new therapeutic agent and a step toward a functional HBV cure.

    DOI: 10.1016/j.jcmgh.2018.10.010

    PubMed

    researchmap

  • Expression of circular RNA CDR1‑AS in colon cancer cells increases cell surface PD‑L1 protein levels. 査読 国際誌

    Eri Tanaka, Yu Miyakawa, Takahiro Kishikawa, Takahiro Seimiya, Takuma Iwata, Kazuyoshi Funato, Nariaki Odawara, Kazuma Sekiba, Mari Yamagami, Tatsunori Suzuki, Rei Ishibashi, Motoyuki Otsuka, Kazuhiko Koike

    Oncology reports   42 ( 4 )   1459 - 1466   2019年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The expression of CDR1‑AS, a representative circular RNA, is closely linked with poor prognosis in gastrointestinal cancers, such as colon, liver, and pancreatic cancers. Although it is well known that CDR1‑AS antagonizes microRNA‑7 function through its sequence similarities in the brain, its biological function and link with the malignant potential of cancer cells remain unclear, partly due to the difficulties of ectopic expression of circular RNAs. In the present study, SW620, a colon cancer cell line that stably expresses CDR1‑AS RNA circularized, was established using the laccase 2 gene cassette, and its biological function associated with malignant behavior was determined. In contrast to previous studies, cell growth or invasion ability was not altered by CDR1‑AS expression. However, the expression levels of CMTM4 and CMTM6, which were recently recognized as critical regulators of PD‑L1 protein expression at the cell surface, were significantly increased. Accordingly, the cell surface PD‑L1 protein levels were increased in CDR1‑AS‑expressing cells. Notably, the effects were not canceled out by overexpressing microRNA‑7, indicating that the increase in cell surface PD‑L1 in CDR1‑AS‑expressing cells was not dependent on microRNA‑7 function. These results indicated that expression of this circular RNA in cancer cells may lead to poor prognosis by increasing cell surface PD‑L1 levels through microRNA‑7‑independent mechanisms.

    DOI: 10.3892/or.2019.7244

    PubMed

    researchmap

  • Inflammation and de-differentiation in pancreatic carcinogenesis. 査読 国際誌

    Takahiro Seimiya, Motoyuki Otsuka, Takuma Iwata, Eri Tanaka, Tatsunori Suzuki, Kazuma Sekiba, Mari Yamagami, Rei Ishibashi, Kazuhiko Koike

    World journal of clinical cases   6 ( 15 )   882 - 891   2018年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pancreatic cancer is a malignancy with an extremely poor prognosis. Chronic pancreatitis is a well-known risk factor for pancreatic cancer. Inflammation is thought to influence carcinogenesis through DNA damage and activation of intracellular signaling pathways. Many transcription factors and signaling pathways co-operate to determine and maintain cell identity at each phase of pancreatic organogenesis and cell differentiation. Recent studies have shown that carcinogenesis is promoted through the suppression of transcription factors related to differentiation. Pancreatitis also demonstrates transcriptional changes, suggesting that multifactorial epigenetic changes lead to impaired differentiation. Taken together, these factors may constitute an important framework for pancreatic carcinogenesis. In this review, we discuss the role of inflammation and de-differentiation in the development of pancreatic cancer, as well as the future of novel therapeutic applications.

    DOI: 10.12998/wjcc.v6.i15.882

    PubMed

    researchmap

  • Liver stiffness measurements in chronic hepatitis C: treatment evaluation and risk assessment. 査読

    Nakagomi R, Tateishi R, Masuzaki R, Soroida Y, Iwai T, Kondo M, Fujiwara N, Sato M, Minami T, Uchino K, Enooku K, Nakagawa H, Asaoka Y, Kondo Y, Tanaka Y, Otsuka M, Kato N, Moriya K, Ikeda H, Koike K

    Journal of gastroenterology and hepatology   2018年11月

  • Circular RNA and exosomes in pancreatic cancer progression

    Takahiro Seimiya, Motoyuki Otsuka, Hung-Yin Liu, Tatsunori Suzuki, Kazuma Sekiba, Mari Yamagami, Eri Tanaka, Rei Ishibashi, Kazuhiko Koike

    Translational Cancer Research   7   S745 - S747   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:AME Publishing Company  

    DOI: 10.21037/tcr.2018.08.03

    Scopus

    researchmap

  • Satellite RNA Increases DNA Damage and Accelerates Tumor Formation in Mouse Models of Pancreatic Cancer. 査読 国際誌

    Takahiro Kishikawa, Motoyuki Otsuka, Tatsunori Suzuki, Takahiro Seimiya, Kazuma Sekiba, Rei Ishibashi, Eri Tanaka, Motoko Ohno, Mari Yamagami, Kazuhiko Koike

    Molecular cancer research : MCR   16 ( 8 )   1255 - 1262   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Highly repetitive tandem arrays such as satellite sequences in the centromeric and pericentromeric regions of chromosomes, which were previously considered to be silent, are actively transcribed in various biological processes, including cancers. In the pancreas, this aberrant expression occurs even in Kras-mutated pancreatic intraepithelial neoplasia (PanIN) tissues, which are precancerous lesions. To determine the biological role of satellite RNAs in carcinogenesis in vivo, we constructed mouse major satellite (MajSAT) RNA-expressing transgenic mice. However, these transgenic mice did not show spontaneous malignant tumor formation under normal breeding. Importantly, however, DNA damage was increased in pancreatic tissues induced by caerulein treatment or high-fat diet, which may be due to impaired nuclear localization of Y-Box Binding Protein 1 (YBX1), a component of the DNA damage repair machinery. In addition, when crossed with pancreas-specific Kras-mutant mice, MajSAT RNA expression resulted in an earlier increase in PanIN formation. These results suggest that aberrant MajSAT RNA expression accelerates oncogenesis by increasing the probability of a second driver mutation, thus accelerating cells to exit from the breakthrough phase to the expansion phase.Implications: Aberrant expression of satellite RNAs accelerates oncogenesis through a mechanism involving increased DNA damage. Mol Cancer Res; 16(8); 1255-62. ©2018 AACR.

    DOI: 10.1158/1541-7786.MCR-18-0139

    PubMed

    researchmap

  • CPT2 downregulation adapts HCC to lipid-rich environment and promotes carcinogenesis via acylcarnitine accumulation in obesity. 査読 国際誌

    Naoto Fujiwara, Hayato Nakagawa, Kenichiro Enooku, Yotaro Kudo, Yuki Hayata, Takuma Nakatsuka, Yasuo Tanaka, Ryosuke Tateishi, Yohko Hikiba, Kento Misumi, Mariko Tanaka, Akimasa Hayashi, Junji Shibahara, Masashi Fukayama, Junichi Arita, Kiyoshi Hasegawa, Hadassa Hirschfield, Yujin Hoshida, Yoshihiro Hirata, Motoyuki Otsuka, Keisuke Tateishi, Kazuhiko Koike

    Gut   67 ( 8 )   1493 - 1504   2018年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    OBJECTIVE: Metabolic reprogramming of tumour cells that allows for adaptation to their local environment is a hallmark of cancer. Interestingly, obesity-driven and non-alcoholic steatohepatitis (NASH)-driven hepatocellular carcinoma (HCC) mouse models commonly exhibit strong steatosis in tumour cells as seen in human steatohepatitic HCC (SH-HCC), which may reflect a characteristic metabolic alteration. DESIGN: Non-tumour and HCC tissues obtained from diethylnitrosamine-injected mice fed either a normal or a high-fat diet (HFD) were subjected to comprehensive metabolome analysis, and the significance of obesity-mediated metabolic alteration in hepatocarcinogenesis was evaluated. RESULTS: The extensive accumulation of acylcarnitine species was seen in HCC tissues and in the serum of HFD-fed mice. A similar increase was found in the serum of patients with NASH-HCC. The accumulation of acylcarnitine could be attributed to the downregulation of carnitine palmitoyltransferase 2 (CPT2), which was also seen in human SH-HCC. CPT2 downregulation induced the suppression of fatty acid β-oxidation, which would account for the steatotic changes in HCC. CPT2 knockdown in HCC cells resulted in their resistance to lipotoxicity by inhibiting the Src-mediated JNK activation. Additionally, oleoylcarnitine enhanced sphere formation by HCC cells via STAT3 activation, suggesting that acylcarnitine accumulation was a surrogate marker of CPT2 downregulation and directly contributed to hepatocarcinogenesis. HFD feeding and carnitine supplementation synergistically enhanced HCC development accompanied by acylcarnitine accumulation in vivo. CONCLUSION: In obesity-driven and NASH-driven HCC, metabolic reprogramming mediated by the downregulation of CPT2 enables HCC cells to escape lipotoxicity and promotes hepatocarcinogenesis.

    DOI: 10.1136/gutjnl-2017-315193

    PubMed

    researchmap

  • Hepatitis B virus pathogenesis: Fresh insights into hepatitis B virus RNA. 査読 国際誌

    Kazuma Sekiba, Motoyuki Otsuka, Motoko Ohno, Mari Yamagami, Takahiro Kishikawa, Tatsunori Suzuki, Rei Ishibashi, Takahiro Seimiya, Eri Tanaka, Kazuhiko Koike

    World journal of gastroenterology   24 ( 21 )   2261 - 2268   2018年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatitis B virus (HBV) is still a worldwide health concern. While divergent factors are involved in its pathogenesis, it is now clear that HBV RNAs, principally templates for viral proteins and viral DNAs, have diverse biological functions involved in HBV pathogenesis. These functions include viral replication, hepatic fibrosis and hepatocarcinogenesis. Depending on the sequence similarities, HBV RNAs may act as sponges for host miRNAs and may deregulate miRNA functions, possibly leading to pathological consequences. Some parts of the HBV RNA molecule may function as viral-derived miRNA, which regulates viral replication. HBV DNA can integrate into the host genomic DNA and produce novel viral-host fusion RNA, which may have pathological functions. To date, elimination of HBV-derived covalently closed circular DNA has not been achieved. However, RNA transcription silencing may be an alternative practical approach to treat HBV-induced pathogenesis. A full understanding of HBV RNA transcription and the biological functions of HBV RNA may open a new avenue for the development of novel HBV therapeutics.

    DOI: 10.3748/wjg.v24.i21.2261

    PubMed

    researchmap

  • Identification of PTBP1 responsible for caspase dependent YRNA cleavage 査読

    Jun Ogata, Yuki Sugiura, Akinori Kanai, Masafumi Tanaka, Hirotaka Matsui, Masato Ohtsuka, Toshiya Inaba, Motoyuki Otsuka, Ai Kotani

    BioRxiv doi: https://doi.org/10.1101/298851   2018年5月

     詳細を見る

    掲載種別:研究論文(その他学術会議資料等)  

    DOI: 10.1101/298851

    researchmap

  • DHX9 regulates production of hepatitis B virus-derived circular RNA and viral protein levels. 査読 国際誌

    Kazuma Sekiba, Motoyuki Otsuka, Motoko Ohno, Takahiro Kishikawa, Mari Yamagami, Tatsunori Suzuki, Rei Ishibashi, Takahiro Seimiya, Eri Tanaka, Kazuhiko Koike

    Oncotarget   9 ( 30 )   20953 - 20964   2018年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Hepatitis B virus (HBV) infection, which is a major health concern worldwide, can lead to liver cirrhosis and hepatocellular carcinoma. Although current nucleos(t)ide analogs efficiently inhibit viral reverse transcription and viral DNA load clinically, episomal viral covalently closed circular DNA (cccDNA) minichromosomes and transcripts from cccDNA continue to be expressed over the long term. We hypothesized that, under these conditions, viral transcripts may have biological functions involved in pathogenesis. Here, we show that the host protein DExH-box helicase 9 (DXH9) is associated with viral RNAs. We also show that viral-derived circular RNA is produced during HBV replication, and the amount is increased by knockdown of the DHX9 protein, which, in turn, results in decreased viral protein levels but does not affect the levels of HBV DNA. These phenomena were observed in the HBV-producing cell culture model and HBV mini-circle model mimicking HBV cccDNA, as well as in human primary hepatocytes infected with HBV. Based on these results, we conclude that, in HBV infection, the RNA binding factor DHX9 is a novel regulator of viral circular RNA and viral protein levels.

    DOI: 10.18632/oncotarget.25104

    PubMed

    researchmap

  • ISGF3 with reduced phosphorylation is associated with constitutive expression of interferon-induced genes in aging cells. 査読 国際誌

    Mari Yamagami, Motoyuki Otsuka, Takahiro Kishikawa, Kazuma Sekiba, Takahiro Seimiya, Eri Tanaka, Tatsunori Suzuki, Rei Ishibashi, Motoko Ohno, Kazuhiko Koike

    NPJ aging and mechanisms of disease   4   11 - 11   2018年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    During cellular aging, many changes in cellular functions occur. A hallmark of aged cells is secretion of inflammatory mediators, which collectively is referred to as the senescence-associated secretory phenotype (SASP). However, the mechanisms underlying such changes are unclear. Canonically, the expression of interferon (IFN)-stimulated genes (ISGs) is induced by IFNs through the formation of the tripartite transcriptional factor ISGF3, which is composed of IRF9 and the phosphorylated forms of STAT1 and STAT2. However, in this study, the constitutive expression of ISGs in human-derived senescent fibroblasts and in fibroblasts from a patient with Werner syndrome, which leads to premature aging, was mediated mainly by the unphosphorylated forms of STATs in the absence of INF production. Under homeostatic conditions, STAT1, STAT2, and IRF9 were localized to the nucleus of aged cells. Although knockdown of JAK1, a key kinase of STAT1 and STAT2, did not affect ISG expression or IFN-stimulated response element (ISRE)-mediated promoter activities in these senescent cells, knockdown of STAT1 or STAT2 decreased ISG expression and ISRE activities. These results suggest that the ISGF3 complex without clear phosphorylation is required for IFN-independent constitutive ISG transcription in senescent cells.

    DOI: 10.1038/s41514-018-0030-6

    PubMed

    researchmap

  • Impact of histone demethylase KDM3A-dependent AP-1 transactivity on hepatotumorigenesis induced by PI3K activation 査読

    T. Nakatsuka, K. Tateishi, Y. Kudo, K. Yamamoto, H. Nakagawa, H. Fujiwara, R. Takahashi, K. Miyabayashi, Y. Asaoka, Y. Tanaka, H. Ijichi, Y. Hirata, M. Otsuka, M. Kato, J. Sakai, M. Tachibana, H. Aburatani, Y. Shinkai, K. Koike

    ONCOGENE   36 ( 45 )   6262 - 6271   2017年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/onc.2017.222

    Web of Science

    researchmap

  • 膵発癌過程における反復配列RNA異常発現の生物学的意義の検討 査読

    岸川 孝弘, 大塚 基之, 大野 元子, 山上 まり, 石橋 嶺, 關場 一磨, 鈴木 辰典, 小池 和彦

    日本消化器病学会雑誌   114 ( 臨増大会 )   A743 - A743   2017年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • RASAL1 is a potent regulator of hepatic stellate cell activity and liver fibrosis 査読

    Akemi Takata, Motoyuki Otsuka, Takahiro Kishikawa, Mari Yamagami, Rei Ishibashi, Kazuma Sekiba, Tatsunori Suzuki, Motoko Ohno, Yui Yamashita, Takaya Abe, Ryota Masuzaki, Tsuneo Ikenoue, Kazuhiko Koike

    ONCOTARGET   8 ( 39 )   64840 - 64852   2017年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.18632/oncotarget.17609

    Web of Science

    PubMed

    researchmap

  • Biliary epithelial injury-induced regenerative response by IL-33 promotes cholangiocarcinogenesis from peribiliary glands 査読

    Hayato Nakagawa, Nobumi Suzuki, Yoshihiro Hirata, Yohko Hikiba, Yoku Hayakawa, Hiroto Kinoshita, Sozaburo Ihara, Koji Uchino, Yuji Nishikawa, Hideaki Ijichi, Motoyuki Otsuka, Junichi Arita, Yoshihiro Sakamoto, Kiyoshi Hasegawa, Norihiro Kokudo, Keisuke Tateishi, Kazuhiko Koike

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   114 ( 19 )   E3806 - E3815   2017年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1073/pnas.1619416114

    Web of Science

    PubMed

    researchmap

  • Transcriptional activation of the MICA gene with an engineered CRISPR-Cas9 system 査読

    Kazuma Sekiba, Mari Yamagami, Motoyuki Otsuka, Tatsunori Suzuki, Takahiro Kishikawa, Rei Ishibashi, Motoko Ohno, Masaya Sato, Kazuhiko Koike

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   486 ( 2 )   521 - 525   2017年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.bbrc.2017.03.076

    Web of Science

    PubMed

    researchmap

  • MicroRNAs and liver disease 査読

    Motoyuki Otsuka, Takahiro Kishikawa, Takeshi Yoshikawa, Mari Yamagami, Motoko Ohno, Akemi Takata, Chikako Shibata, Rei Ishibashi, Kazuhiko Koike

    JOURNAL OF HUMAN GENETICS   62 ( 1 )   75 - 80   2017年1月

     詳細を見る

  • Mutual antagonism between hepatitis B viral mRNA and host microRNA let-7 査読

    Akemi Takata, Motoyuki Otsuka, Motoko Ohno, Takahiro Kishikawa, Takeshi Yoshikawa, Kazuhiko Koike

    SCIENTIFIC REPORTS   6   23237   2016年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/srep23237

    Web of Science

    PubMed

    researchmap

  • Development of a screening method to identify regulators of MICA shedding 査読

    Takahiro Kishikawa, Motoyuki Otsuka, Motoko Ohno, Takeshi Yoshikawa, Masaya Sato, Kazuhiko Koike

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   465 ( 4 )   764 - 768   2015年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.bbrc.2015.08.081

    Web of Science

    PubMed

    researchmap

  • ROCK inhibition enhances microRNA function by promoting deadenylation of targeted mRNAs via increasing PAIP2 expression 査読

    Takeshi Yoshikawa, Jianfeng Wu, Motoyuki Otsuka, Takahiro Kishikawa, Motoko Ohno, Chikako Shibata, Akemi Takata, Felicia Han, Young Jun Kang, Chyi-Ying A. Chen, Ann-Bin Shyu, Jiahuai Han, Kazuhiko Koike

    NUCLEIC ACIDS RESEARCH   43 ( 15 )   7577 - 7589   2015年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/nar/gkv728

    Web of Science

    PubMed

    researchmap

  • Circulating RNAs as new biomarkers for detecting pancreatic cancer 査読

    Takahiro Kishikawa, Motoyuki Otsuka, Motoko Ohno, Takeshi Yoshikawa, Akemi Takata, Kazuhiko Koike

    WORLD JOURNAL OF GASTROENTEROLOGY   21 ( 28 )   8527 - 8540   2015年7月

     詳細を見る

  • Novel therapeutic approaches for hepatitis B virus covalently closed circular DNA 査読

    Motoko Ohno, Motoyuki Otsuka, Takahiro Kishikawa, Takeshi Yoshikawa, Akemi Takata, Kazuhiko Koike

    WORLD JOURNAL OF GASTROENTEROLOGY   21 ( 23 )   7084 - 7088   2015年6月

     詳細を見る

  • Tissue-Specific Regulation of p38α-Mediated Inflammation in Con A-Induced Acute Liver Damage. 査読

    Kang YJ, Bang BR, Otsuka M, Otsu K

    Journal of immunology (Baltimore, Md. : 1950)   194 ( 10 )   4759 - 4766   2015年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.4049/jimmunol.1402954

    Web of Science

    PubMed

    researchmap

  • Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine 査読

    Takahiro Kishikawa, Motoyuki Otsuka, Poh Seng Tan, Motoko Ohno, Xiaochen Sun, Takeshi Yoshikawa, Chikako Shibata, Akemi Takata, Kentaro Kojima, Kenji Takehana, Maki Ohishi, Sana Ota, Tomoyuki Noyama, Yuji Kondo, Masaya Sato, Tomoyoshi Soga, Yujin Hoshida, Kazuhiko Koike

    Oncotarget   6 ( 10 )   8339 - 8352   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Impact Journals LLC  

    DOI: 10.18632/oncotarget.3234

    Scopus

    PubMed

    researchmap

  • Diagnostic and therapeutic application of noncoding RNAs for hepatocellular carcinoma 査読

    Chikako Shibata, Motoyuki Otsuka, Takahiro Kishikawa, Motoko Ohno, Takeshi Yoshikawa, Akemi Takata, Kazuhiko Koike

    World Journal of Hepatology   7 ( 1 )   1 - 6   2015年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:Baishideng Publishing Group Co  

    DOI: 10.4254/wjh.v7.i1.1

    Scopus

    PubMed

    researchmap

  • Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBPα 査読

    Yamamoto K, Tateishi K, Kudo Y, Sato T, Yamamoto S, Miyabayashi K, Matsusaka K, Asaoka Y, Ijichi H, Hirata Y, Otsuka M, Nakai Y, Isayama H, Ikenoue T, Kurokawa M, Fukayama M, Kokudo N, Omata M, Koike K

    Carcinogenesis   35 ( 11 )   2404 - 2414   2014年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/carcin/bgu136

    Web of Science

    PubMed

    researchmap

  • Impact of PNPLA3 polymorphisms on the development of hepatocellular carcinoma in patients with chronic hepatitis C virus infection 査読

    Masaya Sato, Naoya Kato, Ryosuke Tateishi, Ryosuke Muroyama, Norie Kowatari, Wenwen Li, Kaku Goto, Motoyuki Otsuka, Shuichiro Shiina, Haruhiko Yoshida, Masao Omata, Kazuhiko Koike

    HEPATOLOGY RESEARCH   44 ( 10 )   E137 - E144   2014年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1111/hepr.12258

    Web of Science

    PubMed

    researchmap

  • The flavonoid apigenin inhibits hepatitis C virus replication by decreasing mature microRNA122 levels 査読

    Chikako Shibata, Motoko Ohno, Motoyuki Otsuka, Takahiro Kishikawa, Kaku Goto, Ryosuke Muroyama, Naoya Kato, Takeshi Yoshikawa, Akemi Takata, Kazuhiko Koike

    VIROLOGY   462   42 - 48   2014年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.virol.2014.05.024

    Web of Science

    PubMed

    researchmap

  • Specific delivery of microRNA93 into HBV-replicating hepatocytes downregulates protein expression of liver cancer susceptible gene MICA 査読

    Motoko Ohno, Motoyuki Otsuka, Takahiro Kishikawa, Chikako Shibata, Takeshi Yoshikawa, Akemi Takata, Ryosuke Muroyama, Norie Kowatari, Masaya Sato, Naoya Kato, Shun'ichi Kuroda, Kazuhiko Koike

    ONCOTARGET   5 ( 14 )   5581 - 5590   2014年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection 査読

    Masaya Sato, Naoya Kato, Ryosuke Tateishi, Ryosuke Muroyama, Norie Kowatari, Wenwen Li, Kaku Goto, Motoyuki Otsuka, Shuichiro Shiina, Haruhiko Yoshida, Masao Omata, Kazuhiko Koike

    JOURNAL OF GASTROENTEROLOGY   49 ( 4 )   748 - 754   2014年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s00535-013-0826-x

    Web of Science

    PubMed

    researchmap

  • The role of microRNAs in hepatocarcinogenesis: current knowledge and future prospects 査読

    Motoyuki Otsuka, Takahiro Kishikawa, Takeshi Yoshikawa, Motoko Ohno, Akemi Takata, Chikako Shibata, Kazuhiko Koike

    JOURNAL OF GASTROENTEROLOGY   49 ( 2 )   173 - 184   2014年2月

     詳細を見る

  • Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells 査読

    Shinzo Yamamoto, Keisuke Tateishi, Yotaro Kudo, Keisuke Yamamoto, Takayuki Isagawa, Genta Nagae, Takuma Nakatsuka, Yoshinari Asaoka, Hideaki Ijichi, Yoshihiro Hirata, Motoyuki Otsuka, Tsuneo Ikenoue, Hiroyuki Aburatani, Masao Omata, Kazuhiko Koike

    CARCINOGENESIS   34 ( 10 )   2380 - 2388   2013年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1093/carcin/bgt174

    Web of Science

    PubMed

    researchmap

  • Activation of p38α in T cells regulates the intestinal host defense against attaching and effacing bacterial infections. 査読

    Shim EJ, Bang BR, Kang SG, Ma J, Otsuka M, Kang J, Stahl M, Han J, Xiao C, Vallance BA, Kang YJ

    Journal of immunology (Baltimore, Md. : 1950)   191 ( 5 )   2764 - 2770   2013年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:5  

    DOI: 10.4049/jimmunol.1300908

    Scopus

    PubMed

    researchmap

  • Unique Haploinsufficient Role of the MicroRNA-Processing Molecule Dicer1 in a Murine Colitis-Associated Tumorigenesis Model 査読

    Takeshi Yoshikawa, Motoyuki Otsuka, Takahiro Kishikawa, Akemi Takata, Motoko Ohno, Chikako Shibata, Young Jun Kang, Haruhiko Yoshida, Kazuhiko Koike

    PLOS ONE   8 ( 9 )   e71969   2013年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.pone.0071969

    Web of Science

    PubMed

    researchmap

  • Inhibition of microRNA122 decreases SREBP1 expression by modulating suppressor of cytokine signaling 3 expression 査読

    Chikako Shibata, Takahiro Kishikawa, Motoyuki Otsuka, Motoko Ohno, Takeshi Yoshikawa, Akemi Takata, Haruhiko Yoshida, Kazuhiko Koike

    Biochemical and Biophysical Research Communications   438 ( 1 )   230 - 235   2013年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:1  

    DOI: 10.1016/j.bbrc.2013.07.064

    Scopus

    PubMed

    researchmap

  • The flavonoid apigenin improves glucose tolerance through inhibition of microRNA maturation in miRNA103 transgenic mice 査読

    Motoko Ohno, Chikako Shibata, Takahiro Kishikawa, Takeshi Yoshikawa, Akemi Takata, Kentaro Kojima, Masao Akanuma, Young Jun Kang, Haruhiko Yoshida, Motoyuki Otsuka, Kazuhiko Koike

    SCIENTIFIC REPORTS   3   2553   2013年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/srep02553

    Web of Science

    PubMed

    researchmap

  • Transdifferentiation of human fibroblasts into hepatocyte-like cells by defined transcriptional factors 査読

    Tomomi Kogiso, Hikaru Nagahara, Motoyuki Otsuka, Keiko Shiratori, Steven F. Dowdy

    HEPATOLOGY INTERNATIONAL   7 ( 3 )   937 - 944   2013年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12072-013-9432-5

    Web of Science

    researchmap

  • A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region 査読

    Yuji Urabe, Hidenori Ochi, Naoya Kato, Vinod Kumar, Atsushi Takahashi, Ryosuke Muroyama, Naoya Hosono, Motoyuki Otsuka, Ryosuke Tateishi, Paulisally Hau Yi Lo, Chizu Tanikawa, Masao Omata, Kazuhiko Koike, Daiki Miki, Hiromi Abe, Naoyuki Kamatani, Joji Toyota, Hiromitsu Kumada, Michiaki Kubo, Kazuaki Chayama, Yusuke Nakamura, Koichi Matsuda

    Journal of Hepatology   58 ( 5 )   875 - 882   2013年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.jhep.2012.12.024

    Scopus

    PubMed

    researchmap

  • MicroRNA-140 acts as a liver tumor suppressor by controlling NF-κB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression. 国際誌

    Akemi Takata, Motoyuki Otsuka, Takeshi Yoshikawa, Takahiro Kishikawa, Yohko Hikiba, Shuntaro Obi, Tadashi Goto, Young Jun Kang, Shin Maeda, Haruhiko Yoshida, Masao Omata, Hiroshi Asahara, Kazuhiko Koike

    Hepatology (Baltimore, Md.)   57 ( 1 )   162 - 70   2013年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    UNLABELLED: MicroRNAs (miRNAs) are small RNAs that regulate the expression of specific target genes. While deregulated miRNA expression levels have been detected in many tumors, whether miRNA functional impairment is also involved in carcinogenesis remains unknown. We investigated whether deregulation of miRNA machinery components and subsequent functional impairment of miRNAs are involved in hepatocarcinogenesis. Among miRNA-containing ribonucleoprotein complex components, reduced expression of DDX20 was frequently observed in human hepatocellular carcinomas, in which enhanced nuclear factor-κB (NF-κB) activity is believed to be closely linked to carcinogenesis. Because DDX20 normally suppresses NF-κB activity by preferentially regulating the function of the NF-κB-suppressing miRNA-140, we hypothesized that impairment of miRNA-140 function may be involved in hepatocarcinogenesis. DNA methyltransferase 1 (Dnmt1) was identified as a direct target of miRNA-140, and increased Dnmt1 expression in DDX20-deficient cells hypermethylated the promoters of metallothionein genes, resulting in decreased metallothionein expression leading to enhanced NF-κB activity. MiRNA-140-knockout mice were prone to hepatocarcinogenesis and had a phenotype similar to that of DDX20 deficiency, suggesting that miRNA-140 plays a central role in DDX20 deficiency-related pathogenesis. CONCLUSION: These results indicate that miRNA-140 acts as a liver tumor suppressor, and that impairment of miRNA-140 function due to a deficiency of DDX20, a miRNA machinery component, could lead to hepatocarcinogenesis.

    DOI: 10.1002/hep.26011

    PubMed

    researchmap

  • MicroRNA-140 acts as a liver tumor suppressor by controlling NF-kappa B activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression 査読

    Akemi Takata, Motoyuki Otsuka, Takeshi Yoshikawa, Takahiro Kishikawa, Yohko Hikiba, Shuntaro Obi, Tadashi Goto, Young Jun Kang, Shin Maeda, Haruhiko Yoshida, Masao Omata, Hiroshi Asahara, Kazuhiko Koike

    HEPATOLOGY   57 ( 1 )   162 - 170   2013年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/hep.26011

    Web of Science

    researchmap

  • A genome-wide association study of HCV-induced liver cirrhosis in the Japanese population identifies novel susceptibility loci at the MHC region 査読 国際誌

    Urabe Y, Ochi H, Kato N, Kumar V, Takahashi A, Muroyama R, Hosono N, Otsuka M, Tateishi R, Lo P. H, Tanikawa C, Omata M, Koike K, Miki D, Abe H, Kamatani N, Toyota J, Kumada H, Kubo M, Chayama K, Nakamura Y, Matsuda K

    J Hepatol   58 ( 5 )   875 - 82   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.jhep.2012.12.024

    PubMed

    researchmap

  • Current status of miRNA-targeting therapeutics and preclinical studies against gastroenterological carcinoma. 査読

    Shibata C, Otsuka M, Kishikawa T, Yoshikawa T, Ohno M, Takata A, Koike K

    Molecular and cellular therapies   1   5   2013年

  • Regulation of the expression of the liver cancer susceptibility gene MICA by microRNAs 査読

    Takahiro Kishikawa, Motoyuki Otsuka, Takeshi Yoshikawa, Motoko Ohno, Akemi Takata, Chikako Shibata, Yuji Kondo, Masao Akanuma, Haruhiko Yoshida, Kazuhiko Koike

    Scientific Reports   3   2739   2013年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/srep02739

    Scopus

    PubMed

    researchmap

  • Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation. 査読

    Yoshikawa T, Takata A, Otsuka M, Kishikawa T, Kojima K, Yoshida H, Koike K

    Scientific reports   2   637   2012年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/srep00637

    Web of Science

    PubMed

    researchmap

  • A miRNA machinery component DDX20 controls NF-κB via microRNA-140 function. 査読

    Takata A, Otsuka M, Yoshikawa T, Kishikawa T, Kudo Y, Goto T, Yoshida H, Koike K

    Biochemical and biophysical research communications   420 ( 3 )   564 - 569   2012年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.bbrc.2012.03.034

    Web of Science

    PubMed

    researchmap

  • Altered composition of fatty acids exacerbates hepatotumorigenesis during activation of the phosphatidylinositol 3-kinase pathway 査読

    Yotaro Kudo, Yasuo Tanaka, Keisuke Tateishi, Keisuke Yamamoto, Shinzo Yamamoto, Dai Mohri, Yoshihiro Isomura, Motoko Seto, Hayato Nakagawa, Yoshinari Asaoka, Motohisa Tada, Miki Ohta, Hideaki Ijichi, Yoshihiro Hirata, Motoyuki Otsuka, Tsuneo Ikenoue, Shin Maeda, Shuichiro Shiina, Haruhiko Yoshida, Osamu Nakajima, Fumihiko Kanai, Masao Omata, Kazuhiko Koike

    JOURNAL OF HEPATOLOGY   55 ( 6 )   1400 - 1408   2011年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.jhep.2011.03.025

    Web of Science

    PubMed

    researchmap

  • Direct differentiation of hepatic cells from human induced pluripotent stem cells using a limited number of cytokines 査読

    Akemi Takata, Motoyuki Otsuka, Tomomi Kogiso, Kentaro Kojima, Takeshi Yoshikawa, Ryosuke Tateishi, Naoya Kato, Shuichiro Shiina, Haruhiko Yoshida, Masao Omata, Kazuhiko Koike

    HEPATOLOGY INTERNATIONAL   5 ( 4 )   890 - 898   2011年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12072-011-9251-5

    Web of Science

    PubMed

    researchmap

  • Receptor for Activated Protein Kinase C: Requirement for Efficient MicroRNA Function and Reduced Expression in Hepatocellular Carcinoma 査読

    Motoyuki Otsuka, Akemi Takata, Takeshi Yoshikawa, Kentaro Kojima, Takahiro Kishikawa, Chikako Shibata, Mutsuhiro Takekawa, Haruhiko Yoshida, Masao Omata, Kazuhiko Koike

    PLOS ONE   6 ( 9 )   2011年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.pone.0024359

    Web of Science

    researchmap

  • MicroRNA-22 and microRNA-140 suppress NF-κB activity by regulating the expression of NF-κB coactivators. 査読

    Takata A, Otsuka M, Kojima K, Yoshikawa T, Kishikawa T, Yoshida H, Koike K

    Biochemical and biophysical research communications   411 ( 4 )   826 - 831   2011年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.bbrc.2011.07.048

    Web of Science

    PubMed

    researchmap

  • HCV関連肝細胞癌患者の高齢化と非硬変肝からの発癌の増加

    吉田 晴彦, 建石 良介, 佐藤 雅哉, 三神 信太郎, 内野 康史, 新野 徹, 榎奥 健一郎, 後藤 絵里子, 中川 隼人, 増崎 良太, 浅岡 良成, 大塚 基之, 山敷 宣代, 五藤 忠, 椎名 秀一朗, 小俣 政男, 小池 和彦

    肝臓   52 ( Suppl.1 )   A411 - A411   2011年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Reduced expression of RAS protein activator like-1 in gastric cancer 査読

    Motoko Seto, Miki Ohta, Tsuneo Ikenoue, Takafumi Sugimoto, Yoshinari Asaoka, Motohisa Tada, Dai Mohri, Yotaro Kudo, Hideaki Ijichi, Keisuke Tateishi, Motoyuki Otsuka, Yoshihiro Hirata, Shin Maeda, Kazuhiko Koike, Masao Omata

    INTERNATIONAL JOURNAL OF CANCER   128 ( 6 )   1293 - 1302   2011年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/ijc.25459

    Web of Science

    PubMed

    researchmap

  • Epithelial p38 alpha Controls Immune Cell Recruitment in the Colonic Mucosa 査読

    Young Jun Kang, Motoyuki Otsuka, Arjen van den Berg, Lixin Hong, Zhe Huang, Xiurong Wu, Duan-Wu Zhang, Bruce A. Vallance, Peter S. Tobias, Jiahuai Han

    PLOS PATHOGENS   6 ( 6 )   e1000934   2010年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1371/journal.ppat.1000934

    Web of Science

    PubMed

    researchmap

  • DDX20 deficiency enhances NF-kappa B by impairing NF-kappa B suppressive-microRNA function and leads to hepatocarcinogenesis 査読

    Takata Akemi, Otsuka Motoyuki, Kudo Yotaro, Kojima Kentaro, Maeda Shin, Tateishi Keisuke, Ikenoue Tsuneo, Ijichi Hideaki, Hirata Yoshihiro, Yoshida Haruhiko, Omata Masao, Koike Kazuhiko

    CANCER RESEARCH   70   2010年4月

  • Apoptosis Signal-Regulating Kinase 1 Regulates Colitis and Colitis-Associated Tumorigenesis by the Innate Immune Responses 査読

    Yoku Hayakawa, Yoshihiro Hirata, Hayato Nakagawa, Kei Sakamoto, Yohko Hikiba, Motoyuki Otsuka, Hideaki Ijichi, Tsuneo Ikenoue, Keisuke Tateishi, Masao Akanuma, Keiji Ogura, Haruhiko Yoshida, Hidenori Ichijo, Masao Omata, Shin Maeda

    GASTROENTEROLOGY   138 ( 3 )   1055 - U334   2010年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2009.11.015

    Web of Science

    PubMed

    researchmap

  • TNF-alpha stimulation inhibits siRNA-mediated RNA interference through a mechanism involving poly-(A) tail stabilization. 査読

    Mols J, van den Berg A, Otsuka M, Zheng M, Chen J, Han J

    Biochimica et biophysica acta   1779   712 - 719   2008年11月

     詳細を見る

    出版者・発行元:11  

    DOI: 10.1016/j.bbagrm.2008.03.007

    PubMed

    researchmap

  • TNF-alpha stimulation inhibits siRNA-mediated RNA interference through a mechanism involving poly-(A) tail stabilization 査読

    Johann Mols, Arjen van den Berg, Motoyuki Otsuka, Min Zheng, Jianming Chen, Jiahuai Han

    BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS   1779 ( 11 )   712 - 719   2008年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.bbagrm.2008.03.007

    Web of Science

    researchmap

  • Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus 査読

    Narayan Dharel, Naoya Kato, Ryosuke Muroyama, Hiroyoshi Taniguchi, Motoyuki Otsuka, Yue Wang, Amarsanaa Jazag, Run-Xuan Shao, Jin-Hai Chang, Mark K. Adler, Takao Kawabe, Masao Omata

    HEPATOLOGY   47 ( 4 )   1136 - 1149   2008年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/hep.22176

    Web of Science

    PubMed

    researchmap

  • Macrophage deletion of p38 alpha partially impairs lipopolysaccharide-induced cellular activation 査読

    Young Jun Kang, Jianming Chen, Motoyuki Otsuka, Johann Mols, Shuxun Ren, Yinbin Wang, Jiahuai Han

    JOURNAL OF IMMUNOLOGY   180 ( 7 )   5075 - 5082   2008年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • Calcineurin negatively regulates TLR-Mediated activation pathways 査読

    Young Jun Kang, Brenda Kusler, Motoyuki Otsuka, Michael Hughes, Nobutaka Suzuki, Shinobu Suzuki, Wen-Chen Yeh, Shizuo Akira, Jiahuai Han, Patricia P. Jones

    JOURNAL OF IMMUNOLOGY   179 ( 7 )   4598 - 4607   2007年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • Interferon-beta is activated by hepatitis C virus NS5B and inhibited by NS4A, NS4B, and NS5A 査読

    Masaru Moriyama, Naoya Kato, Motoyuki Otsuka, Run-Xuan Shao, Hiroyoshi Taniguchi, Takao Kawabe, Masao Omata

    HEPATOLOGY INTERNATIONAL   1 ( 2 )   302 - 310   2007年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1007/s12072-007-9003-8

    Web of Science

    PubMed

    researchmap

  • Gene expressions associated with chemosensitivity in human hepatoma cells 査読

    Yujin Hoshida, Masaru Moriyama, Motoyuki Otsuka, Naoya Kato, Hiroyoshi Taniguchi, Yasushi Shiratori, Naohiko Seki, Masao Omata

    HEPATO-GASTROENTEROLOGY   54 ( 74 )   489 - 492   2007年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • Absence of tyrosine kinase mutations in Japanese colorectal cancer patients 査読

    R-X Shao, N. Kato, L-J Lin, R. Muroyama, M. Moriyama, T. Ikenoue, H. Watabe, M. Otsuka, B. Guleng, M. Ohta, Y. Tanaka, S. Kondo, N. Dharel, J-H Chang, H. Yoshida, T. Kawabe, M. Omata

    ONCOGENE   26 ( 14 )   2133 - 2135   2007年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/sj.onc.1210007

    Web of Science

    researchmap

  • Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma 査読

    Ryosuke Muroyama, Naoya Kato, Haruhiko Yoshida, Motoyuki Otsuka, Masaru Moriyama, Yue Wang, Run-Xuan Shao, Narayan Dharel, Yasuo Tanaka, Miki Ohta, Ryosuke Tateishi, Shuichiro Shiina, Masashi Tatsukawa, Kenichi Fukai, Fumio Imazeki, Osamu Yokosuka, Yasushi Shiratori, Masao Omata

    JOURNAL OF HEPATOLOGY   45 ( 6 )   805 - 812   2006年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.jhep.2006.07.025

    Web of Science

    PubMed

    researchmap

  • Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response 査読

    Y Wang, N Kato, A Jazag, N Dharel, M Otsuka, H Taniguchi, T Kawabe, M Omata

    GASTROENTEROLOGY   130 ( 3 )   883 - 892   2006年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2005.12.028

    Web of Science

    PubMed

    researchmap

  • Identifying genes with differential expression in gemcitabine-resistant pancreatic cancer cells using comprehensive transcriptome analysis 査読

    Y Nakai, M Otsuka, Y Hoshida, M Tada, Y Komatsu, T Kawabe, M Omata

    ONCOLOGY REPORTS   14 ( 5 )   1263 - 1267   2005年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • Large-scale search of single nucleotide polymorphisms for hepatocellular carcinoma susceptibility genes in patients with hepatitis C 査読

    N Kato, GJ Ji, Y Wang, M Baba, Y Hoshida, M Otsuka, H Taniguchi, M Moriyama, N Dharel, T Goto, RX Shao, T Matsuura, K Ishii, S Shiina, T Kawabe, M Muramatsu, M Omata

    HEPATOLOGY   42 ( 4 )   846 - 853   2005年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/hep.20860

    Web of Science

    PubMed

    researchmap

  • NF-kappa B and ERK-signaling pathways contribute to the gene expression induced by cag PAI-positive-Helicobacter pylori infection 査読

    Wataru Shibata, Yoshihiro Hirata, Haruhiko Yoshida, Motoyuki Otsuka, Yujin Hoshida, Keiji Ogura, Shin Maeda, Tomoya Ohmae, Ayako Yanai, Yuzo Mitsuno, Naohiko Seki, Takao Kawabe, Masao Omata

    WORLD JOURNAL OF GASTROENTEROLOGY   11 ( 39 )   6134 - 6143   2005年10月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • No mutations in the tyrosine kinases of human hepatic, pancreatic, and gastric cancer cell lines 査読

    RX Shao, M Otsuka, N Kato, JH Chang, R Muroyama, H Taniguchi, M Moriyama, Y Wang, T Kawabe, M Omata

    JOURNAL OF GASTROENTEROLOGY   40 ( 9 )   918 - 918   2005年9月

     詳細を見る

  • Hepatitis C virus core protein and hepatitis activity are associated through transactivation of interleukin-8 査読

    Y Hoshida, N Kato, H Yoshida, Y Wang, M Tanaka, T Goto, M Otsuka, H Taniguchi, M Moriyama, F Imazeki, O Yokosuka, T Kawabe, Y Shiratori, M Omata

    JOURNAL OF INFECTIOUS DISEASES   192 ( 2 )   266 - 275   2005年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1086/430924

    Web of Science

    PubMed

    researchmap

  • Interaction between the HCVNS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses 査読

    M Otsuka, N Kato, M Moriyama, H Taniguchi, Y Wang, N Dharel, T Kawabe, M Omata

    HEPATOLOGY   41 ( 5 )   1004 - 1012   2005年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/hep.20666

    Web of Science

    PubMed

    researchmap

  • Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients 査読

    Run-Xuan Shao, Yujin Hoshida, Motoyuki Otsuka, Naoya Kato, Ryosuke Tateishi, Takuma Teratani, Shuichiro Shiina, Hiroyoshi Taniguchi, Masaru Moriyama, Takao Kawabe, Masao Omata

    WORLD JOURNAL OF GASTROENTEROLOGY   11 ( 13 )   1995 - 1999   2005年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • Vitamin K2 binds 17 beta-hydroxysteroid dehydrogenase 4 and modulates estrogen metabolism 査読

    M Otsuka, N Kato, T Ichimura, S Abe, Y Tanaka, H Taniguchi, Y Hoshida, M Moriyama, Y Wang, RX Shao, D Narayan, R Muroyama, F Kanai, T Kawabe, T Isobe, M Omata

    LIFE SCIENCES   76 ( 21 )   2473 - 2482   2005年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.lfs.2004.12.020

    Web of Science

    PubMed

    CiNii Article

    researchmap

  • Acyclic retinoid inhibits human hepatoma cell growth by suppressing fibroblast growth factor-mediated signaling pathways 査読

    RX Shao, M Otsuka, N Kato, H Taniguchi, Y Hoshida, M Moriyama, T Kawabe, M Omata

    GASTROENTEROLOGY   128 ( 1 )   86 - 95   2005年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/j.gastro.2004.09.077

    Web of Science

    PubMed

    researchmap

  • A simple combination of serum type IV collagen and prothrombin time to diagnose cirrhosis in patients with chronic active hepatitis C 査読

    Y Qiu, YJ Hoshida, N Kato, M Moriyama, M Otsuka, H Taniguchi, T Kawabe, M Omata

    HEPATOLOGY RESEARCH   30 ( 4 )   214 - 220   2004年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.hepres.2004.10.006

    Web of Science

    researchmap

  • Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy 査読

    M Moriyama, Y Hoshida, N Kato, M Otsuka, H Yoshida, T Kawabe, M Omata

    INTERNATIONAL JOURNAL OF ONCOLOGY   25 ( 5 )   1279 - 1287   2004年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • Vitamin K-2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation 査読

    M Otsuka, N Kato, RX Shao, Y Hoshida, H Ijichi, Y Koike, H Taniguchi, M Moriyama, Y Shiratori, T Kawabe, M Omata

    HEPATOLOGY   40 ( 1 )   243 - 251   2004年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/hep.20260

    Web of Science

    PubMed

    researchmap

  • UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma in Japanese patients with hepatitis C virus infection 査読

    Y Wang, N Kato, Y Hoshida, M Otsuka, H Taniguchi, M Moriyama, S Shiina, T Kawabe, YM Ito, M Omata

    CLINICAL CANCER RESEARCH   10 ( 7 )   2441 - 2446   2004年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1158/1078-0432.CCR-1187-3

    Web of Science

    PubMed

    researchmap

  • Smad4-independent regulation of p21/WAF1 by transforming growth factor-beta 査読

    H Ijichi, M Otsuka, K Tateishi, T Ikenoue, T Kawakami, F Kanai, Y Arakawa, N Seki, K Shimizu, K Miyazono, T Kawabe, M Omata

    ONCOGENE   23 ( 5 )   1043 - 1051   2004年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1038/sj.onc.1207222

    Web of Science

    PubMed

    researchmap

  • Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription 査読

    H Taniguchi, N Kato, M Otsuka, T Goto, H Yoshida, Y Shiratori, M Omata

    JOURNAL OF MEDICAL VIROLOGY   72 ( 1 )   52 - 59   2004年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1002/jmv.10545

    Web of Science

    PubMed

    researchmap

  • Antiapoptotic regulation by hepatitis C virus core protein through up-regulation of inhibitor of caspase-activated DNase 査読

    R Sacco, T Tsutsumi, R Suzuki, M Otsuka, H Aizaki, S Sakamoto, M Matsuda, N Seki, Y Matsuura, T Miyamura, T Suzuki

    VIROLOGY   317 ( 1 )   24 - 35   2003年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/j.virol.2003.08.028

    Web of Science

    PubMed

    CiNii Article

    researchmap

  • Comparing gene expression profiles in human liver, gastric, and pancreatic tissues using full-length-enriched cDNA libraries 査読

    M Otsuka, M Arai, M Mori, M Kato, N Kato, O Yokosuka, T Ochiai, M Takiguchi, M Omata, N Seki

    HEPATOLOGY RESEARCH   27 ( 1 )   76 - 82   2003年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/S1386-6346(03)0161-X

    Web of Science

    PubMed

    CiNii Article

    researchmap

  • 肝細胞癌患者血清のプロテオミクス解析 査読

    星田 有人, 川上 高幸, 大塚 基之, 谷口 寿章, 西村 信一郎, 小尾 俊太郎, 椎名 秀一朗, 川邊 隆夫, 小俣 政男

    肝臓   44 ( Suppl.1 )   A174 - A174   2003年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • Liver chip and gene shaving 査読

    M Otsuka, Y Hoshida, N Kato, M Moriyama, H Taniguchi, M Arai, M Mori, N Seki, M Omata

    JOURNAL OF GASTROENTEROLOGY   38   89 - 92   2003年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • Synergistic activation of the serum response element-dependent pathway by hepatitis B virus X protein and large-isoform hepatitis delta antigen 査読

    T Goto, N Kato, H Yoshida, M Otsuka, M Moriyama, Y Shiratori, K Koike, M Matsumura, M Omata

    JOURNAL OF INFECTIOUS DISEASES   187 ( 5 )   820 - 828   2003年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1086/368389

    Web of Science

    PubMed

    researchmap

  • Study of digestive diseases in post-genome era 査読

    Masao Omata, Motoyuki Otsuka, Takayuki Kawakami, Yujin Hoshida

    Japanese Journal of Gastroenterology   100 ( 2 )   135 - 143   2003年2月

     詳細を見る

    記述言語:日本語   掲載種別:研究論文(学術雑誌)   出版者・発行元:2  

    Scopus

    PubMed

    researchmap

  • Relevance network between chemosensitivity and transcriptome in human hepatoma cells 査読

    M Moriyama, Y Hoshida, M Otsuka, S Nishimura, N Kato, T Goto, H Taniguchi, Y Shiratori, N Seki, M Omata

    MOLECULAR CANCER THERAPEUTICS   2 ( 2 )   199 - 205   2003年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • Interieukin-1 beta gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection 査読

    Y Wang, N Kato, Y Hoshida, H Yoshida, H Taniguchi, T Goto, M Moriyama, M Otsuka, S Shiina, Y Shiratori, Y Ito, M Omata

    HEPATOLOGY   37 ( 1 )   65 - 71   2003年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/jhep.2003.50017

    Web of Science

    PubMed

    researchmap

  • Differential cellular gene expression induced by hepatitis B and C viruses 査読

    M Otsuka, H Aizaki, N Kato, T Suzuki, T Miyamura, M Omata, N Seki

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   300 ( 2 )   443 - 447   2003年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/S0006-291X(02)02861-9

    Web of Science

    PubMed

    CiNii Article

    researchmap

  • Signals induced by HCV proteins 査読

    M Otsuka, N Kato, H Taniguchi, H Yoshida, Y Shiratori, M Omata

    HCV/OXIDATIVE STRESS AND LIVER DISEASE   32 - 47   2003年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)  

    Web of Science

    researchmap

  • [HCV-related hepatocellular carcinoma]. 査読

    Otsuka M, Kato N, Yoshida H, Yoshida H, Shiratori Y, Omata M

    Uirusu   52 ( 2 )   295 - 300   2002年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:2  

    PubMed

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2003167214

  • Expression profiling of liver cell lines expressing entire or parts of hepatitis C virus open reading frame 査読

    H Aizaki, T Harada, M Otsuka, N Seki, M Matsuda, YW Li, H Kawakami, Y Matsuura, T Miyamura, T Suzuki

    HEPATOLOGY   36 ( 6 )   1431 - 1438   2002年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1053/jhep.2002.36937

    Web of Science

    PubMed

    researchmap

  • Identification of candidate genes for Sjögren's syndrome using MRL/lpr mouse model of Sjögren's syndrome and cDNA microarray analysis. 査読

    Azuma T, Takei M, Yoshikawa T, Nagasugi Y, Kato M, Otsuka M, Shiraiwa H, Sugano S, Mitamura K, Sawada S, Masuho Y, Seki N

    Immunology letters   81 ( 3 )   171 - 176   2002年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1016/S0165-2478(01)00344-3

    Web of Science

    PubMed

    researchmap

  • Hepatitis C virus core protein inhibits apoptosis via enhanced Bcl-x(L) expression 査読

    M Otsuka, N Kato, H Taniguchi, H Yoshida, T Goto, Y Shiratori, M Omata

    VIROLOGY   296 ( 1 )   84 - 93   2002年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1006/viro.2002.1371

    Web of Science

    PubMed

    CiNii Article

    researchmap

  • The evaluation of putative virulence factors of Helicobacter pylori for gastroduodenal disease by use of a short-term Mongolian gerbil infection model 査読

    M Akanuma, S Maeda, K Ogura, Y Mitsuno, Y Hirata, T Ikenoue, M Otsuka, T Watanabe, Y Yamaji, H Yoshida, T Kawabe, Y Shiratori, M Omata

    JOURNAL OF INFECTIOUS DISEASES   185 ( 3 )   341 - 347   2002年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1086/338772

    Web of Science

    PubMed

    researchmap

  • Identification of genes associated with sensitivity to 5-fluorouracil and cisplatin in hepatoma cells 査読

    Y Hoshida, M Moriyama, M Otsuka, N Kato, T Goto, H Taniguchi, Y Shiratori, N Seki, M Omata

    JOURNAL OF GASTROENTEROLOGY   37   92 - 95   2002年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    PubMed

    researchmap

  • Induction of proliferation-related signals by hepatitis C virus 査読

    N Kato, H Yoshida, M Otsuka, Y Shiratori, M Omata

    GROWTH, PROLIFERATION, AND APOPTOSIS IN HEPATOCYTES   81 - 98   2002年

     詳細を見る

    記述言語:英語   掲載種別:研究論文(国際会議プロシーディングス)  

    Web of Science

    researchmap

  • Differential expression of the L-plastin gene in human colorectal cancer progression and metastasis 査読

    M Otsuka, M Kato, T Yoshikawa, H Chen, EJ Brown, Y Masuho, M Omata, N Seki

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   289 ( 4 )   876 - 881   2001年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1006/bbrc.2001.6047

    Web of Science

    PubMed

    researchmap

  • cDNA microarray analysis of Helicobacter pylori-mediated alteration of gene expression in gastric cancer cells 査読

    S Maeda, M Otsuka, Y Hirata, Y Mitsuno, H Yoshida, Y Shiratori, Y Masuho, M Muramatsu, N Seki, M Omata

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   284 ( 2 )   443 - 449   2001年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    DOI: 10.1006/bbrc.2001.5006

    Web of Science

    researchmap

  • Hepatitis C virus core protein activates nuclear factor kappa B-dependent signaling through tumor necrosis factor receptor-associated factor 査読

    H Yoshida, N Kato, Y Shiratori, M Otsuka, S Maeda, J Kato, M Omata

    JOURNAL OF BIOLOGICAL CHEMISTRY   276 ( 19 )   16399 - 16405   2001年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    researchmap

  • Improvement of Chemosensitivity Prediction by Transcriptional Profiling in Hepatoma Cells

    Hoshida Yujin, Moriyama Masaru, Otsuka Motoyuki, Kato Naoya, Shiratori Yasushi, Seki Naohiko, Omata Masao

    Genome Informatics   12   257 - 258   2001年

     詳細を見る

    記述言語:英語   出版者・発行元:Japanese Society for Bioinformatics  

    DOI: 10.11234/gi1990.12.257

    CiNii Article

    researchmap

  • Large isoform of hepatitis delta antigen activates serum response factor-associated transcription 査読

    T Goto, N Kato, SK Ono-Nita, H Yoshida, M Otsuka, Y Shiratori, M Omata

    JOURNAL OF BIOLOGICAL CHEMISTRY   275 ( 48 )   37311 - 37316   2000年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    researchmap

  • Hepatitis C virus core protein enhances p53 function through augmentation of DNA binding affinity and transcriptional ability 査読

    Motoyuki Otsuka, Naoya Kato, Keng-Hsin Lan, Hideo Yoshida, Jun Kato, Tadashi Goto, Yasushi Shiratori, Masao Omata

    Journal of Biological Chemistry   275 ( 44 )   34122 - 34130   2000年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)   出版者・発行元:American Society for Biochemistry and Molecular Biology Inc.  

    DOI: 10.1074/jbc.M000578200

    Scopus

    PubMed

    researchmap

  • Activation of intracellular signaling by hepatitis B and C viruses: C-viral core is the most potent signal inducer 査読

    N Kato, H Yoshida, SK Ono-Nita, J Kato, T Goto, M Otsuka, KH Lan, K Matsushima, Y Shiratori, M Omata

    HEPATOLOGY   32 ( 2 )   405 - 412   2000年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Web of Science

    researchmap

  • 超音波内視鏡下吸引細胞診(EUS-FNA)による膵腫瘍性病変の診断

    小松 裕, 多田 稔, 平田 喜裕, 大塚 基之, 笹平 直樹, 山形 道子, 戸田 信夫, 大橋 誠, 川邊 隆夫, 白鳥 康史

    超音波医学   27 ( 5 )   816 - 816   2000年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本超音波医学会  

    researchmap

▼全件表示

書籍等出版物

  • 肝炎

    大塚 基之, 小俣 政男

    現代医療社  1998年  ( ISBN:4877430083

     詳細を見る

    記述言語:日本語

    CiNii Books

    researchmap

MISC

  • 非アルコール性脂肪肝炎を背景とした肝癌のスクリーニングの現状と問題点

    大塚 基之

    岡山医学会雑誌   135 ( 1 )   18 - 21   2023年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:岡山医学会  

    researchmap

  • この症例から何を学ぶか 肝不全に至ったB型肝炎関連肝硬変の一例

    大塚 基之

    Medical Practice   39 ( 11 )   1726 - 1731   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)文光堂  

    researchmap

  • 【膵癌研究最前線】膵癌で発現するcircular RNAとバイオマーカー応用

    清宮 崇博, 大塚 基之, 藤城 光弘

    消化器・肝臓内科   10 ( 3 )   336 - 341   2021年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • 【ガイドライン2020から読み解くNAFLD/NASH】予後 NAFLD/NASHにおける脳・心血管イベントリスクの絞り込み 招待

    大塚 基之

    肝胆膵   83 ( 1 )   129 - 134   2021年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • 【<最新>NAFLD/NASH 診療ガイドラインを読む】NAFLD/NASHの発癌とスクリーニング体制 招待

    大塚 基之

    臨床消化器内科   36 ( 7 )   777 - 782   2021年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本メディカルセンター  

    researchmap

  • 【NAFLD/NASHの診断と治療-ガイドラインの改訂点と問題点】NAFLD/NASHの予後と発癌、そのスクリーニング体制の問題点 招待

    大塚 基之

    医学のあゆみ   277 ( 7 )   545 - 549   2021年5月

  • NAFLD:新ガイドラインの評価と診断、治療の最前線 NAFLD診療ガイドライン改訂のポイントと今後の課題 招待

    大塚 基之

    日本消化器病学会雑誌   118 ( 臨増総会 )   A76 - A76   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • 【B型肝炎ウイルスの感染機構と治療薬開発の最前線】新規作用機序によるB型肝炎治療薬の開発 招待

    大塚 基之

    ファルマシア   56 ( 12 )   1084 - 1088   2020年12月

  • 【NAFLD/NASHの進歩と新たな展開】発癌とそのスクリーニング体制の考え方 招待

    大塚 基之, 小池 和彦

    消化器・肝臓内科   7 ( 5 )   446 - 451   2020年5月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    researchmap

  • 【B型肝炎Trends & Topics】新規抗B型肝炎ウイルス薬の開発の現状と展望 招待

    大塚 基之, 關場 一磨, 船戸 和義, 小池 和彦

    臨床消化器内科   35 ( 2 )   205 - 210   2020年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本メディカルセンター  

    researchmap

  • 【B型肝炎の新たな展開-進化を続ける基礎と臨床-】B型肝炎に対する新たな創薬研究 HBV RNAの転写を抑制する新規化合物ニタゾキサニドとペボネディスタットの同定 招待

    大塚 基之, 關場 一磨, 船戸 和義, 小池 和彦

    肝胆膵   78 ( 6 )   993 - 997   2019年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • 【炎症・免疫疾患とmicroRNA】microRNAの機能異常に着目した炎症性発癌の病態解明 招待

    大塚 基之

    臨床免疫・アレルギー科   69 ( 1 )   68 - 72   2018年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:(有)科学評論社  

    J-GLOBAL

    researchmap

  • 肝疾患における輸液処方の組み立て方 招待

    大塚 基之

    内科   120 ( 1 )   65 - 70   2017年

     詳細を見る

    記述言語:日本語   掲載種別:記事・総説・解説・論説等(学術雑誌)   出版者・発行元:南江堂  

    DOI: 10.15106/J00974.2017288235

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2017288235

  • 消化管の炎症を診る クローン病小腸病変評価における経腹超音波検査の有用性

    高原 政宏, 平岡 佐規子, 青山 祐樹, 井川 翔子, 井口 俊博, 大西 秀樹, 大塚 基之

    超音波医学   51 ( Suppl. )   S187 - S187   2024年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本超音波医学会  

    researchmap

  • 神経線維腫症の消化管合併症に関する検討

    本田 真奈美, 岩室 雅也, 山崎 泰史, 田中 健大, 川野 誠司, 平岡 佐規子, 河原 祥朗, 大塚 基之

    日本消化器病学会雑誌   121 ( 臨増総会 )   A349 - A349   2024年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一財)日本消化器病学会  

    researchmap

  • ぶどう膜炎所見を呈した肝細胞癌による転移性眼内腫瘍の1例

    高須絵理, 塩出雄亮, 金道寛弥, 木村修平, 細川海音, 的場亮, 神崎勇希, 森田哲郎, 足立卓哉, 大塚基之, 森實祐基

    日本眼科学会雑誌   128   2024年

     詳細を見る

  • 大腸神経節細胞腫により診断に至ったCowden症候群の1例

    本田 真奈美, 山崎 泰史, 豊澤 惇希, 井口 俊博, 衣笠 秀明, 高原 政宏, 田中 健大, 平岡 佐規子, 大塚 基之

    日本消化器病学会中国支部例会・日本消化器内視鏡学会中国支部例会プログラム・抄録集   120回・131回   68 - 68   2023年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本消化器病学会-中国支部  

    researchmap

  • 10mm以上20mm以下の大腸鋸歯状病変(SSL)に対するUnderwater EMR(UEMR)の有効性

    大森 正泰, 山崎 泰史, 豊澤 惇希, 山本 峻平, 衣笠 秀明, 原田 馨太, 平岡 佐規子, 竹中 龍太, 大塚 基之

    Gastroenterological Endoscopy   65 ( Suppl.2 )   2000 - 2000   2023年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • IBD診療におけるtreat to targetを考える Treat to targetを意識したクローン病におけるsurrogate markerの組み合わせ

    井口 俊博, 平岡 佐規子, 青山 祐樹, 竹井 健介, 井川 翔子, 高原 政宏, 大塚 基之

    日本大腸肛門病学会雑誌   76 ( 9 )   A51 - A51   2023年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本大腸肛門病学会  

    researchmap

  • 消化器癌の撲滅をめざして 早期診断のための囲い込みとliquid biopsyの新展開

    大塚 基之

    岡山医学会雑誌   135 ( 2 )   105 - 105   2023年8月

     詳細を見る

    記述言語:日本語   出版者・発行元:岡山医学会  

    researchmap

  • 【ウイルス性肝炎学2023-最新の病態・診断・治療情報-】B型肝炎 臨床をめざした基礎研究 HBxタンパクの機能とウイルスの複製

    大塚 基之

    日本臨床   81 ( 増刊7 ウイルス性肝炎学2023 )   282 - 286   2023年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)日本臨床社  

    researchmap

  • 【肝胆膵領域におけるアルコール医学の新潮流】アルコール性肝障害の臨床研究における新知見 アルコール性肝障害における肝移植の現状

    高木 章乃夫, 竹内 康人, 八木 孝仁, 大塚 基之

    肝胆膵   86 ( 4 )   523 - 528   2023年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)アークメディア  

    researchmap

  • Clinical application of pancreatic juice-derived small extracellular vesicles of pancreatic ductal adenocarcinoma

    Koichiro Tsutsumi, Motoyuki Otsuka

    Clinical and Translational Discovery   3 ( 2 )   2023年4月

     詳細を見る

    掲載種別:書評論文,書評,文献紹介等  

    DOI: 10.1002/ctd2.177

    Scopus

    researchmap

  • 【肝炎・肝硬変-知っておくべき最新の知見と実診療でのマネージメント法】肝炎・肝硬変をめぐる最近の状況 効率的な病診連携に向けて

    山内 敏正, 大塚 基之, 小木曽 智美, 糸林 詠

    Medical Practice   39 ( 11 )   1598 - 1609   2022年11月

     詳細を見る

    記述言語:日本語   出版者・発行元:(株)文光堂  

    researchmap

  • RNA結合蛋白ELAVL1のB型肝炎ウイルス複製と肝細胞癌増殖への関わり

    神崎 洋彰, 千葉 哲博, 興梠 慧輔, 日下部 裕子, 小林 和史, 叶川 直哉, 清野 宗一郎, 中村 昌人, 近藤 孝行, 齊藤 朋子, 中川 良, 小笠原 定久, 室山 良介, 中本 晋吾, 神田 達郎, 丸山 紀史, 加藤 順, 關場 一磨, 大塚 基之, 大塚 将之, 加藤 直也

    肝臓   63 ( Suppl.1 )   A335 - A335   2022年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    J-GLOBAL

    researchmap

  • RNA編集酵素ADARのexosomeを介した伝播による老化に伴う肝発癌リスク増大機構の解明

    大塚 基之

    日本応用酵素協会誌   ( 55 )   20 - 21   2021年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公財)日本応用酵素協会  

    researchmap

  • MicroRNAs and liver disease (SPECIAL ISSUE : Dysregulated Non-coding RNAs and Human Diseases : A Fine-Tuner Changes into a Confuser)

    Otsuka Motoyuki, Kishikawa Takahiro, Yoshikawa Takeshi, Yamagami Mari, Ohno Motoko, Takata Akemi, Shibata Chikako, Ishibashi Rei, Koike Kazuhiko

    Journal of human genetics   62 ( 1 )   75 - 80   2017年1月

     詳細を見る

    記述言語:英語   出版者・発行元:Springer Nature  

    CiNii Article

    CiNii Books

    researchmap

    その他リンク: http://search.jamas.or.jp/link/ui/2017269369

  • レジパスビル/ソホスブビル2剤併用療法の治療効果と安全性の検討

    西畠 瑞希, 南 達也, 建石 良介, 藤原 直人, 中塚 拓馬, 佐藤 雅哉, 榎奥 健一郎, 工藤 洋太郎, 中川 勇人, 浅岡 良成, 泉谷 昌志, 近藤 祐嗣, 藤永 秀剛, 田中 康雄, 大塚 基之, 加藤 直也, 四柳 宏, 池田 均, 森屋 恭爾, 小池 和彦

    肝臓   57 ( Suppl.2 )   A549 - A549   2016年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本肝臓学会  

    researchmap

  • 肝臓での慢性炎症とmicroRNA 招待

    大塚 基之

    別冊BIO Clinica 慢性炎症と疾患 2015年秋号「肝・胆・膵の慢性炎症」   4 ( 4 )   15 - 20   2015年

     詳細を見る

  • B型肝癌における自然免疫の機能解明とその制御による発癌抑止法開発 B型肝癌感受性遺伝子MICAの発現とsheddingに関する研究

    小池和彦, 大塚基之

    B型肝癌における自然免疫の機能解明とその制御による発癌抑止法開発 平成26年度 総括・分担研究報告書   23 - 26   2015年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • RNA疾患―最新の病態解析から治療法展望まで―肝疾患とマイクロRNA 招待

    大塚基之

    月刊メディカル・サイエンス・ダイジェスト   40 ( 7 )   342 - 345   2014年6月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • HCV研究の最先端 7 HCVとmiRNA 招待

    大塚基之, 吉川剛史, 岸川孝弘, 大野元子, 高田朱弥, 柴田智華子, 小池和彦

    臨床消化器内科   29 ( 7 )   821 - 826   2014年5月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 抗ウイルス補助療法としての臨床応用を見すえたフラボノイドによるmicroRNAの成熟阻害を利用したC型肝炎ウイルス増殖抑制効果について

    大塚基之, 大野元子, 小池和彦

    肝臓   55 ( Supplement 1 )   A84   2014年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • ポリフェノールによるマイクロRNA成熟抑制作用を介したインスリン抵抗性改善効果

    大野元子, 柴田智華子, 岸川孝弘, 吉川剛史, 高田朱弥, 大塚基之, 小池和彦

    消化と吸収   36 ( 2 )   234 - 237   2014年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • microRNA産生に必須なRNA分解酵素Dicerの発現量変化にともなう炎症性発癌の特徴

    大塚基之

    日本応用酵素協会誌   ( 48 )   46 - 47   2014年3月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • B型肝炎ウイルスの完全排除等,完治を目指した新規治療法の開発に関する包括的研究 B型肝炎ウイルス複製のmiRNAによる制御

    小池和彦, 大塚基之

    B型肝炎ウイルスの完全排除等、完治を目指した新規治療法の開発に関する包括的研究 平成25年度 総括・分担研究報告書   24 - 30   2014年

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 肝細胞癌とmicroRNA

    大塚基之, 小池和彦

    The Liver Cancer Journal   6 ( 3 )   2014年

     詳細を見る

    記述言語:日本語  

    researchmap

  • C型慢性肝炎からの肝癌感受性遺伝子MICAを標的とするmicroRNAの発現制御による肝癌の発症予防法と治療法の開発

    大塚基之, 高田朱弥, 吉川剛史, 岸川孝弘, 大野元子, 吉田晴彦, 小池和彦

    冲中記念成人病研究所年報   ( 39 )   51 - 52   2013年6月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • miR122とαフェトプロテイン

    大塚基之, 小島健太郎, 高田朱弥, 吉川剛史, 岸川孝弘, 吉田晴彦, 小池和彦

    細胞   45 ( 3 )   157 - 160   2013年3月

     詳細を見る

    記述言語:日本語   出版者・発行元:ニューサイエンス社  

    CiNii Article

    CiNii Books

    J-GLOBAL

    researchmap

  • 肝臓 11.肝発癌の分子機構 招待

    大塚基之, 小池和彦

    Annual Review 消化器   2013   158 - 163   2013年1月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 持続炎症性発癌の病態におけるmicroRNA機能不全の関わりの解明と制御法の開発

    大塚 基之

    細胞科学研究財団助成研究報告集   24   11 - 19   2013年

     詳細を見る

    記述言語:日本語   出版者・発行元:細胞科学研究財団  

    CiNii Article

    researchmap

  • PNPLA3(I148M)遺伝子多型とC型慢性肝炎患者からの発癌リスクの検討

    佐藤雅哉, 加藤直也, 建石良介, 室山良介, 古渡礼恵, LI W, 後藤覚, 大塚基之, 椎名秀一朗, 吉田晴彦, 小俣政男, 小池和彦

    肝臓   53 ( Supplement 2 )   A715   2012年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • Stem Cell,iPS研究;再生医療,癌診療への展開 iPS関連 iPS細胞から肝細胞への分化制御

    大塚基之, 高田朱弥, 小木曽智美, 吉川剛史, 岸川孝弘, 吉田晴彦, 小俣政男, 小池和彦

    肝胆膵   65 ( 1 )   139-143   2012年7月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 炎症と消化器癌 持続炎症に伴うmicroRNA機能異常を一因とした大腸発癌の病態解明

    吉川剛史, 大塚基之, 高田朱弥, 岸川孝弘, 小池和彦

    月刊消化器内科   54 ( 6 )   727-733 - 733   2012年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:科学評論社  

    CiNii Article

    CiNii Books

    J-GLOBAL

    researchmap

  • IL28BマイナーアリルはC型慢性肝炎患者における低年齢発癌の危険因子である

    佐藤雅哉, 加藤直也, 建石良介, 室山良介, 古渡礼恵, LI Wenwen, 後藤覚, 大塚基之, 椎名秀一朗, 吉田晴彦, 小俣政男, 小池和彦

    肝臓   53 ( Supplement 1 )   A336   2012年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • microRNA122の機能的抑制によるIFNシグナル増強作用を介した抗ウイルス作用の増幅

    大塚基之, 高田朱弥, 小池和彦

    肝臓   53 ( Supplement 1 )   A151   2012年4月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • C型肝炎のすべて2012 HCVと発癌 C型肝癌のGWAS研究:MICA SNP

    加藤直也, 室山良介, 古渡礼恵, 後藤覚, 李ぶんぶん, 中川良, 大塚基之, 建石良介, 吉田晴彦, 小池和彦, 小俣政男, 中村祐輔, 松田浩一

    肝胆膵   63 ( 6 )   1045-1051   2011年12月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 持続炎症に伴うmicroRNA機能異常が原因となる消化器癌の病態解明

    吉川剛史, 大塚基之, 小池和彦

    日本消化器病学会雑誌   108   A497   2011年9月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 第47回日本肝臓学会総会

    大塚 基之

    The liver cancer journal : 季刊学術雑誌   3 ( 3 )   223 - 226   2011年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:メディカルレビュー社  

    CiNii Article

    researchmap

  • マイクロRNAと循環器疾患 2)血管新生とマイクロRNA

    大塚基之

    血管医学   12 ( 3 )   233-240   2011年8月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • Genome Wide Association Studyは肝胆膵診療をいかに変えるか?肝胆膵疾患各論 GWASによるC型肝癌感受性遺伝子の同定

    加藤直也, 室山良介, 古渡礼恵, 大塚基之, 建石良介, 吉田晴彦, 小池和彦, 小俣政男, 中村祐輔, 松田浩一

    肝胆膵   62 ( 5 )   919-925   2011年5月

     詳細を見る

    記述言語:日本語  

    J-GLOBAL

    researchmap

  • 癌分子標的治療--歩みと今後(1)癌分子標的治療とはなにか(基本概念・開発の歴史)(2)癌分子標的治療薬の開発の歴史(歴史・分類一覧)

    大塚 基之, 小池 和彦

    リバーキャンサージャーナル   1 ( 3 )   111 - 115   2009年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:メディカルレビュー社  

    CiNii Article

    researchmap

  • 第10回C型肝炎ウイルスおよび関連ウイルスに関する国際会議の報告--第一回東京C型肝炎ウイルス国際シンポジウムと併せて

    大塚 基之, 谷口 博順, 加藤 直也

    日本医事新報   ( 4162 )   37 - 41   2004年1月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本医事新報社  

    CiNii Article

    CiNii Books

    researchmap

  • Mechanisms and significance of apoptosis suppression by HCV core protein

    Motoyuki Otsuka, Naoya Kato, Masao Omata

    Nippon rinsho. Japanese journal of clinical medicine   62 ( 1 )   185 - 190   2004年

     詳細を見る

    記述言語:日本語   掲載種別:書評論文,書評,文献紹介等  

    Scopus

    PubMed

    researchmap

  • Hepatitis B viral infection and apoptosis

    Motoyuki Otsuka, Yasuo Tanaka, Naoya Kato, Masao Omata

    Nippon rinsho. Japanese journal of clinical medicine   62   116 - 120   2004年

     詳細を見る

    記述言語:日本語   掲載種別:書評論文,書評,文献紹介等  

    Scopus

    PubMed

    researchmap

  • 目でみるバイオサイエンス C型肝炎ウイルスタンパクの惹起する細胞内シグナル

    加藤 直也, 大塚 基之, 吉田 英雄

    内科   92 ( 1 )   159 - 162   2003年7月

     詳細を見る

    記述言語:日本語   出版者・発行元:南江堂  

    CiNii Article

    CiNii Books

    researchmap

  • ポストゲノム時代の消化器病研究の展望

    小俣 政男, 大塚 基之, 川上 高幸, 星田 有人

    日本消化器病學會雜誌 = The Japanese journal of gastro-enterology   100 ( 2 )   135 - 143   2003年2月

     詳細を見る

    記述言語:日本語   出版者・発行元:財団法人 日本消化器病学会  

    DOI: 10.11405/nisshoshi1964.100.135

    Scopus

    PubMed

    researchmap

  • HCVと肝癌

    大塚 基之, 加藤 直也, 吉田 英雄, 吉田 晴彦, 白鳥 康史, 小俣 政男

    ウイルス   52 ( 2 )   295 - 300   2002年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:日本ウィルス学会  

    DOI: 10.2222/jsv.52.295

    CiNii Article

    CiNii Books

    researchmap

  • 4. B, C型慢性肝炎における特異的発現遺伝子抽出の試み

    星田 有人, 大塚 基之, 小俣 政男

    肝臓   43 ( 10 )   471 - 472   2002年10月

     詳細を見る

  • Inhibition of hepatoma cell growth and invasion by vitamin K2 administration in vitro.

    M Otsuka, Y Koike, N Kato, M Moriyama, T Kawakami, H Ijichi, H Taniguchi, Y Hoshida, M Omata

    HEPATOLOGY   36 ( 4 )   445A - 445A   2002年10月

     詳細を見る

    記述言語:英語   掲載種別:研究発表ペーパー・要旨(国際会議)  

    Web of Science

    researchmap

  • 実験講座 マイクロアレイの使い方 微量サンプルを用いたcDNAマイクロアレイ解析

    新井 誠人, 加藤 真樹, 大塚 基之

    ゲノム医学   2 ( 5 )   505 - 511   2002年10月

     詳細を見る

    記述言語:日本語   出版者・発行元:メディカルレビュー社  

    CiNii Article

    CiNii Books

    researchmap

  • 実験講座 マイクロアレイの使い方 肝癌細胞における抗癌剤感受性に関連する遺伝子の解析

    森山 優, 星田 有人, 大塚 基之

    ゲノム医学   2 ( 3 )   289 - 295   2002年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:メディカルレビュー社  

    CiNii Article

    CiNii Books

    researchmap

  • 実験講座 マイクロアレイの使い方 肝臓疾患における遺伝子発現プロファイル

    大塚 基之, 加藤 直也, 小俣 政男

    ゲノム医学   2 ( 2 )   167 - 173   2002年4月

     詳細を見る

    記述言語:日本語   出版者・発行元:メディカルレビュー社  

    CiNii Article

    CiNii Books

    researchmap

  • Liver chip and gene shaving

    OTSUKA Motoyuki, HOSHIDA Yuujin, OMATA Masao

    日本消化器病學會雜誌 = The Japanese journal of gastro-enterology   99   A363   2002年3月

     詳細を見る

  • テーラーメイド医療と臨床検査 遺伝子解析でのDNAチップの位置づけ in‐house cDNAマイクロアレイを用いた遺伝子発現解析

    関直彦, 吉川勉, 加藤真樹, 大塚基之

    臨床検査   46 ( 1 )   38 - 45   2002年1月

     詳細を見る

    記述言語:日本語  

    DOI: 10.11477/mf.1542905015

    J-GLOBAL

    researchmap

  • C型肝炎ウイルスコア蛋白による肝細胞死の制御とその分子機構

    大塚 基之, 加藤 直也, 小俣 政男

    肝臓   42 ( 10 )   568 - 569   2001年10月

     詳細を見る

  • カラードプラー超音波内視鏡で見た食道静脈瘤治療前後における壁内外の血行動態変化

    大塚 基之, 赤沼 真夫, 小椋 啓司, 光野 雄三, 前田 慎, 岡本 真, 小松 裕, 吉田 晴彦, 白鳥 康史, 川邊 陸夫

    Gastroenterological Endoscopy   41 ( Suppl.2 )   1888 - 1888   1999年9月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本消化器内視鏡学会  

    researchmap

  • EUS-FNAが診断に有用であった食道癌の腹腔動脈周囲リンパ節転移の1例

    小松 裕, 山形 道子, 大塚 基之, 平田 喜裕, 藤島 知則, 伊佐山 浩通, 大橋 誠, 多田 稔, 吉田 晴彦, 川邊 隆夫

    超音波医学   25 ( 12 )   1150 - 1150   1998年12月

     詳細を見る

    記述言語:日本語   出版者・発行元:(公社)日本超音波医学会  

    researchmap

  • 【総胆管結石症の治療を再考する】 総胆管結石に対する内視鏡的アプローチ バルーン法を中心に

    小松 裕, 伊佐山 浩通, 大塚 基之

    胆と膵   19 ( 6 )   487 - 491   1998年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:医学図書出版(株)  

    researchmap

  • 閉塞性黄疸: 胆と膵への内科的アプローチの新しい展開

    小俣 政男, 大塚 基之, 小松 裕, 土屋 幸浩, 山雄 健次

    日本内科学会雑誌   86 ( 4 )   652 - 665   1997年4月

     詳細を見る

  • [Obstructive jaundice: new development in the medical approach to the bile duct and pancreas. Discussion].

    M Omata, M Otsuka, Y Komatsu, Y Tsuchiya, K Yamao

    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine   86 ( 4 )   652 - 65   1997年4月

     詳細を見る

    記述言語:日本語  

    PubMed

    researchmap

▼全件表示

産業財産権

  • がん細胞由来細胞外小胞群の単離濃縮方法、分析方法 、薬剤選択方法、キット、及び抗がん剤

    柴田智華子, 大塚基之, 藤城光弘

     詳細を見る

    出願番号:特願PCT/JP2023/ 16313  出願日:2023年4月25日

    researchmap

  • Screening For Anti-Hepatitis B Compounds

    關場一磨, 大塚基之, 小池和彦

     詳細を見る

    出願人:ROMARK

    出願番号:特願PCT/US2019/053461  出願日:2019年9月27日

    researchmap

  • 新規な全長cDNA

    磯貝 隆夫, 杉山 友康, 大槻 哲嗣, 若松 愛, 佐藤 寛之, 石井 静子, 入江 亮太郎, 吉川 勉, 大塚 基之, 仲 大地, 河合 勲二, 鈴木 克彦, 中野 浩史, 近藤 淳, 橋本 秀美, 白鳥 美和

     詳細を見る

    出願人:バイオテクノロジー開発技術研究組合

    出願番号:特願2005-076974  出願日:2005年3月17日

    公開番号:特開2005-237384  公開日:2005年9月8日

    J-GLOBAL

    researchmap

  • PKA活性調節剤

    大塚 基之, 小俣 政男

     詳細を見る

    出願人:エーザイ株式会社

    出願番号:JP2003016386  出願日:2003年12月19日

    公開番号:WO2004-056351  公開日:2004年7月8日

    J-GLOBAL

    researchmap

  • 新規な全長cDNA

    磯貝 隆夫, 杉山 友康, 大槻 哲嗣, 若松 愛, 佐藤 寛之, 石井 静子, 山本 順一, 五十野 祐子, 肥尾 弓利, 大塚 薫, 永井 啓一, 入江 亮太郎, 為近 一郎, 関 直彦, 吉川 勉, 大塚 基之, 長張 健二, 増保 安彦, 仲 大地, 河合 勲二, 鈴木 克彦, 中野 浩史, 近藤 淳, 橋本 秀美, 白鳥 美和

     詳細を見る

    出願人:バイオテクノロジー開発技術研究組合

    出願番号:特願2003-157290  出願日:2003年3月24日

    公開番号:特開2004-008216  公開日:2004年1月15日

    J-GLOBAL

    researchmap

  • 新規な全長cDNA

    磯貝 隆夫, 杉山 友康, 大槻 哲嗣, 若松 愛, 佐藤 寛之, 石井 静子, 山本 順一, 五十野 祐子, 肥尾 弓利, 齋藤 薫, 永井 啓一, 入江 亮太郎, 為近 一郎, 関 直彦, 吉川 勉, 大塚 基之, 長張 健二, 増保 安彦

     詳細を見る

    出願人:バイオテクノロジー開発技術研究組合

    出願番号:特願2001-379298  出願日:2001年11月5日

    公開番号:特開2003-135075  公開日:2003年5月13日

    J-GLOBAL

    researchmap

  • 新規な全長cDNA

    磯貝 隆夫, 杉山 友康, 大槻 哲嗣, 若松 愛, 佐藤 寛之, 石井 静子, 山本 順一, 五十野 祐子, 肥尾 弓利, 齋藤 薫, 永井 啓一, 入江 亮太郎, 為近 一郎, 関 直彦, 吉川 勉, 大塚 基之, 長張 健二, 増保 安彦

     詳細を見る

    出願人:株式会社ヘリックス研究所, バイオテクノロジー開発技術研究組合

    出願番号:特願2001-328381  出願日:2001年9月14日

    公開番号:特開2003-088388  公開日:2003年3月25日

    J-GLOBAL

    researchmap

▼全件表示

受賞

  • 奨励賞(大正富山Award)

    2012年   第25回肝臓フォーラム(東部)  

    大塚 基之

     詳細を見る

  • 第4回中外Award

    2011年   日本肝臓学会  

    大塚 基之

     詳細を見る

  • Hepatology Research 賞

    2003年   日本肝臓学会  

    大塚 基之

     詳細を見る

  • 消化器がんプロジェクト研究奨励賞

    2009年   中山がん研究財団  

    大塚 基之

     詳細を見る

共同研究・競争的資金等の研究

  • RNAを中心に据えたB型肝炎の病態解明と完全排除法開発

    2023年04月 - 2026年03月

    日本医療研究開発機構(AMED)  肝炎等克服実用化研究事業 肝炎等克服緊急対策研究事業 

      詳細を見る

  • 加齢に伴う血中細胞外小胞の性状変化による加齢疾患の発現機構の解明

    研究課題/領域番号:202310009  2023年

    三菱財団  研究助成 

      詳細を見る

  • 膵癌における反復配列RNAの機能解析と治療選択最適化への応用

    研究課題/領域番号:22H02828  2022年04月 - 2025年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    大塚 基之

      詳細を見る

    配分額:17420000円 ( 直接経費:13400000円 、 間接経費:4020000円 )

    researchmap

  • B型肝炎ウイルスのゲノム活性化・複製機序解明と創薬・標的因子同定に資する研究

    2022年04月 - 2025年03月

    日本医療研究開発機構(AMED)  肝炎等克服実用化研究事業 

      詳細を見る

    担当区分:研究分担者 

    researchmap

  • 慢性炎症を背景とした肝発癌の機序解明と肝癌高危険群の囲い込み法の開発

    2021年04月 - 2024年03月

    日本医療研究開発機構(AMED)  肝炎等克服実用化研究事業 

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • 血中反復配列RNAの高感度検出を基盤とした新規膵癌スクリーニング法の検証

    2020年04月 - 2023年03月

    日本医療研究開発機構(AMED)  革新的がん医療実用化研究事業 

    大塚基之

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • 膵癌に高発現する新しい環状RNAの同定と機能解析

    研究課題/領域番号:19H03430  2019年04月 - 2022年03月

    日本学術振興会  文部科学省 科学研究費補助金(基盤研究(B))  基盤研究(B)

    大塚基之

      詳細を見る

    担当区分:研究代表者 

    配分額:17420000円 ( 直接経費:13400000円 、 間接経費:4020000円 )

    環状RNA(circRNA)は特定の条件下で発現するが、それらの包括的な発現状態の解析は限られていた。本研究では、環状RNAに特化したRNAシークエンシングを行い、ヒト膵腺癌(PDAC)組織で網羅的なcircRNA分析を行った。その結果、正常な膵臓組織と比較して、PDAC組織で発現が増えている40,000を超える新規の環状RNAを特定した。 その中で、12番染色体上の非コードRNA遺伝子座に由来する新規環状RNAの全長配列を決定した。circPDAC-RNAという名前をつけたこの環状RNAは、正常なヒト細胞では発現していないものの、PDACを含む癌では高発現していた。

    researchmap

  • B型肝炎に関する病態生理の新たな解明に基づく制御法開発

    2019年04月 - 2022年03月

    日本医療研究開発機構(AMED)  感染症実用化研究事業(肝炎等克服実用化研究事業) 

    大塚基之

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • 膵癌特異的な新規環状RNAの同定とその血中での検出による新規膵癌マーカーとしての有用性

    2019年04月 - 2021年03月

    東京大学橋渡し研究戦略的推進プログラム研究シーズA 

    大塚基之

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • 細胞外微粒子の 1 粒子解析技術の開発を基 盤とした高次生命科学の新展開(代表 渡邉 力也)

    2019年 - 2025年03月

    科学技術振興機構  戦略的創造研究推進事業(CREST)「細胞外微粒子に起因する生命現象の解明とその制御に向けた基盤技術の創出」領域 

    大塚基之

      詳細を見る

    担当区分:研究分担者 

    researchmap

  • 新規樹脂チップを基材とした血中循環腫瘍細胞の捕捉・遺伝子解析システムの実用化

    2019年 - 2024年03月

    東大病院ニプロ「次世代医療技術の開発と実用化」共同研究 

    大塚基之

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • 膵がん特異的リピートRNAの新規探索と応用

    2017年 - 2020年03月

    日本医療研究開発機構(AMED)  次世代がん医療創生研究事業 

    大塚基之

      詳細を見る

    担当区分:研究代表者 

    researchmap

  • B型肝炎ウイルスRNAと相互作用する宿主因子の網羅的同定とその制御による病態制御法開発

    2016年04月 - 2019年03月

    日本医療研究開発機構(AMED)  感染症実用化研究事業(肝炎等克服実用化研究事業) 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 加齢に伴うmicroRNAの機能低下と発癌ポテンシャル増大の分子機構の解明と制御

    研究課題/領域番号:16H05149  2016年04月 - 2019年03月

    文部科学省  科学研究費補助金 基盤研究(B)  基盤研究(B)

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    加齢に伴う発癌リスクの増加の機構を解明するために、microRNAの機能変化に着目して研究をすすめた。ヒト正常線維芽細胞は細胞老化にともない炎症性サイトカインの発現が増加した。特にインターフェロン下流の応答遺伝子の発現がSTATの発現増加と核内移行によって増えてくることを見出した。この現象は、肝臓内では非実質細胞で起きていた。したがって、加齢によって細胞老化が起きると微小な慢性炎症が起き、その結果microRNAの機能が低下して発癌リスクになることが推定された。この現象はmicroRNAの機能を増強する作用をもつ化合物ROCK阻害剤で抑制できる可能性も示した。

    researchmap

  • ヘテロクロマチン由来RNAがもたらす複雑系攪乱による発癌機構解明と病態検出法開発

    研究課題/領域番号:16KT0109  2016年04月 - 2019年03月

    文部科学省  学術研究助成基金助成金 基盤研究(B)(特設分野研究)  基盤研究(B)

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    膵癌早期からヘテロクロマチン領域から反復配列をもつRNAが発現してくることに着目し、その生物学的意義を検討した。反復配列RNAの過剰発現は、YBX1蛋白との結合を介して、DNA損傷の蓄積や染色体分裂異常を惹起し、それにより癌化のポテンシャルを上げていることが示された。さらに反復配列RNAを高感度に血中から検出することで、膵癌早期診断マーカーとして有用であることが示唆された。さらに特殊な非コードRNAとして 膵癌特異的な環状RNAを同定し全長配列を決定したうえでその組織内発現を確認し、今後の複雑系の解析次第では、新規の膵癌マーカーとして有用になる可能性が考えられた

    researchmap

  • 膵臓癌の早期発見のための血清中の反復配列RNAの高感度検出法の開発

    2015年04月 - 2016年03月

    文科省橋渡し研究加速ネットワークプログラム  平成27年度研究開発委託費シーズA 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 炎症に伴うmicroRNA機能不全が惹起する炎症性発癌の病態解明と制御法の開発

    2012年10月 - 2016年03月

    科学技術振興機構(JST)  戦略的創造研究推進事業 さきがけ 「慢性炎症」領域 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    慢性胃炎や慢性肝炎などの持続炎症は、当該臓器の癌を高率に惹起します。近年、遺伝子発現制御に関わるmicroRNAという分子群が炎症や発癌に関わる可能性が示唆されています。本研究では、microRNAの機能を制御する薬剤と炎症発癌マウスモデルを用いて、持続炎症に伴って生じるmicroRNAの機能変化と発癌との関連に着目し、炎症に続発する癌の原因を解明し予防法や新規治療法の開発をめざします。

    researchmap

  • C型慢性肝炎からの肝癌発症感受性遺伝子MICAを標的とするmicroRNAの発現制御による新規の肝癌の発症予防法と治療法の開発

    2011年

    高松宮妃癌研究基金  研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • MASLD関連肝細胞がんにおけるミトコンドリア異常の抗腫瘍免疫応答への影響の解明

    研究課題/領域番号:24K11153  2024年04月 - 2027年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    上田 優輝, 冨樫 庸介, 大塚 基之

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • 血中細胞外小胞因子を加えた機械学習による脂肪性肝疾患からの発癌高危険群の同定

    研究課題/領域番号:23K06397  2023年04月 - 2026年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    佐藤 雅哉, 大塚 基之

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    researchmap

  • 膵癌における反復配列RNAの機能解析と治療選択最適化への応用

    研究課題/領域番号:23K24090  2022年04月 - 2025年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    大塚 基之, 丸山 玲緒

      詳細を見る

    配分額:17420000円 ( 直接経費:13400000円 、 間接経費:4020000円 )

    通常の解析では解析対象から外されることの多い反復配列RNAと呼ばれる特徴的な配列を持つnon-coding RNAが 膵癌で高発現しており、それを血中で高感度に検出可能にする方法(TRAP-digital PCR法)を考案して癌スクリーニングでの有用性を見いだした。
    本年は、その新たな展開として、ヒト膵発癌過程の早期から異常発現してくる反復配列RNAのひとつであるHSTII-RNAについて、癌化プロセスにおける生物学的な機能を解析することとした。HSATII RNAを発現するコンストラクト(基本となる配列を3つ連結したもの)をヒト不死化膵管上皮細胞に発現させ、a) RNA sequencing による遺伝子発現変化、b) 細胞内シグナル伝達機構の活性化状態の変化、c) HSATII RNAに結合する蛋白の同定、を中心としてHSATII RNA発現がもたらす機能変化を解析する予定として、特にRNA IP と質量分析によって同定したHSATII RNAと結合する蛋白に、Smc6蛋白 に着目した。
    Smc6蛋白はSmc5蛋白らと複合体を作り染色体安定性や相同組み換え修復に寄与するが、HSATII RNAの細胞内局在は細胞質が主体のため、細胞癌化の観点からは「RNAによるDNA修復蛋白の細胞質での捕捉が 遺伝子変異蓄積を惹起する」と考え、「遺伝子変異の惹起」とリンクする現象について注目した解析を進めている。実際に、HSATII RNA発現細胞ではDNA障害のマーカーであるgH2AXの発現が核内で増えていることも確認した。反復配列を持つRNAの研究は近年少しずつ散見されてきたが、シークエンスの反復性のために扱いにくい研究対象であることは変わらない。HSATII RNAに関しては、「CTCFの機能を変化させ慢性炎症を惹起する」ことが報告されたが、我々の検討結果とは相違点もあり、さらなる研究が必要と考えている。

    researchmap

  • 血中循環腫瘍細胞を利用した癌の遺伝子解析技術に関する基礎検討

    研究課題/領域番号:19K07746  2019年04月 - 2023年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    大永 崇, 藤井 努, 大塚 基之

      詳細を見る

    配分額:4290000円 ( 直接経費:3300000円 、 間接経費:990000円 )

    本研究では、がんゲノム医療において不可欠な患者さんから必要時に繰り返し癌遺伝子情報を取得することを低侵襲で実現するため、血中循環腫瘍細胞(CTC)をマイクロ流体デバイス;”ポリマーCTCチップ”で捕捉し、ゲルによりCTCを回収して遺伝子解析する技術の確立を目指している。今年度は、これまでに見出したゲル材料を用いて、癌細胞捕捉後のチップにゲルを充填したのちに細胞回収するテストを行い、さらに回収細胞の癌遺伝子解析を実施した。
    ゲル材料に関するテストでは、ゲルを充填したチップをホルダー等の送液装置からリリースする際にゲルの一部が欠損する場合が見られたため、その防止を目的に次の検討を行った。(1)ゲル化条件を最適化し、十分な強度のゲルを得る。(2)ホルダーリリース時の温度などの条件もゲルの強度に影響するため、その最適化を行った。
    次にチップ上のゲルに包埋された細胞を回収し、遺伝子解析を試みた。はじめに全血中に混合したMIAPaCa2(すい臓がん細胞株)をチップで捕捉したのち、そこにゲルを充填した。細胞回収では、既に見出しているゲルの溶剤を用い、細胞周辺のゲルを局所的に溶解したのちにマイクロピペットにより、エッペンドルフチューブ中にシングルセルで細胞を回収した。このようにして得た細胞サンプルについて、(1)単一の癌遺伝子のPCR適用性、(2)ddPCRによるKRAS遺伝子およびBRAF遺伝子の変異解析、を検討した。今のところPCRや遺伝子変異解析に対し、回収に関わるゲル素材などの影響は見られないが、再現性確認を含めさらに検討を重ねる。

    researchmap

  • RNA機能変化を端緒とした炎症細胞社会学の確立

    研究課題/領域番号:18H05024  2018年04月 - 2020年03月

    日本学術振興会  科学研究費助成事業  新学術領域研究(研究領域提案型)

    大塚 基之

      詳細を見る

    配分額:8060000円 ( 直接経費:6200000円 、 間接経費:1860000円 )

    消化器系の組織では、慢性炎症が惹起されると、高率にその臓器組織での腫瘍形成を見る(肝臓癌・大腸癌など)。本研究では、過去の消化器組織での持続炎症からの発癌機構の解明とそれに基づく発癌予防法の開発研究で明らかにした「慢性炎症の刺激が、細胞内の遺伝子発現の調節を司る小分子RNA(microRNA)の機能を全般的に低下させ、その結果 腫瘍が発生する」という持続炎症に続発する腫瘍の形成メカニズムについて、一細胞レベルでの検討をすすめることを目的とする。つまり、炎症の場における個々の細胞内でのmicroRNA機能を定量的に解析し、炎症の持続過程における時空間的な個々の細胞内のmicroRNAの機能の変化、およびその後の遺伝子発現の量的変化について統合的な解析を行う。さらに特に上皮の癌化に注目して、「non-coding RNA の機能から見た炎症細胞社会学とそれによる癌化機構」の概念を確立するとともに、その結果に基づく炎症と腫瘍の科学的な予防法の確立を目ざすものである。
    本年度は、これまでマウスで行われていた検討をヒト細胞・組織で検討するために、iPS細胞から腸管上皮細胞を分化誘導し、その細胞群をair-liquid interface 培養をすることで、ヒト腸管上皮組織と類似の組織上皮が培養皿内で再構成できることを見出した。しかも、腸管上皮は胚細胞や腸上皮細胞に分化しており、かつ、上皮細胞の下には線維細胞も誘導されていることから、この系は極めてヒト腸管上皮に類似した形態・細胞構成を持つことが示唆された。この系を用いて、Crohn病患者由来のiPS細胞を用いて同様の腸管上皮組織系を構築し、たとえば炎症性サイトカインの刺激に対する反応性の違い、一細胞解析による各構成細胞の細胞群のグループ分けなどを検討していく予定となっている。

    researchmap

  • MICA蛋白の翻訳後修飾の分子機構解明による抗腫瘍免疫活性の増強

    研究課題/領域番号:17K09405  2017年04月 - 2020年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    佐藤 雅哉, 大塚 基之

      詳細を見る

    配分額:4680000円 ( 直接経費:3600000円 、 間接経費:1080000円 )

    C型肝炎感染から肝臓癌を発生しやすい宿主因子としてMICA遺伝子の上流の一塩基多型を 以前に報告した。その際、肝癌になりやすい人はMICAの発現量が少ない(癌になっても腫瘍免疫を惹起することが出来ない)ことが推定された。しかし、MICAの発現制御は、転写レベルだけではなく、転写・翻訳語の切断による癌細胞表面からの離脱も挙げられる。本研究では、MICA蛋白の切断離脱を阻害する化合物を蛋白分解酵素阻害剤ライブラリーからFAAH阻害剤にその作用があることを同定した。FAAH阻害剤はTIMP3発現増強を介してMICA蛋白の切断を阻害した。この結果を応用すると腫瘍免疫の増強につながる可能性がある。

    researchmap

  • 宿主microRNAとB型肝炎ウイルス転写産物との相互作用による病態生理の解析

    研究課題/領域番号:16K09344  2016年04月 - 2019年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    近藤 祐嗣, 大塚 基之

      詳細を見る

    配分額:4810000円 ( 直接経費:3700000円 、 間接経費:1110000円 )

    HBVと宿主因子との相互作用を検討するうえで、HBV-RNAと宿主非コードRNAに着目した。配列の相同性から、HBV preS2 領域の配列と宿主let7の配列が近似することから、preS2領域のRNAが発現していると宿主のlet7の機能を減弱させることを見出した。いっぽうで、let7の過剰発現はHBVRNAに作用しcccDNAの産生を妨げる作用があることも見出した。ウイルスと宿主の相互作用がRNAを介して起こり、病態形成に関与していることが示唆された。

    researchmap

  • 未来の癌予防法の確立をめざした加齢に伴う消化器癌の発生リスク増大の分子機構の解明

    2016年

    日本対がん協会  リレーフォーライフジャパン プロジェクト未来 研究助成 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 膵多段階発癌におけるmicroRNAの発現動態とその診断治療への応用

    研究課題/領域番号:15K09038  2015年04月 - 2018年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    山本 夏代, 伊地知 秀明, 大塚 基之

      詳細を見る

    配分額:4810000円 ( 直接経費:3700000円 、 間接経費:1110000円 )

    正常マウスの膵組織と、膵特異的K-ras変異マウス内で誘導されるPanIN組織と、通常型浸潤性膵癌組織との三者でのmiRNA発現状況を比較した。その結果、miR-125b が正常膵組織から段階的に発現量が増えるmicroRNAとして同定できた。さらに、3次元培養では microRNA125bが核内に移行することを見いだした。microRNA125bと結合する蛋白を質量分析にて同定したところ、Galectin 3 というシャトリング蛋白が同定され、miR-125bの核移行への関与が示唆された。さらに、核内のmiR-125bは配列特異的にmRNAのスプライシングに関与していた。

    researchmap

  • 肝癌感受性遺伝子MICAのshedding制御による肝発癌予防法の開発

    2015年04月 - 2016年03月

    沖中記念成人病研究所  平成27年度研究助成 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 肝癌発症予防を目的とした肝癌関連分子MICAの小分子核酸による発現制御法の開発

    研究課題/領域番号:26460984  2014年04月 - 2017年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    佐藤 雅哉, 大塚 基之

      詳細を見る

    配分額:4810000円 ( 直接経費:3700000円 、 間接経費:1110000円 )

    当研究者らは、ゲノムワイドアソシエーションスタディ(GWAS)解析で、1394例のC型肝炎罹患者と5486例の非感染者のサンプルを用いてC型肝炎感染から肝臓癌を発生しやすい宿主因子としてMICA遺伝子の上流に位置するSNPを 同定し報告した(Nat Genet. 2011)。本研究ではmicroRNA25-106クラスターに由来するmicroRNAがMICA遺伝子の発現量を負に制御しうることを同定した。また、CRISPR-Cas9系を用いて Cas9に VP16の転写活性化ドメインを融合した蛋白を用いた遺伝子編集手法の応用によってMICA遺伝子座からの転写を10倍以上高めることに成功した。

    researchmap

  • C型慢性肝炎からの肝癌感受性遺伝子MICAを標的としたmicroRNAの肝細胞特異的なデリバリー法の確立による新しい肝癌予防法の開発

    2014年04月 - 2015年03月

    沖中記念成人病研究所  平成26年度研究助成 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 野菜に含まれるポリフェノール類の一種アピゲニンによるmicroRNA成熟抑制作用を介した抗C型肝炎ウイルス作用

    2014年04月 - 2015年03月

    本庄国際奨学財団  「食と健康プログラム」研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 肝癌幹細胞維持および悪性化に関わるシグナル分子の解析

    研究課題/領域番号:25290045  2013年04月 - 2016年03月

    日本学術振興会  科学研究費助成事業  基盤研究(B)

    前田 愼, 大塚 基之, 芝田 渉

      詳細を見る

    配分額:17030000円 ( 直接経費:13100000円 、 間接経費:3930000円 )

    我が国では肝癌によって毎年約3.5万人が死亡しており、難治進行癌に対する治療法はいまだ確立せずに予後は悪い。癌部の多くの割合を占める分化した癌細胞に対する治療では十分ではなく、治療抵抗性や転移、再発の原因として幹細胞の特異的な形質を理解する必要がある。本研究では新たな肝臓癌マウスモデルの作成、肝癌幹細胞培養による細胞株の樹立、癌幹細胞変化のメカニズムとしての上皮ー間葉転換の解析を行い、肝癌幹細胞をターゲットとする治療開発へ向けた基盤を構築した。

    researchmap

  • 肝特異的microRNAの発現低下に伴う細胞内代謝物量変化とその肝癌治療への応用

    研究課題/領域番号:25460979  2013年04月 - 2016年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    近藤 祐嗣, 大塚 基之, 吉田 晴彦

      詳細を見る

    配分額:5070000円 ( 直接経費:3900000円 、 間接経費:1170000円 )

    進行肝癌における有効な治療法が不十分である中、本研究では、肝癌におけるmiRNA122の低下に着目し検討した。その結果、miRNA122の発現が低下した肝組織ではアルギニンの量が増えていた。アルギニンは、miRNA122の標的因子であるCAT-1の発現量が増えることにより、取り込まれる量が増えていた。アルギニンは一酸化窒素(NO)合成酵素の基質であるが、実際 miR122低下肝癌では細胞内NOの量が増えており、それに伴って癌幹細胞マーカーの発現が増加した。これらから、miRNA122発現の低下した肝癌においては、アルギニン摂取の制限が癌幹細胞的な形質を減弱させる補助療法となることが示唆された。

    researchmap

  • microRNA122の発現低下に伴うアミノ酸代謝系の変化を介した肝臓癌の癌幹細胞の形質獲得機構の解析とそれに基づく制御法の開発

    2013年04月 - 2014年03月

    日本消化器病学会  研究助成 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • MICAの発現調節による肝炎からの肝発癌予防法の開発

    2013年04月 - 2014年03月

    Liver Forum in Kyoto 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 非コード反復配列RNAの発現を主因とした多段階発癌の発癌機構の解明と制御

    研究課題/領域番号:25293076  2013年 - 2015年

    文部科学省  科学研究費補助金(基盤研究(B))  基盤研究(B)

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:6500000円 ( 直接経費:5000000円 、 間接経費:1500000円 )

    癌は癌遺伝子・癌抑制遺伝子の変異に伴う多段階発癌が主要な発癌経路であると推定されているが、なぜそれらの遺伝子変異が最終的に雑多な遺伝子異常を伴う細胞癌化に結びつくのかはいまだ明確になっていない。本申請では、多段階発癌の初期の遺伝子異常の段階から非コード反復配列RNAが発現し、DNA修復因子であるYB-1蛋白と結合し細胞質に局在させることを明らかにした。この反復配列がゲノムDNAやミトコンドリアDNAの変異修復を阻害することで、細胞内環境を攪乱しDNA損傷を惹起することをつきとめた。反復配列RNAのYB1への結合を阻害するなどの介入法によって発癌を抑制できる可能性が示唆された。

    researchmap

  • 膵癌モデルマウスを用いた非機能性反復配列RNAの膵発癌における生物学的意義の検討

    研究課題/領域番号:24591005  2012年04月 - 2015年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    山本 夏代, 大塚 基之, 伊地知 秀明

      詳細を見る

    配分額:5330000円 ( 直接経費:4100000円 、 間接経費:1230000円 )

    膵癌で早期に発現する非コードRNAの一種、反復配列RNAの発現状況を検討したところ、膵癌組織特異的で正常組織では全く発現が見られなかった。そのためこの反復配列RNAが癌の表現型に何か寄与しているのではないかと考え、細胞で発現する状況を創ってみたところ、遺伝子異常の修復障害や染色体の分裂異常が惹起された。その分子機構はまだ解明すべき点があるが、この非コードRNAの発現が癌の悪性化に寄与していると考えられた。

    researchmap

  • 非コードRNAによるIFN作用増強効果の機構解析とC型肝炎ウイルス治療への応用

    研究課題/領域番号:24590956  2012年04月 - 2015年03月

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    吉田 晴彦, 大塚 基之

      詳細を見る

    配分額:5460000円 ( 直接経費:4200000円 、 間接経費:1260000円 )

    IFNの作用を増強するmicroRNAをスクリーニングしたところ、miR122が同定された。miR122はインターフェロンシグナルを負に制御するSOCS3のプロモーターのメチル化を促進することが示された。従ってIFNの投与によりmiR122の発現が低下するとSOCS3の発現も増強しnegative feedbackになることが示唆された。miR122の発現を減らすアピゲニンはHCVの複製をIFNと併用することで効率的に抑えることが示された。

    researchmap

  • コーヒーの持つmicroRNA機能の増強作用を介した脂肪肝と肝発癌の予防効果の検討

    2012年

    全日本コーヒー協会  研究助成 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • microRNA産生に必須なRNA分解酵素Dicerの機能撹乱が原因となる炎症性発癌機構の解明

    2012年

    日本応用酵素協会  酵素研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • RNP構成因子DDX20によるB型肝炎関連肝癌の抑制機構の解析

    研究課題/領域番号:23590960  2011年 - 2013年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    五藤 忠, 大塚 基之, 吉田 晴彦

      詳細を見る

    配分額:5200000円 ( 直接経費:4000000円 、 間接経費:1200000円 )

    肝発癌の一因として網羅的解析で同定されたDDX20の発現低下によって惹起される分子変化を検討した。その結果、DDX20はmicroRNAの成熟に必須の因子であるRISCの構成因子であり、発現が減ると特定のmicroRNAの成熟が阻害されることが判明した。特にmicroRNA140-5pの発現低下は発癌に密接に関わるNF-KBの活性化に関与することを見いだしたが、それは、microRNA140の発現低下によってDnmt1の発現が増え、メタロチオネインを減らすためと考えられた。これらの現象はmicroRNA140のノックアウトマウスでも確認された。今後これらの結果を応用した肝癌予防策が期待される。

    researchmap

  • 上皮細胞と樹状細胞による腸管免疫と宿主恒常性の制御機構の解明

    研究課題/領域番号:23590933  2011年 - 2013年

    日本学術振興会  科学研究費助成事業  基盤研究(C)

    平田 喜裕, 大塚 基之, 山田 篤生

      詳細を見る

    配分額:5200000円 ( 直接経費:4000000円 、 間接経費:1200000円 )

    腸管の恒常性制御機構の解明のため、腸管上皮細胞と樹状細胞の役割を検討した。上皮特異的IKKノックアウトは、Citrobacter感染腸炎の減弱を認めなかった。一方血球細胞ではIKKシグナルが樹状細胞と病原体の制御に重要であった。上皮細胞の細胞間接着分子は腸管内細菌の制御と腸炎の抑制作用があると考えられた。一方樹状細胞ではTGFbシグナルが、大腸、胃など消化管の抗炎症作用に必須であった。樹状細胞のTGFbR2のヘテロノックアウトマウスではCitrobacter腸炎の悪化がみられた。樹状細胞のTGFbシグナルは腸内細菌を感知、制御し個体の恒常性維持に寄与することが明らかになった。

    researchmap

  • 膵癌における非機能性反復配列RNAが惹起する癌と間質相互作用の解析

    2011年

    佐川がん研究振興財団  研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • C型慢性肝炎からの肝癌感受性遺伝子MICAを標的とするmicroRNAの発現制御による肝癌の発症予防法と治療法の開発

    2011年

    沖中記念成人病研究所  研究助成 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 非機能性反復配列RNAが惹起する癌と間質相互作用

    2011年

    アステラス病態代謝研究会  研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 難治消化器がんの発生・進展におけるNF-kappaBシグナルの関与

    研究課題/領域番号:22300317  2010年 - 2012年

    文部科学省  科学研究費補助金(基盤研究(B))  基盤研究(B)

    前田 愼, 大塚 基之, 伊地知 秀明

      詳細を見る

    担当区分:連携研究者  資金種別:競争的資金

    配分額:17160000円 ( 直接経費:13200000円 、 間接経費:3960000円 )

    1)難治がんモデルの作成とNF-kappaB活性化との関連の検討膵臓がん:膵特異的oncogenic K-ras発現と膵特異的TGFβレセプターIIノックアウトによってヒトの膵臓癌に病理学的に近い癌が観察されるが(Ijichi H et al.Genes Dev 2005)、このマウスにIKKβ floxedおよびIKKαAAマウスを交配することにより、その影響を検討した結果、腫瘍発生は抑制された。スキルス胃がん:Her2(ErbB2)トランスジェニックマウスの作成を行ったが、これまでのところ(4ヶ月目まで)異常は見られていない。現在長期経過観察中である。さらにHelicobacterモデルを行っている。2)恒常的IKKβ活性化マウスの作成恒常的IKKβ活性化が発癌に及ぼす影響を検討するため、恒常活性型IKKβ(IKKβEE(S177E,S181E))を胃、腸で強く発現するCK-19プロモーター下に発現させた。7か月目までは大きな異常は見られなかった。大腸炎症発癌モデルであるAOM+DSSモデルを用いて、検討を行い、やや炎症が増悪する傾向が得られた。現在詳細を解析中である。3)プロテアソーム阻害剤を用いた胃癌治療への可能性の検討胃癌ではIn vitroおよびIn vivoにおいて明らかにその抗腫瘍効果を認めた。その原因として増殖抑制およびアポトーシス亢進によるものであることが...

    researchmap

  • 肝特異microRNAの機能解析とその発現制御による効率的肝細胞分化誘導法の開発

    研究課題/領域番号:22590718  2010年 - 2012年

    文部科学省  科学研究費補助金(基盤研究(C))  基盤研究(C)

    近藤 祐嗣, 大塚 基之, 吉田 晴彦

      詳細を見る

    担当区分:連携研究者  資金種別:競争的資金

    配分額:4420000円 ( 直接経費:3400000円 、 間接経費:1020000円 )

    肝細胞内の全microRNAの80%以上を占めているmiR122は肝細胞特異的に発現するmicroRNAであり、かつ肝癌でその発現が落ちているなどの背景から、肝細胞を正常な肝細胞として維持する機能を有している可能性が考えられる。本年度はmiR122の肝細胞分化に与える生理機能をin vitroでのmiR122過剰発現系・ノックダウン系とmiR122の機能的ノックアウトマウスによりin vivoで解明することを目的とした。miR122に対するanti-sense配列RNAをH1 promoter下に発現するレンチウイルスを作製しこれを肝細胞株に感染させmiR122の機能をノックダウンしたstable cell lineを樹立した。miR122の機能についてはluciferase遺伝子の下流5'UTRにmiR122の標的配列を組み込んだレポーターコンストラクトを作製しtransfectionすることでluciferaseの発光を定量することにより確認した。反対に過剰発現系については、miR122のprecursorをCMV promoter下に発現するコンストラクトを作製しレンチウイルスに組み込んで発現した。miR122のanti-senseを発現するコンストラクトを切り出し、マウスゲノムに組み込んでtransgenic mouseを作製する。これにより機能的にmiR122をノッ...

    researchmap

  • 持続炎症に併発するmiRNA機能減弱が原因となる消化器癌の発癌機構と制御法の探索

    研究課題/領域番号:22390058  2010年 - 2012年

    文部科学省  科学研究費補助金(基盤研究(B), 基盤研究(B))  基盤研究(B), 基盤研究(B)

    大塚 基之, 立石 敬介, 前田 愼

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:18590000円 ( 直接経費:14300000円 、 間接経費:4290000円 )

    「炎症性ストレスによる慢性的な『miRNA機能阻害』によって引き起こされる炎症性発癌」という新規の疾患概念を検証するために、昨年度に樹立したmiRNA反応性GFPマウスを用いて、炎症性発癌モデルにおけるmiRNAの機能変化を検定した。CMVプロモーターで転写される蛍光蛋白であるGFP遺伝子の3'UTRにmiRNA122/let7b/miR29bの標的配列を組み込んだコンストラクトを恒常的に発現するトランスジェニックマウスで、AOM/DSSを用いた大腸の炎症性発癌モデルの過程でのGFPの発現強度を免疫組織染色で検討したところ、持続炎症によってGFPの発現は増強し、慢性炎症に伴ってmicroRNAの機能が減弱することが示唆された。今年度は介入試験を行なうため、薬剤ライブラリーとレポーター細胞を用いてmicroRNAの機能を増強する薬剤を探索した。300種以上の化合物からある種のkinaseがmicroRNA機能を増強することをみいだし、その機構を解析した。その結果、この薬剤はPAIP2と呼ばれるpoly Abinding proteinに相互作用する分子の発現を増やしてその機能を抑制し、microRNAによるpolyAの短縮を増強する作用があることをみいだした。この薬剤を先のAOM/DSSによる炎症性発癌モデルでin vivo投与したところ、確かに腫瘍形成が抑制された。Dicer遺伝子ノックアウトマウスではその効果は見られなかったことから、その作用はmicroRNAの機能を介していることが示唆された。今後さらにその分子機構を解析するのと並行して、他の炎症発癌モデルを用いて炎症性発癌におけるその薬効の普遍性を検証する予定である。

    researchmap

  • p38コンディショナルノックアウトマウスを用いた消化器領域の炎症性疾患(感染性・炎症性腸疾患)についての病態解析

    2010年

    三共生命科学研究振興財団  海外共同研究支援助成 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • インターフェロン作用増強を介する microRNAを用いた慢性C型肝炎に対する核酸療法開発のための分子機構の解明

    2010年

    持田記念医学薬学振興財団  研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • トランスジェニックマウスとメタボロミクスによる肝特異的microRNA122の機能解析

    2010年

    荒木記念医学・生化学研究振興基金  研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 腸管内病原性細菌に対する腸管上皮細胞から免疫担当細胞への免疫応答連携におけるp38 MAPKの組織特異的機能の解析

    2010年

    ヤクルト・バイオサイエンス振興財団  研究助成 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 持続炎症性発癌の病態におけるmicroRNA機能不全の関わりの解明と制御法の開発

    2010年

    細胞科学研究財団  研究助成 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • iPS細胞からのヒト肝炎ウイルス複製マウスモデルの作製と応用

    研究課題/領域番号:21890052  2009年 - 2010年

    文部科学省  科学研究費補助金(若手研究(スタートアップ), 研究活動スタート支援)  若手研究(スタートアップ), 研究活動スタート支援

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    配分額:2652000円 ( 直接経費:2040000円 、 間接経費:612000円 )

    researchmap

  • 生体ストレスが惹起するmiRNA機能異常に関わる分子機構の同定

    2009年

    武田科学振興財団  医学系研究奨励 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 消化器発癌の原因としての慢性持続炎症に伴うmicroRNA機能不全の機構解明と治療介入法の開発

    2009年

    千里ライフサイエンス振興財団  研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 持続炎症に伴う発癌の原因としての炎症性サイトカインが惹起するmicroRNA機能異常の解析

    2009年

    病態代謝研究会  研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

  • 持続炎症に伴うmicroRNA機能不全が惹起する肝発癌機構解明とその発癌機構への新規介入法の開発

    2009年

    がん研究振興財団  研究助成金 

    大塚 基之

      詳細を見る

    担当区分:研究代表者  資金種別:競争的資金

    researchmap

▼全件表示

その他研究活動

  • Editorial Board

     詳細を見る

    1) Academic Editor: PLoS ONE (2013.6.~ ),
    2) Editorial Board: World Journal of Gastroenterology (2014.1.~ )
    3) Editorial Board: Scientific Reports (2015.3.~ )
    4) Editorial Board: Hepatology International (2015.4.~ )
    5) Editorial Board: Experimental and Therapeutic Medicine (2020.4.~ )
    6) Editorial Board: Oncology Letters (2020.6.~ )

    researchmap

 

担当授業科目

  • 内科学 (2024年度) 1・2学期  - [第1学期]月4,月5,水6, [第2学期]月4,月5,金6

  • 消化器・肝臓内科学実習 (2024年度) 特別  - その他

  • 消化器・肝臓内科学演習 (2024年度) 特別  - その他

  • 消化器・肝臓内科学I(演習・実習) (2024年度) 特別  - その他

  • 消化器・肝臓内科学I(講義・演習) (2024年度) 特別  - その他

  • 消化器・肝臓内科学II(演習・実習) (2024年度) 特別  - その他

  • 消化器・肝臓内科学II(講義・演習) (2024年度) 特別  - その他

  • 消化器系(臓器・系別統合講義) (2024年度) 特別  - その他

  • 病態機構学演習 (2024年度) 特別  - その他

  • 内科学 (2023年度) 1・2学期  - [第1学期]月4,月5,水6, [第2学期]月4,月5,金6

  • 消化器・肝臓内科学実習 (2023年度) 特別  - その他

  • 消化器・肝臓内科学演習 (2023年度) 特別  - その他

  • 消化器・肝臓内科学I(演習・実習) (2023年度) 特別  - その他

  • 消化器・肝臓内科学I(講義・演習) (2023年度) 特別  - その他

  • 消化器・肝臓内科学II(演習・実習) (2023年度) 特別  - その他

  • 消化器・肝臓内科学II(講義・演習) (2023年度) 特別  - その他

  • 消化器系(臓器・系別統合講義) (2023年度) 特別  - その他

▼全件表示